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Alzheimer disease (AD) is the most prevalent form of dementia in the United States affecting an 
estimated 5.3 million individuals in 2015. Clinically, AD presents with progressive memory loss, 
decline in cognitive abilities, and behavioral changes. Neuropathologically, increased synaptic 
pathology and neuronal loss correlate with cognitive impairment in AD. While the specific 
neurobiological mechanisms underlying AD neuronal loss are not fully understood, a growing 
pool of evidence implicates soluble amyloid-β (Aβ) oligomers as a primary neurotoxic agent.  
Previous work has demonstrated that Aβ disrupts neuronal Ca2+ homeostasis, initiating a cascade 
of pathological events that ultimately culminate in widespread neuronal death.  Recently, 
neuronal calcium sensor protein visinin-like protein 1 (Vilip-1) has been identified an AD-
specific peripheral biomarker, however little is known about Vilip-1 in the AD brain. Previous 
work has alluded to associations between Vilip-1, Aβ, and neuronal death. VSNL1, the gene that 
encodes Vilip-1, coexpresses with genes related to AD throughout normal aging, notably 
amyloid precursor protein (APP), which is cleaved in the pathogenesis of AD to form Aβ. Vilip-
1 immunoreactivity also associates with neuritic plaques in the neocortex of the human AD 
brain. Finally, overexpression of Vilip-1 in a cell line increased death rates following a Ca2+ 
challenge, suggesting Vilip-1 may play a functional role in neuronal loss. To determine if Vilip-1 
plays a causal role in AD, first we investigated Vilip-1 levels in two regions of the human AD 
brain. Then we used model systems to evaluate the impact of Aβ on Vilip-1 expression and 
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determined whether manipulation of Vilip-1 expression affected Aβ-induced neuronal death. We 
demonstrated that Vilip-1 is reduced within brain regions characterized by prominent neuronal 
loss in both AD and frontotemporal lobar degeneration (FTLD). We reported that Vilip-1 
expression is not driven by Aβ. Finally, we found that Aβ-initiated neuron death was unaffected 
by the extent of Vilip-1 expression.  Together, these data suggest that Vilip-1 is a general marker 
for neuronal loss in brain tissue rather than participant in an AD-specific neuronal death process. 
In addition, Vilip-1 may have value as a novel marker for neuronal integrity and loss in human 
brain tissue. 
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1.0  INTRODUCTION 
1.1 OVERVIEW OF ALZHEIMER DISEASE 
1.1.1 Disease Prevalence, Cost, and Projections  
Alzheimer disease (AD) is the most prevalent form of dementia, accounting for 60-80% of all 
dementia cases (2014).  According to the Centers for Disease Control and Prevention, AD ranks 
as the sixth leading cause of death in the United States, while some estimates indicate it could be 
as high as third, right after heart disease and cancer, resulting in the loss of more than half a 
million lives each year (James et al., 2014).  Excluding rare genetic mutations that only occur in 
one percent of AD cases, advanced age is the strongest risk factor for AD, with most diagnoses 
occurring at age 65 or older. One in nine people (11 percent) age 65 or older have AD. This 
number jumps to one in three people (32 percent) age 85 and over. As the “baby boomer” 
generation continues to age and reach unprecedented life expectancies, the proportion of the 
population meeting the advanced age criteria continues to rise and the number of Americans 
living with AD is slated to dramatically escalate in coming years. In 2014, an estimated 5.2 
million people in the United States were living with AD.  Barring medical breakthroughs that 
effectively prevent, delay onset, or halt the progression of the disease, this number of existing 
AD cases is projected to reach as high as 16 million by some estimates in the year 2050.  
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As AD numbers are poised to rise and death rates for other major diseases like HIV, 
stroke, heart disease, and cancer are in decline, AD remains the only top 10 cause of death 
without a cure or even a way to slow disease progression. Lack of effective intervention is 
creating an enormous economic burden on society. In 2014, the direct costs to society for 
providing AD care were projected to total $214 billion, and are expected to rise to an 
astronomical $1.2 trillion in 2050 (not accounting for inflation). These figures only touch on 
direct costs and do not account for the estimated 17.7 billion hours of care provided by family 
and other unpaid caregivers in 2013 that would account for more than $220.2 billion in economic 
value. By some estimates, if the onset of AD could be delayed by 5 years through the 
development of a successful intervention, the number of patients affected by AD would be 
reduced by 57 percent and the annual Medicare costs could be cut by almost 50 percent (Fagan, 
2014).   
1.1.2 Clinical Presentation and Neuropathological Hallmarks 
In the early 1900s, Auguste D., a woman in her early 50s, was admitted to the hospital after 
exhibiting increasingly peculiar behavior; she was experiencing memory impairment, sleep 
disturbances, increased aggression, hallucinations, and delusions. German psychiatrist, Alois 
Alzheimer, chronicled Auguste’s case. He detailed her symptomatology, progression, and 
disease course, which would later be recognized as the first documentation of a patient with AD. 
After her death in 1906, Alzheimer was able to study the brain of Auguste D. and describe the 
organ both morphologically and histologically, correlating her cognitive and behavioral changes 
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with neuropathological elements he observed in her cerebral cortex (Alzheimer et al., 1995, 
Holtzman et al., 2011). 
The clinical expression of AD is defined by declining memory, progressive loss of 
cognitive ability, and behavioral impairments that worsen over time. Progression of the disease 
tracks from an asymptomatic preclinical stage to the prodromal symptomatic stage known as 
mild cognitive impairment (MCI), before reaching the fully expressed symptomatic stage 
characterized by dementia.  The time course of this continuous decline in mental faculties 
averages between 7 to 10 years and ultimately culminates in death (Holtzman et al., 2011). AD is 
clinically diagnosed based on the established National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria (McKhann et al., 1984). 
AD can only be definitively diagnosed postmortem after histological examination of the 
brain through identification of the two characteristic pathological hallmarks originally described 
by Alzheimer: extracellular amyloid plaques comprised of aggregations of the amyloid-β (Aβ) 
peptide and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated 
microtubule-associated tau protein (Selkoe, 2004, Ballatore et al., 2007). Three sets of diagnostic 
histological criteria currently exist that describe the quantification and regional distribution of 
these classic AD pathological features: Consortium to Establish a Registry for Alzheimer 
Disease (CERAD), National Institute on Aging-Reagan (NIA-Reagan), and Khachaturian (Mirra 
et al., 1991, Hyman and Trojanowski, 1997).  
In the AD brain, NFTs form in a predictable spatiotemporal pattern (Serrano-Pozo et al., 
2011). As described in the clinicopathological study by Braak and Braak, NFTs initially present 
in the perirhinal region, followed by the entorhinal cortex and hippocampus before proceeding to 
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develop in the further limbic structures and finally all neocortical regions (Braak and Braak, 
1991). Notably, until very end stage disease the primary sensory, motor, and visual cortices are 
largely spared. Distribution of amyloid plaques is less predictable than NFTs and the majority of 
accumulation occurs in the neocortex, with entorhinal cortex and hippocampus being effected to 
a lesser extent (Serrano-Pozo et al., 2011). 
1.1.3 Neuronal Loss in AD 
In addition to accumulating protein aggregates, AD also exhibits gross atrophy of the brain and 
enlargement of the ventricles that results from prominent neuronal death, synapse loss, and 
reactive gliosis (Gomez-Isla et al., 1996, Ingelsson et al., 2004). Atrophy primarily occurs in the 
medial temporal and parietal lobes and is limited in the primary motor, sensory, and visual 
corticies (Serrano-Pozo et al., 2011). The primary source of cortical atrophy is often attributed to 
neuronal loss (Serrano-Pozo et al., 2011). A number of stereological studies have investigated 
neuronal loss in varying brain regions in AD.  
In particular, the entorhinal cortex is highly vulnerable in AD, being one of the first 
regions affected by neurofibrillary tangles (Braak and Braak, 1991). In a study using an unbiased 
stereological approach, neuron counts in the ERC were compared between AD subjects with 
early and late stage disease (n =10) and cognitively normal control subjects (n =10). Neuron 
numbers in normal control subjects remained consistent across aging, with no detectible loss 
from age 60 to 90. In contrast, neuron numbers in AD individuals were significantly reduced 
compared to normal controls with an observed 48% decrease in total number of ERC neurons 
(Gomez-Isla et al., 1996). This reduction was significant even at early stages of AD. All ERC 
layers had significantly fewer neurons than normal control subjects, with layer II displaying the 
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greatest deficit. Additionally, in AD subjects, cognitive function correlated with degree of 
neuron loss in all ERC layers, with the most impaired individuals exhibiting the most severe 
neuron deficits (Gomez-Isla et al., 1996).  
Another brain region that is primarily affected by neuronal loss in AD is the 
hippocampus. Several studies have documented severe loss of neurons within several 
hippocampal areas including CA1, hilus, and subiculum in end stage disease (West et al., 1994, 
Simic et al., 1997, Rossler et al., 2002, West et al., 2004).  
Unlike the consistently documented dramatic neuron loss in the ERC and hippocampus, 
the degree of neuron loss in the neocortex of AD subjects is more widely debated. Regeur and 
colleagues used an unbiased, uniform sampling stereological approach to estimate total neuron 
population in the neocortex of late stage Alzheimer disease. Brains from 11 severely demented 
females from a chronic psychogeriatric ward in Copenhagen, Denmark and 10 age-matched 
controls were evaluated. They found that neocortical neuron numbers generated from frontal, 
temporal, parietal, and occipital brain regions in AD were decreased by 6% compared to normal 
controls, however the reduction was not statistically significant (Regeur et al., 1994). In another 
larger stereological study investigating the superior temporal sulcus in 34 individuals with AD 
and 17 cognitively normal control subjects saw a significant 53% decrease in neuron number, 
with loss increasing to 75% in subjects with more advanced disease (Gomez-Isla et al., 1997). 
Importantly, no significant difference in neuron number was observed with increasing age in 
normal subjects (Gomez-Isla et al., 1997). An additional study investigated neuron number in 
prefrontal cortex deep layer III and superficial layer V within 10 AD cases of varying degrees of 
cognitive impairment and 9 elderly controls. Neuron counts were dramatically decreased in AD 
subjects compared to controls in both layers, with numbers in layer V demonstrating the greatest 
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reduction. In addition, neuron loss again correlated with severity of disease, with more than 90% 
loss at end stages of AD (Bussiere et al., 2003). These differences are likely attributed to 
differences in the brain regions investigated, stage of disease, small subject cohort sizes, and 
technical variations, however it does appear that ERC is a primarily effected region even at early 
stages of AD, while other regions like the prefrontal cortex are more greatly impacted later as the 
disease progresses.  
Neuronal loss not only positively correlates with the temporal-regional and laminar 
distribution of NFT pathology, but it far exceeds the number of NFTs formed within a region, 
and thus serves as a better correlate of cognitive impairment than NFTs (Gomez-Isla et al., 1996, 
Gomez-Isla et al., 1997). However, synapse loss also follows the same spatiotemporal pattern as 
neuronal loss and is widely considered to be the best correlate of cognitive decline in AD 
(Serrano-Pozo et al., 2011). This is likely because synapse loss not only precedes neuronal loss 
but is also caused by neuronal loss. Neurons with synaptic connections in regions of widespread 
neuron death become less well connected leading to cognitive impairments (DeKosky and 
Scheff, 1990, Terry et al., 1991, Scheff and Price, 1993, Scheff et al., 2007).  
1.1.4 Soluble Aβ Toxicity 
Aβ peptides aggregate in the extracellular space of the brain and comprise the principle 
proteinaceous component in amyloid plaques. Produced from the cleavage of transmembrane 
amyloid precursor protein (APP) by β-secretase and γ-secretase enzyme complexes, Aβ peptides 
can vary in length, ranging from 36- to 43- amino acids long (Thal et al., 2015). In the human 
brain, the Aβ1-40 is the most abundantly produced peptide isoform (Esbjorner et al., 2014). 
Different lengths of Aβ exhibit varying degrees of toxicity, with Aβ1-42 widely considered to be 
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the most toxic species in humans. Its toxicity may be in part due to the Aβ1-42 isoform having a 
higher propensity for self-aggregation and oligomerization in vivo than other species like Aβ1-40 
(Haass and Selkoe, 2007, Murray et al., 2012). In fact, many of the known familial mutations in 
APP and presenilin-1, the enzymatic element of the γ-secretase complex, result in increased 
production of Aβ1-42 (Haass and Selkoe, 2007). During the process of self-aggregation Aβ 
peptides form several different transient immediate species between monomers and fibrils 
including dimers, trimers, dodecamers, higher molecular weight oligomers and protofibrils 
(Mucke and Selkoe, 2012, Thal et al., 2015). Currently, Aβ dimers are the most studied 
oligomeric species, likely because they are elevated in overexpressing transgenic mouse brains 
and following extraction from human AD brain tissue dimers have been shown to impair long 
term potentiation (Larson and Lesne, 2012). Additionally, dimers have been shown to induce 
dendritic spine loss (Shankar et al., 2007), increase tau phosphorylation, and produce 
cytoskeletal abnormalities in culture (Jin et al., 2011). Amyloid plaques may actually serve as 
reservoirs of soluble Aβ oligomers (Koffie et al., 2009), as a halo of nonfibrillar Aβ exists in the 
plaque surround (Appendix A). 
Recently soluble Aβ oligomers have emerged as the leading neurotoxic agent in AD, 
however the precise mechanism(s) behind the peptide’s actions remain elusive. The amyloid or 
Aβ cascade hypothesis posits that the deposition of Aβ protein is a central event in AD 
pathogenesis initiating numerous damaging pathways involving synaptic dysfunction, oxidative 
stress, microglia activation, and disruption of Ca2+ homeostasis, which ultimately culminate in 
neuron loss and cognitive impairment.  
The particular manner by which Aβ oligomers perturb neuronal Ca2+ homeostasis and 
increase neurotoxicity is complex and still a matter of debate, however a number of potential 
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mechanisms have been identified. One theory is that Aβ oligomers fuse with lipid bilayers 
creating annular structures that function as artificial pores or channels in the membrane, allowing 
for increased cation flux into the cell (Arispe et al., 1993). Other studies have demonstrated that 
Aβ interacts with endogenous highly Ca2+-permeable channels including voltage-gated calcium 
channels, glutamate receptors (N-methyl D-aspartate-receptors (NMDARs) and α-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid receptors (AMPARs)), and nicotinic acetylcholine 
receptors (nAChRs), increasing Ca2+ influx through these channels (Li et al., 2009, Demuro et 
al., 2010). Additional studies have shown that Aβ can cause the release of Ca2+ from internal 
stores through altering the sensitivity of inositol triphosphate receptor (IP3R) and ryanodine 
receptor (RyR) channels in the endoplasmic reticulum (Stutzmann et al., 2004, Bezprozvanny 
and Mattson, 2008).   
While a clear sequence of events following Aβ-induced Ca2+ dysregulation have yet to be 
established, both Aβ and increases in intracellular Ca2+ have been demonstrated to increase tau 
phosphorylation (Busciglio et al., 1995, Hartigan and Johnson, 1999, Zheng et al., 2002, Oliveira 
et al., 2015) and initiate neuronal apoptosis cascades (Loo et al., 1993, Mark et al., 1995). 
Identifying more of the key players in the Aβ cascade hypothesis will enhance our understanding 
of the disease process and shed light on possible therapeutic targets for intervention prior to 
cognitive impairment. 
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1.2 VILIP-1 
1.2.1 Structure and Function 
Neuronal calcium sensor (NCS) proteins are a large family of calcium-dependent molecular 
switches that modulate many intracellular signaling cascades involving neuronal functions like 
neurotransmitter release, receptor trafficking, and apoptosis. Visinin-like protein 1 (Vilip-1, gene 
name VSNL1) is an NCS protein that is highly and widely expressed throughout the brain. In the 
central and peripheral nervous systems, Vilip-1 expression is neuron specific (Bernstein et al., 
1999). One comprehensive study investigating Vilip-1 mRNA expression in the rat brain found 
robust VILIP-1 expression throughout all brain regions except in the caudate and putamen 
(Paterlini et al., 2000). Outside of the brain, Vilip-1 is present in the heart, liver, lungs, pancreas, 
skin, colon, and testis of the human and rat (Gierke et al., 2004). Vilip-1 expression in the adult 
brain is higher compared to embryonic development (Gierke et al., 2004). In mice, knocking out 
the VSNL1 gene is embryonic lethal. 
Vilip-1 belongs to the Vilip subfamily of NCS proteins. Members of the Vilip NCS 
subfamily share between 67 – 94 percent identical amino acids and include: Vilip-1, Vilip-2, 
Vilip-3, hippocalcin, and neurocalcin-δ (Braunewell and Klein-Szanto, 2009). The amino acid 
sequence for Vilip-1 is evolutionarily highly conserved, sharing 100% homology in mouse, rat, 
chicken, bovine, and human. Vilip-1 is 191 amino acids residues long. Like all NCS proteins in 
the Vilip subfamily, it contains 4 EF-hand binding domains: EF1 – EF4. Each EF-hand motif 
consists of a standard core of amino acids (D-X-D/N-X-D/N-X-Y-X4-E, where X is any amino 
acid) (Braunewell and Klein-Szanto, 2009). The first EF-hand contains the sequence CPXG, 
which eliminates its ability to bind Ca2+ (Li et al., 2011). EF-1 is also the most variable part of 
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the sequence in NCS proteins and is thought to be a point of interaction with other target 
proteins. At the N-terminus, Vilip-1 has an M-G-X3-S consensus sequence for myristoylation. 
Independent of Ca2+ and myristoylation, Vilip-1 forms a dimeric structure in solution (Li et al., 
2011). Upon binding two Ca2+ at EF-2 and EF-3, Vilip-1 undergoes a conformational change 
that exposes a hydrophobic myristoylated side chain region. The extrusion of the myristoyl group 
allows the protein to translocate and interact with cellular membrane compartments or target 
proteins (Spilker and Braunewell, 2003, Li et al., 2011).  Vilip-1 has a higher binding affinity for 
Ca2+ than calmodulin (Burgoyne and Weiss, 2001) and myristoylation lowers the binding affinity 
of Vilip-1 (Li et al., 2011). In culture after an increase in intracellular Ca2+ levels, Vilip-1 has 
been shown to reversibly translocate to subcellular membrane compartments, like the trans-Golgi 
membranes in hippocampal neurons (Spilker and Braunewell, 2003), and associate with cell 
surface membranes, including in dendrites and axons (Lin et al., 2002). This localization of 
Vilip-1 to the cell surface membrane is Ca2+ binding dependent (Spilker et al., 2002).  
Consistent with other subfamily members, Vilip-1 appears to modulate membrane 
trafficking, surface expression, and function of various ion channels and receptors including 
nicotinic acetylcholine receptors (nAChRs) (Lin et al., 2002, Zhao et al., 2009), receptor 
guanylyl cyclases (GC-B) (Brackmann et al., 2005), and adenosine triphosphate (ATP) receptor 
P2X2 (Chaumont et al., 2008).  Vilip-1 interacts with the cytoplasmic loop of the α4-subunit of 
the α4β2 nAChR, the most abundant nAChR subtype in the brain (Hogg et al., 2003, Zhao et al., 
2009). Coexpression of Vilip-1 with recombinant α4β2 nAChR in cell lines resulted in 
significant increases in receptor surface expression and sensitivity to acetylcholine. Additionally, 
mutating Vilip-1 in a way that renders the protein incapable of being myristoylated or binding 
Ca2+, thus losing its ability to associate with the cell membrane, attenuated Vilip-1’s ability to 
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interact and modulate α4β2 nAChRs (Lin et al., 2002). Overexpression of Vilip-1 in 
hippocampal neurons also leads to enhanced surface expression of nAChRs and increased 
responsiveness to acetylcholine. In contrast, siRNA knockdown of Vilip-1 leads to reduced α4β2 
nAChR currents (Zhao et al., 2009). Additionally, in at least some cases, such as with GC-B 
receptors Vilip-1 receptor modulation has been linked to clathrin-dependent receptor recycling 
(Brackmann et al., 2005).  However, whether Vilip-1 impacts synaptic plasticity, particularly in 
the setting of neurodegenerative disease is not known. 
Previous work has also suggested a role for Vilip-1 in cell death. Overexpression of 
Vilip-1 in PC12 cells increased death rates following a Ca2+ challenge (Schnurra et al., 2001). 
Hippocalcin, a highly homologous Vilip subfamily member has been shown to be 
neuroprotective against Ca2+-mediated death in neural cell lines, further connecting NCS proteins 
to neuronal death processes (Mercer et al., 2000).  
1.2.2 Vilip-1 and Alzheimer Disease 
Originally pioneered as an indicator of neuronal integrity for stroke, several studies have since 
identified Vilip-1 as a peripheral early stage AD biomarker. Findings in cerebrospinal fluid 
(CSF) and blood plasma showed Vilip-1 levels were elevated in individuals with AD compared 
to cognitively normal control subjects (Tarawneh et al., 2011). Additionally, CSF levels of Vilip-
1 were predictive of the progression of cognitive decline, with higher concentrations at time of 
collection indicating a more rapid loss in mental faculties over the duration of the illness 
(Tarawneh et al., 2012). Some studies suggest that the CSF elevation of Vilip-1 is specific to 
AD, as CSF collected from other neurodegenerative disorders, like Lewy Body dementia, show 
no change compared to cognitively normal controls (Tarawneh et al., 2011, Luo et al., 2013).  
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To date, there is limited information about the status of Vilip-1 in human AD brain tissue. 
Data from mRNA and protein studies suggests that Vilp-1 expression is decreased in the 
temporal cortex, parts of the limbic system, and the entorhinal cortex (Loring et al., 2001, 
Schnurra et al., 2001). In a whole-genome expression profiling study investigating the frontal 
cortex of AD subjects with varying degrees of disease severity, expression of Vilip-1 mRNA was 
shown to correlate with NFT burden and MMSE scores (Wilmot et al., 2008). In addition to the 
frontal cortex data, downregulation of Vilip-1 mRNA in the hippocampus has also been observed 
(Miller et al., 2008, Gomez Ravetti et al., 2010). Furthermore, qualitative immunohistochemistry 
data has suggested an association of Vilip-1 with neuritic plaques and neurofibrillary tangles in 
the neocortex of AD subjects (Schnurra et al., 2001).  
Recently, in a microarray study investigating VSNL1 expression in 209 cognitively 
normal subjects spanning the adult age range we found that VSNL1 is present and unaffected 
across the adult lifespan. In addition, VSNL is significantly coexpressed with genes related to 
AD pathways, including APP (Appendix B).  
Finally, genetics studies evaluating putative psychosis risk genes in AD with psychosis 
(AD+P), a phenotype of AD characterized by a more severe trajectory of cognitive deterioration 
than seen in AD subjects without psychosis (Murray et al., 2014b), have identified an association 
of VSNL1, the gene that encodes the protein Vilip-1 (Hollingworth et al., 2012). This data 
coincides with findings of reduced expression of VSNL1 mRNA and protein in the brain tissue 
of schizophrenia subjects (Martins-de-Souza et al., 2009, Braunewell et al., 2011).  
Collectively these findings suggest a role for Vilip-1 in the AD pathogenesis, but it is 
unknown to what extent it participates, particularly in regards to Aβ-mediated pathways. 
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1.3 GOALS AND RELEVANCE OF THIS DISSERTATION 
AD is a devastating neurodegenerative disease that is a top leading cause of death in the United 
States. Here in the General Introduction (Chapter 1.0), I have presented evidence that increased 
synaptic pathology and neuronal loss underlie cognitive decline in AD. Further, while the 
specific mechanisms underlying neuronal loss in AD are not fully understood, a growing pool of 
evidence implicates soluble amyloid-β (Aβ) oligomers as a primary neurotoxic agent.  Previous 
work has demonstrated that Aβ disrupts neuronal Ca2+ homeostasis, initiating a cascade of 
pathological events that ultimately culminate in widespread neuronal death. Recent human data 
has shown an association of neuronal calcium sensing protein Vilip-1 and AD. CSF and plasma 
Vilip-1 concentrations are elevated in AD subjects compared to cognitively normal control 
subjects. This CSF phenomenon appears to be AD-specific, as other neurodegenerative 
disorders, like FTLD, do not exhibit a change. In addition, Vilip-1 mRNA is significantly 
coexpressed with genes related to AD across normal aging, notably APP, which is cleaved in the 
pathogenesis of AD to form Aβ. Vilip-1 immunoreactivity also associates with neuritic plaques 
in the neocortex of the human AD brain. Finally, overexpression of Vilip-1 in PC12 cells 
increased death rates following a Ca2+ challenge suggesting Vilip-1 may play a functional role in 
neuronal loss.  
Based on this evidence, we proposed a model (Figure 1.1) where Vilip-1 protein 
expression is altered in response to Aβ, increasing vulnerability to Aβ-induced neuronal death in 
AD. Understanding the distinct causal neurobiological factors, like the role of Vilip-1 in AD, 
will lead to improved therapeutic strategies and profoundly impact patients, caregivers, and 
society as a whole.  
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The purpose of this dissertation is to determine how Vilip-1 is altered in the AD brain and 
whether it is actively participating in the process of Aβ-initiated neuronal loss. This dissertation 
aims to address this purpose by answering the following questions: 1) Are Vilip-1 levels altered 
in the brain tissue of individuals with Alzheimer disease? (Chapter 2.0); 2) Does Aβ cause 
increased Vilip-1 expression in model systems? (Chapter 3.0); 3) Are rates of Aβ-induced 
neuronal death influenced by neuronal Vilip-1 expression level? (Chapter 4.0).  
 
 
Figure 1.1 Proposed model of Vilip-1 interactions in AD. Vilip-1 protein expression is altered in response to Aβ, 
increasing vulnerability to Aβ-induced neuronal death in AD and resulting in Vilip-1 release into the CSF. Solid 
lines are established in the literature and dashed lines are hypothesized based on supportive preliminary data.  
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2.0  VILIP-1 LEVELS ARE ALTERED IN THE BRAIN TISSUE OF INDIVIDUALS 
WITH ALZHEIMER DISEASE 
2.1 ABSTRACT 
Recent studies have implicated the neuronal calcium-sensing protein visinin-like 1 protein 
(Vilip-1) as a peripheral biomarker in Alzheimer disease (AD), however little is known about 
expression of Vilip-1 in the AD brain. We used targeted and quantitative mass spectrometry to 
measure Vilip-1 peptide levels in early to moderate stage AD within two brain regions of varying 
neuronal loss: the entorhinal cortex (ERC) and the superior frontal gyrus (SF). In an initial cohort 
of 12 AD subjects and 12 normal controls, we found Vilip-1 levels were significantly lower in 
the ERC, a region with prominent neuronal death even at early stages of the disease. However, in 
the SF, a region with lower levels of neuronal loss, Vilip-1 levels did not differ from normal 
control subjects. Additionally, in a group of frontotemporal lobar degeneration (FTLD) subjects 
(n = 10), Vilip-1 levels in the SF were significantly lower compared to normal controls, 
suggesting a potential role for Vilip-1 as a neuronal integrity biomarker, at least within ERC. 
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2.2 INTRODUCTION 
Alzheimer disease (AD) is the leading cause of dementia in the United States affecting more than 
5 million people. Clinically, this progressive neurodegenerative disease is characterized by loss 
of memory, decline in cognitive abilities, and behavioral changes that worsen over time. 
Neuropathologically, AD is classified by two major hallmarks: extracellular amyloid plaques 
comprised of the amyloid-β (Aβ) peptide and intracellular neurofibrillary tangles composed of 
hyperphosphorylated tau protein (Selkoe, 2004, Ballatore et al., 2007). In addition to 
accumulating protein aggregates, AD also exhibits gross anatomical changes, such as dramatic 
shrinkage of the brain tissue that results from prominent neuronal death, synapse loss, and gliosis 
(Gomez-Isla et al., 1996, Ingelsson et al., 2004). 
Several studies have identified the primarily brain-expressed neuronal calcium sensing 
protein, visinin-like protein 1 (Vilip-1), as a peripheral early stage AD biomarker. Findings in 
cerebrospinal fluid (CSF) and plasma showed Vilip-1 levels were elevated in individuals with 
AD compared to cognitively normal control subjects (Tarawneh et al., 2011). Additionally, CSF 
levels of Vilip-1 were predictive of the progression of cognitive decline, with higher 
concentrations at time of collection indicating a more rapid loss in mental faculties over the 
duration of the illness. Some studies suggest that Vilip-1 CSF elevation phenomenon is specific 
to AD, as CSF collected from other neurodegenerative disorders, like Lewy Body dementia, 
show no change compared to cognitively normal controls (Tarawneh et al., 2011, Luo et al., 
2013).  
Recently we have shown mRNA evidence for VSNL1, the gene that encodes the Vilip-1 
protein, is significantly coexpressed with genes related to AD pathways, such as amyloid 
precursor protein (APP), throughout normal aging (Appendix B) (Lin et al., 2015). Furthermore, 
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qualitative immunohistochemistry data has suggested an association of Vilip-1 with neuritic 
plaques and neurofibrillary tangles in the neocortex of AD subjects (Schnurra et al., 2001). 
However, to date, relatively little is known about the levels of Vilip-1 in AD brain tissue.  
Additionally there is limited data indicating a potential a role for Vilip-1 in cell death. 
One previous study found that overexpression of Vilip-1 in PC12 cells increased cell death in 
response to a calcium challenge (Schnurra et al., 2001).  
Based on these studies, we hypothesized that Vilip-1 would be altered in the brain tissue 
of AD and associated with neuronal loss. To test this hypothesis we examined two different brain 
regions (ERC and SF) of early to moderate stage AD subjects. We found that Vilip-1 levels were 
decreased in the entorhinal cortex (ERC) of AD subjects and unchanged in the superior frontal 
gyrus (SF) compared to normal controls. In the SF, the primarily affected area in another 
neurodegenerative disease, frontotemporal lobar degeneration (FTLD), subjects had significantly 
lower levels of Vilip-1 compared to normal controls, suggesting that decreased Vilip-1 levels 
may reflect neuronal loss. 
2.3 METHODS 
2.3.1 Subjects 
2.3.1.1 AD subjects & FTLD subjects. Fifty-eight AD subjects and 10 FTLD subjects (Table 2) 
were identified through the brain bank of the Alzheimer Disease Research Center (ADRC) at the 
University of Pittsburgh, using protocols approved by the University of Pittsburgh Institutional 
Review Board and Committee for Oversight of Research Involving the Dead. Individuals 
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underwent neurologic, neuropsychological, and psychiatric diagnostic evaluations at successive 
time points as part of the participation in the Clinical Core of the ADRC as previously described 
(Sweet et al., 2000, Lopez et al., 2013).  
Postmortem interval (PMI) was recorded at the time of brain removal. At autopsy, the 
brain was removed intact, examined grossly, and divided in the midsagittal plane. Gray matter 
samples from the right entorhinal cortex (ERC) and superior frontal gyrus (SF) were dissected 
and frozen at −80°C. The left hemibrain was immersion fixed in 10% buffered formalin for at 
least one week, sectioned into 1.0 cm coronal slabs, and sampled according to CERAD protocol 
for neuropathological diagnosis of AD. AD pathology was evaluated using modified 
Bielschowsky silver stain and immunohistochemical staining for tau and beta-amyloid (4G8. 
Neuritic plaque density was assessed according to CERAD criteria (Mirra et al., 1991); 
distribution of tau pathology was classified according to Braak stages (Braak et al., 2006). Lewy 
body pathology was assessed by alpha-synuclein immunohistochemistry and classified into 
brainstem-predominant, limbic and neocortical types following consensus criteria (McKeith et 
al., 2005).   Immunohistochemical staining for TDP-43 was performed on sections of middle 
frontal gyrus and mesial temporal lobe as previously described (Vatsavayi et al., 2014). Sections 
were evaluated for the absence or presence of TDP-43 positive neuronal cytoplasmic inclusions, 
neuronal intranuclear inclusions and dystrophic neurites.   
Neuropathologic diagnoses of Alzheimer disease were made according to CERAD 
criteria (Mirra et al., 1991), although all AD subjects also met NIA-Reagan criteria (Hyman and 
Trojanowski, 1997) for intermediate to high probability that their dementia was due to AD 
lesions. Neuropathologic diagnosis of FTLD-TDP, FTLD-FUS or FTLD-tau was determined 
following consensus criteria (Cairns et al., 2007, Mackenzie et al., 2010, Mackenzie et al., 2011). 
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When TDP pathology was present in cases that fulfilled diagnostic criteria for another 
neurodegenerative disease, no distinct diagnosis of FTLD-TDP was rendered following 
consensus recommendations (Mackenzie et al., 2009). 
2.3.1.2 Normal control subjects. Two normal control subject brain specimens were obtained 
through the ADRC as described above. The remaining 10 normal control subject brain specimens 
were obtained through the Allegheny County Medical Examiner’s Office, with consent obtained 
from the subjects’ next-of-kin. The protocol used to obtain consent was approved by the 
University of Pittsburgh Institutional Review Board and Committee for Oversight of Research 
Involving the Dead. An independent committee of experienced clinicians made consensus DSM-
IV diagnoses for each subject, using information obtained from clinical records and structured 
interviews with surviving relatives. Samples from subjects without any DSM-IV diagnosis (i.e. 
including no diagnosis of a cognitive disorder) were used in this study.  
The right hemisphere was blocked coronally at 1-2 cm intervals and the resultant slabs 
snap frozen in 2-methyl butane on dry ice, and stored at -80°C. Samples from the frontal pole, 
hippocampus, ERC, and cerebellum were collected and an experienced neuropathologist 
reviewed sections stained using hematoxylin and eosin, Bielschowsky silver stain, amyloid β 
immunohistochemistry, and alpha-synuclein immunohistochemistry were determined to be 
without evidence of any neurodegenerative disease. Tissue slabs containing either the SF 
immediately caudal to the genu of the corpus collosum or the ERC were indentified. From these 
slabs, SF and ERC were removed as single blocks. Gray matter was collected by cutting 40 μM 
sections and frozen at −80°C.  
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Table 2.1 Descriptive information of subjects in Cohort 1. Mean values ± SD or number of subjects with 
percentage of group in parentheses. Groups not sharing superscript letters differ significantly on these variables. 
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Table 2.2 Descriptive information of subjects in Cohort 2. This expanded cohort contains all subjects from Cohort 1 
with an additional 46 AD subjects. 
 
It is of note that AD and FTLD subjects had significantly lower postmortem intervals 
(PMIs) than normal controls. However, using quantitative Western blot, we have previously 
established the stability of Vilip-1 protein across a 48-hour PMI in a mouse model (Figure 2.1), 
and therefore did not match subjects groups on PMI. 
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Figure 2.1 Postmortem interval (PMI) of Vilip-1 expression from mouse whole brain homogenate. ANOVA 
analysis of Vilip-1 protein levels normalized to tubulin showed no significant change over 48 hours (p = 0.952). 
2.3.2 Sample Preparation 
Tissue homogenates were prepared from fresh frozen human SF and ERC gray matter. Total 
protein was extracted using SDS extraction buffer (0.125 M Tris – HCl (pH 7), 2% SDS, and 
10% glycerol) at 70°C. Using bicinchoninic acid assay (Micro BCATM Protein Assay, Pierce) 
protein concentration was measured. A pooled technical replicate sample composed of 
homogenate aliquots from all subjects was also prepared for each experiment (SF and ERC). 20 
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ug of total protein from the gray matter homogenate or pooled sample was mixed with Lysine 
13C6 Stable Isotope Labeled Neuronal Proteome Standard (13C6 STD; 20 ug) for on gel trypsin 
digestion. To evenly distribute AD, FTLD, and normal control subjects throughout preparation, 
on-gel digestion, and analysis, samples were organized in a block distribution. For the SF 
experiment, each block was composed of 7 subjects and one pooled technical replicate, for a 
total of 12 blocks. For the ERC experiment each block was also composed of 7 subjects and one 
pooled technical replicate, for a total of 4 blocks. Each block was run on a single 10 well 4-12% 
BisTris gel with two SeeBlue® Plus2 Pre-stained Protein Standards. On-gel trypsin digestion 
was performed as previously described (MacDonald et al., 2012) with samples being run 4 cm 
into the gel and divided into two fractions (above and below 65kd). 
2.3.3 LC-SRM/MS 
Vilip-1 and MAP2 peptides were selected for analysis based on the presence of a lysine, the 
amino acid labeled in the 13C6STD, and 100% homology across mouse and human sequences 
(determined by Uniprot BLAST search). Five peptide sequences were identified from the Vilip-1 
protein for quantification as indicated as underlined text in the following Vilip-1 amino acid 
sequence:  
MGKQNSKLAPEVMEDLVKSTEFNEHELKQWYKGFLKDCPSGRLNLEEFQ
QLYVKFFPYGDASKFAQHAFRTFDKNGDGTIDFREFICALSITSRGSFEQK
LNWAFNMYDLDGDGKITRVEMLEIIEAIYKMVGTVIMMKMNEDGLTPEQ
RVDKIFSKMDKNKDDQITLDEFKEAAKSDPSIVLLLQCDIQK 
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Additionally, four peptide sequences were identified from the microtubule-associated 
protein 2 (MAP2) protein for quantification (Figure 2.2) to assess neuronal loss.  
 LC-SRM/MS analyses were conducted as previously described. (MacDonald et al., 2012) 
In brief, peptide peaks were detected using a TSQ Quantiva triple stage quadrupole mass 
spectrometer (Thermo Scientific) with an UltiMate 3000 Nano LC Systems (Thermo scientific). 
2 μl (~1 μg protein) of sample was loaded/desalted on a PepMap100 Nano-Trap column (Thermo 
scientific) at 8 μl/min for 2 min and separated on a Reprosil-pur 3 µm PicoChip column (New 
Objective) at 400 nl/min over a 20 min gradient from 2-35% mobile phase B (Acetonitrile 
containing 0.1% formic acid). SRM transitions were timed using 1.5 min retention windows.  
Transitions were monitored, allowing for a cycle time of 1 sec, resulting in a dynamic dwell 
time, never falling below 2 msec.  The MS instrument parameters were as follows: capillary 
temperature 275 °C, spray voltage 1100 V, and a collision gas of 1.4 mTorr (argon).  The 
resolving power of the instrument was set to 0.7 Da (Full Width Half Maximum) for the first and 
third quadrupole. All samples were analyzed in triplicate. Using Skyline, integrated peak areas 
for both “light” human peptides and the “heavy” 13C6STD peptides were calculated for each of 
the peptide sequences. The light:heavy integrated area ratio was calculated to obtain peptide 
measures using multiple transitions per peptide.  
 
Figure 2.2 Two peptide sequences were identified for LC-SRM/MS quantification as shown in their 
respective locations within the MAP2 protein. (Modified from (Shelton et al., 2015)) 
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2.3.4 Measurement of soluble Aβ and phospho-tau by sandwich enzyme-linked 
immunosorbent assay 
Levels of soluble Aβ1-40 and Aβ1-42 and of tau protein had been previously performed in a subset 
of study subjects. (Murray et al., 2012, Koppel et al., 2014) Briefly, Aβ1-40 and Aβ1-42 levels were 
quantified from SF gray matter brain tissue samples that were homogenized on ice in phosphate-
buffered saline (PBS; 150 mg/mL). Samples were then rehomogenized in tissue homogenization 
buffer (250 mM sucrose, 20 mM Tris base, and 10 μL Sigma P8340 protease inhibitor cocktail 
[Sigma-Aldrich, St. Louis, Missouri, USA]) and prepared in diethylamine (DEA)-soluble 
fractions for Aβ1-40 and Aβ1-42 peptide concentration quantification as described previously 
(Ikonomovic et al., 2008). The DEA-soluble fraction was prepared by centrifuging the 
homogenate aliquot at 135,000 x g at 4 °C for 1 hour followed by neutralizing the supernatant 
with 0.5 M Tris-Cl. Colorimetric 3,3′,5,5′-tetramethylbenzidine (TMB)-based ELISA 
(Invitrogen, Carlsbad, California) was used to measure Aβ concentrations. Capture antibodies 
specific for the NH2 terminus of human Aβ (amino acids 1-16) and neoepitopes at either the 40- 
or the 42-amino acid COOH-terminus of Aβ were used to detect peptide levels and 
measurements were read at 450 nm. Peptide concentration values were extrapolated using 
standard curves generated by synthetic Aβ peptide (Invitrogen, Carlsbad, California) and 
expressed as picomoles per gram wet brain tissue.  
Levels of tau were quantified as previously described.(Acker et al., 2013) Briefly, SF 
gray matter brain tissue samples were homogenized in a Tris-buffer saline solution (pH 7.4) 
containing 10 mM NaF, 1 mM NaVO3 and 2 mM EGTA with a complete Mini protease 
inhibitor (Roche). Prior to use, samples were stored at – 80 °C. For analysis, thawed 
homogenates, spun at 14,000 g for 10 minutes at 4 °C, were diluted in 20% superblock in 1 x 
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Tris-buffered saline (TheroScientific). Sandwich enzyme linked immunosorbent assay (ELISA) 
measurements using monoclonal antibodies targeted against different forms of tau and phospho-
tau were performed for quantification of tau peptide concentrations. Capture antibodies DA31 
(amino acids 150-190), PHF1 (pSer396/404), CP13 (pSer202), and RZ3 (pThr231) were used at 
a concentration of 6 μg/mL in 4 separate ELISA measurements. DA31 was used to measure 
peptide concentrations of total tau. PHF-1 is used to quantify Ser396/404 phospho-tau 
(pSer396/404), a form of phosphorylated tau that is present in early and late Braak stages and is 
observed in a range of early to mature tau aggregates (Mondragon-Rodriguez et al., 2014). CP13 
was used to quantify Ser202 phospho-tau that is detected in early neuritic pathology (Janocko et 
al., 2012). RZ3 was used to quantify Thr231 phospho-tau, a conformational epitope often 
phosphorylated even in pretangles (Augustinack et al., 2002). Detection antibody DA9-HRP 
(amino acids 102-140) was used at a concentration of 0.3 μg/mL for all assays. 
ELISAs were performed in 96-well plates coated with capture antibodies at a 
concentration of 6 mg/mL in coating buffer for at least 48 hours at 4 °C. To avoid non-specific 
binding, plates were washed 3 x in wash buffer and blocked for 1 hour at room temperature using 
StartingBlock (Thermoscientific). 50 μL of SF brain tissue sample was combined with 50 μL of 
DA9-HRP detection antibody and added to the appropriate well. Plates were incubated overnight 
shaking at 4 °C. The following day wells were washed 9 x in wash buffer and 1-Step ULTRA 
TMB-ELISA (Thermoscientific) was added for 30 minutes at room temperature before stopping 
the reaction with 2 M H2SO4. Plates were read with an Infinite m200 plate reader (Tecan) at 450 
nm. 
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2.3.5 Statistical Analysis 
All light:heavy ratios were log2 transformed for statistical analysis. Replicate peptide values 
were averaged prior to analysis. Assessment of demographic, clinical, and pathological 
differences between groups was performed using analysis of variance (ANOVA), t-tests, and χ2 
tests. Initial comparison of Vilip-1 and MAP2 peptide levels between AD subjects and normal 
control subjects used independent samples T-tests for both the ERC and SF regions. A repeated 
measure ANOVA was employed to evaluate the brain region by diagnosis interaction. In the SF 
region, ANCOVA was used to assess whether demographic, clinical, and pathological subgroups 
affected individual Vilip-1 and MAP2 peptide levels. 
2.4 RESULTS 
2.4.1 Alterations in VILIP-1 levels in brain regions with and without prominent cell death  
In an initial comparison of 12 AD subjects and 12 cognitively normal control subjects (Table 
2.1), Vilip-1 levels were assessed in two brain regions: ERC and SF. The ERC is a brain region 
with prominent cell death in AD, including in earlier disease stages, whereas the SF has 
comparatively little neuronal loss in AD. Vilip-1 peptide levels in the ERC were significantly 
decreased in AD subjects compared to cognitively normal controls (Figure 2.3; Table 2.3). 
However, in the SF, Vilip-1 levels were not significantly different from cognitively normal 
controls. Additionally, for three of the five Vilip-1 peptides (STE, LNL, and LNW), there was a 
significant region by diagnosis interaction (Figure 2.3; Table 2.3).  
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Figure 2.3 Log2-transformed expression ratios of a representative peptide, Vilip-1 (LNW), in the entorhinal cortex 
(ERC) and the superior frontal gyrus (SF) comparing AD subjects (n =12) and cognitively normal control subjects 
(n=12). * indicates p < 0.05. 
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Table 2.3 Summary of Vilip-1 peptide expression in ERC and SF brain regions and the effect of region by diagnosis 
from 34-subject Cohort 1 (AD: n = 12; cognitively normal control: n = 12; FTLD: n = 10) 
 
Because the restriction of the observed decrease in Vilip-1 levels to the ERC suggested it 
resulted from neurodegeneration rather than a specific AD-related pathology, we analyzed Vilip-
1 peptide levels from FTLD subjects (Table 2.1) in the SF, a brain region that in FTLD is 
primarily affected by widespread neuronal loss, and found that SF Vilip-1 levels in FTLD were 
significantly lower than in cognitively normal controls (Figure 2.3; Table 2.4). 
 
Table 2.4 Summary Vilip-1 peptide expression diagnosis differences from expanded AD subject group (n = 58) in 
comparison to FTLD (n = 10) and cognitively normal controls (n = 12). 
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 To confirm this interpretation, we assessed levels of MAP2, a marker that is reduced by 
neuron loss (Huh et al., 2003) in the ERC and SF of all subjects. MAP2 levels were significantly 
decreased in ERC of AD subjects compared to normal controls (all p < 0.001; Table 2.5), and 
decreases in the ERC exceeded those in the SF of these subjects. In the SF of the expanded 
cohort of subjects, the magnitude of reduction in MAP2 levels was greater in FTLD subjects than 
in AD (Table 2.6).  
Table 2.5 Summary of MAP2 peptide expression in ERC and SF brain regions and the effect of region by diagnosis 
from 34-subject Cohort 1 (AD: n = 12; cognitively normal control: n = 12; FTLD: n = 10) 
 
 
Table 2.6 Summary MAP2 peptide expression diagnosis differences from expanded AD subject group (n = 58) in 
comparison to FTLD (n = 10) and cognitively normal controls (n = 12) 
 
2.4.2 VILIP-1 levels in SF of AD subjects and indicators of disease severity 
We examined SF Vilip-1 levels in an expanded group of AD subjects (Table 2.2) to assess 
whether indicators of greater disease severity would be associated with reduced SF Vilip-1 in 
AD. In this expanded group the comparison of Vilip-1 peptide levels to controls remained non-
significant (all p > 0.1). No association was observed between increasing Braak stage and Vilip-1 
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levels in the SF of AD (Figure 2.4). Nor were Vilip-1 levels in the SF correlated with levels of 
soluble Aβ1-42, Aβ1-40, total tau or phosphorylated tau (Figure 2.5). Additionally, history of 
psychosis, Lewy body stage, Mini–Mental State Examination (MMSE) score at death, age at 
death, age of disease onset, and duration of illness were not significantly associated with SF 
Vilip-1 levels (Figure 2.4).  
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Figure 2.4 Log2-transformed expression ratios of a representative peptide, Vilip-1 (LNW), in the superior frontal 
gyrus (SF) of AD subjects (n=58,Table 2) looking at (A) Braak stage, (B) Psychosis status in Alzheimer disease, (C) 
Lewy body pathologic stage, (D) Mini-Mental State Examination, (E) Age at death, (F) Age of disease Onset, and 
(G) Disease duration.  
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Figure 2.5 Correlation of log2-transformed expression ratios of a representative peptide, Vilip-1 (LNW), in the 
superior frontal gyrus (SF) of AD subjects with (A) Aβ1-42, (B) Aβ1-40, (C) DA31, (D) CP13, (E) PHF-1, and (F) 
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RZ3. For soluble Aβ1-42 and Aβ1-40 data was available for 23 AD subjects. For total and phosphotau measures, data 
was available for 53 AD subjects. 
2.5 DISCUSSION 
We evaluated the hypothesis that Vilip-1 is altered in AD and associated with neurodegeneration 
by assessing Vilip-1 brain protein levels in two different regions with varying degrees of 
neuronal loss.  We found Vilip-1 levels were decreased in the ERC of AD subjects, an area of 
prominent neuronal loss even at early stages of the disease. However, in the SF, an area with 
comparatively less neuronal loss in early to moderate disease stages, Vilip-1 levels did not differ 
from normal control subjects. In contrast, FTLD is characterized by profound neuronal loss in 
the frontal and temporal lobes of the brain. Vilip-1 levels in the SF were decreased in these 
subjects. Additionally, in an expanded group of AD subjects, Vilip-1 levels in the SF did not 
associate with other indicators of disease severity including Braak stage, soluble Aβ1-42, Aβ1-40, 
total and phosphorylated tau levels. These findings provide evidence that Vilip-1 is altered in AD 
and may be more closely associated with neuronal loss than with upstream pathologies such as 
Aβ and phosphorylated tau accumulation or synaptic pathology. 
Recent studies have identified a potential role for Vilip-1 as a biomarker in AD. CSF and 
plasma Vilip-1 levels have been shown to be elevated in mild cognitive impairment and AD 
compared to normal control subjects (Lee et al., 2008, Tarawneh et al., 2011, Mroczko et al., 
2015). Additionally, Vilip-1 CSF levels were predictive of progressive cognitive decline, as 
higher Vilip-1 levels indicate a more rapid deterioration in cognitive performance (Tarawneh et 
al., 2012, Fagan et al., 2014, Mroczko et al., 2015). While CSF Vilip-1 levels are elevated in AD, 
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our findings, which are the first reported quantitative levels of Vilip-1 in human brain tissue, 
indicate decreased levels of Vilip-1 in the ERC of AD subjects. Many different scenarios may 
explain this disparity between elevated CSF and decreased brain levels. The most parsimonious 
explanation is that as ERC neurons die, intraneuronal Vilip-1 is released into the interstitium and 
reaches the CSF. For example, Vilip-1 has also been shown to be elevated in the CSF of a rat 
model of stroke and within the plasma of patients after stroke (Laterza et al., 2006, Stejskal et al., 
2011).  
Further CSF findings have suggested a disease-specific association of Vilip-1 by showing 
increased Vilip-1 levels in AD compared to other non-AD dementia subjects, including 
individuals with FTLD, progressive supranuclear palsy, and Lewy body dementia (Tarawneh et 
al., 2011). In contrast to CSF, we have shown that in SF brain tissue, Vilip-1 levels were 
unaffected in AD and significantly decreased in FTLD subjects compared to normal control 
subjects. Without having measurements from a neuropathologically verified population of FTLD 
subjects it is difficult to know for certain whether CSF Vilip-1 levels are unchanged in this 
neurodegenerative disorder. Future CSF studies involving larger numbers of FTLD subjects will 
be necessary to definitively determine that CSF Vilip-1 is not increased in FTLD. Confirming 
this discrepancy between CSF and brain findings in AD and FTLD would support further 
evaluation of additional mechanisms including: active secretion of Vilip-1 into the CSF from the 
ERC in AD; poor clearance of Vilip-1 from the CSF in AD, or; Vilip-1 released from ERC 
neurons has more direct influence on the CSF compartment sampled by lumbar puncture than 
when released from SF neurons. 
Previous reports have qualitatively described Vilip-1 associating with other AD 
pathologies, like neuritic plaques and neurofibrillary tangles in the neocortex (Braunewell et al., 
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2001a) and shown correlations with CSF levels of tau and phosphorylated tau (Tarawneh et al., 
2011). Others have indicated that Vilip-1 may play an active role in tau phosphorylation 
(Schnurra et al., 2001). However, we found that Vilip-1 levels in the SF did not correlate with 
any indicators of disease severity including Braak stage, soluble Aβ1-42, Aβ1-40, total or 
phosphorylated tau levels. The discrepancy between findings may be in part due to the approach 
used. We used quantitative LC-SRM/MS of gray matter brain homogenate to measure total 
levels of Vilip-1 peptide in brain tissue, an approach that allowed for simultaneous measurement 
and quantification of five Vilip-1 peptides with high precision and reproducibility. Peptide 
detection was linear and over repeated runs we observed low variability in peptide measures. 
Similarly, we used a highly specific ELISA assay to measure total and phosphorylated tau with 
multiple antibodies. In contrast, the prior finding indicating an association of Vilip-1 with tau 
pathology used qualitative immunohistochemistry (IHC) (Braunewell et al., 2001a), and thus 
could not speak to the amount of Vilip-1 present. Additionally, albeit only an indirect indicator 
of increased tau pathology, psychosis status in AD was not associated with altered Vilip-1 levels 
in our cohort (Murray et al., 2014b). 
 One potential limitation of this study was the significantly younger normal control group. 
We opted to utilize a neuropathologically normal control group, as previous Western blot data 
from our laboratory (not shown) has suggested decreased levels of Vilip-1 in controls with some 
level of neuropathology, such as mesial temporal sclerosis and cerebrovascular disease, despite 
no clinical diagnosis of a cognitive disorder. Additionally, selection of age-matched control 
subjects is complicated as many biomarker and neuroimaging studies have demonstrated that the 
AD disease process can begin decades prior to the emergence of cognitive symptoms (Resnick et 
al., 2010, Tosun et al., 2013). Thus to obtain neuropathologically normal subjects, many subjects 
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of advanced ages similar to the AD group did not meet this criteria.  Despite these obstacles in 
selecting a proper control group, several observations make it unlikely that age is associated with 
the alterations we observed in Vilip-1. First, it would be difficult to explain an age effect that led 
to differential expression of Vilip-1 only in the ERC, but not SF, of the same subjects. Second, 
we have shown using mRNA microarray analysis of cognitively normal adults that VSNL1 is 
unaffected by age across the adult lifespan (Appendix B) (Lin et al., 2015). Finally, our FTLD 
subjects were substantially younger than our AD cohort, yet still had significantly different 
Vilip-1 protein levels compared to controls. Another potential confound in human tissue studies 
is matching normal control subjects as closely as possible on PMI. Our study included AD with 
significantly lower PMIs than normal controls, however we previously established the stability 
of Vilip-1 protein across a 48-hour PMI in a mouse model (Figure 2.1), a much greater range 
than in the current study. Moreover, as for age difference, it would be difficult to reconcile a PMI 
effect with differential expression of Vilip-1 only in the ERC, but not SF, of the same subject 
pairs.  
Neuronal loss occurs prominently in the ERC of AD subjects and the SF of FTLD 
subjects (Gomez-Isla et al., 1996, Cairns et al., 2003). Conversely, despite reductions in cortical 
volume, stereological studies have found no global change in neuron number within the 
neocortex of females with severe AD (Regeur et al., 1994). As a confirmatory measure to assess 
neuronal loss with the ERC and SF brain regions in our study, we measured MAP2 peptide 
levels. MAP2 is a neuron-specific protein that interacts with microtubules and the cell 
cytoskeleton (Dehmelt and Halpain, 2005). Being among the most vulnerable cytoskeletal 
proteins, MAP2 immunoreactivity is lost in neuronal death (Huh et al., 2003). We found that 
MAP2 levels were significantly decreased in the ERC of AD subjects compared to normal 
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controls. MAP2 levels were also down in the SF of AD subjects compared to normal controls, 
however, in FTLD subjects the magnitude of reduction was greater, suggesting a larger amount 
of neuronal loss in FTLD compared to AD. In addition, our lab has previously reported that 
MAP2 peptide levels are unchanged in schizophrenia subjects, a disease without neuronal loss 
(Shelton et al., 2015).  
 Our findings of decreased Vilip-1 expression levels in brain regions with prominent cell 
death in both AD and FTLD, but not in the SF of AD where cell death is more limited suggest 
that Vilip-1 may serve as a neuronal integrity biomarker, at least within ERC. The role of Vilip-1 
in cell death, whether it is an active participant in the process or an innocent bystander, requires 
further investigation. For example, prior reports have shown that expression of Vilip-1 in PC12 
cells reduced cell survival rate compared to untransfected cells. When transfected cells were 
exposed to ionomycin, a known neurotoxic reagent that increases intracellular calcium 
concentration, an even higher cell death rate was observed, indicating a role for Vilip-1 in Ca2+-
mediated cell death (Schnurra et al., 2001). Future studies using in vitro techniques and animal 
models of Aβ overproduction will help clarify the role of Vilip-1 in AD-related neuronal death. 
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3.0  THE IMPACT OF AΒ ON VILIP-1 EXPRESSION  
3.1 ABSTRACT 
Soluble Aβ oligomers are widely considered to have a central etiological role in Alzheimer 
disease, binding synapses and initiating a cascade of neurotoxic events in the cells that culminate 
in neuron death. Recently, we have shown that mRNA for VSNL1, the gene that encodes the 
protein Vilip-1, a peripheral early stage biomarker for Alzheimer disease (AD), is coexpressed 
with genes associated with AD throughout normal aging. Notably, the gene that encodes the 
amyloid precursor protein, which is cleaved to form Aβ peptide, is correlated with the Vilip-1 
mRNA expression. Additionally, Vilip-1 has been shown to associate with neuritic plaques in 
AD brain tissue. However, whether Aβ impacts Vilip-1 expression is unknown. To assess the 
effect of Aβ on Vilip-1 expression we used two model systems: a transgenic mouse model of 
Aβ-overexpression and exogenous Aβ exposure in primary cortical neuronal cultures. We found 
that Vilip-1 expression was unchanged in both systems by the presence of Aβ peptide. 
3.2 INTRODUCTION 
The amyloid-β (Aβ) peptide chiefly comprises extracellular amyloid plaques, one of the major 
neuropathological hallmarks in Alzheimer disease (AD). Soluble Aβ oligomers have been 
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strongly implicated in the pathogenesis of AD and are posited to initiate a cascade of 
pathological events that involve neuronal Ca2+ dysregulation, synaptic impairment and 
dysfunction, loss of dendritic spines, tau phosphorylation and aggregation, and ultimately 
neuronal death.  
 Visinin-like protein 1 (VILIP-1) is a primarily brain-expressed neuronal calcium-sensing 
protein that has recently been identified by a number of studies as a peripheral early stage 
biomarker in AD. Individuals with AD have elevated levels of Vilip-1 in their cerebrospinal fluid 
(CSF) that correlate with measures of amyloid load in the brain (Tarawneh et al., 2011). 
Recently, in an mRNA microarray study examining expression of VSNL1, the gene that encodes 
for the Vilip-1 protein, we showed that VSNL1 is coexpresses with genes associated with AD 
across normal aging (Appendix B) (Lin et al., 2015). This included a high degree of correlation 
of VSNL1 expression with that of amyloid precursor protein (APP) (Appendix B) (Lin et al., 
2015). Additionally, qualitative immunohistochemistry data from AD subjects has suggested an 
association between Vilip-1 and neuritic plaques in several neocortical brain regions (Braunewell 
et al., 2001a). However, whether amyloid overexpression and exposure to soluble Aβ can induce 
elevations in Vilip-1 is not known. 
In the present study, we hypothesized that Vilip-1 expression would be increased in the 
presence of Aβ peptides. Using two model systems to evaluate this relationship, a mouse model 
of Aβ-overexpression and primary cortical neuronal cultures treated with Aβ peptide, we found 
that Vilip-1 expression is unchanged by the presence of Aβ peptide.  
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3.3 METHODS 
3.3.1 Experimental Animals 
3.3.1.1 B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax mouse model. Six-month-old double 
transgenic B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax (PSAPP; n = 5) and wild-type (n = 5) 
male mice were studied. Double transgenic PSAPP (The Jackson Laboratory, Bar Harbor, 
Maine; Catalog #: 005864) and wild-type mice for study were generated by mating male PSAPP 
mice with female kalirin heterozygous mice that were generated as previously described by 
inserting the neomycin resistance cassette in place of exons 27-28 (Cahill et al., 2009) and 
subsequently maintained on a C57BL/6NJ background. PSAPP mice express chimeric 
mouse/human amyloid precursor protein carrying a mutation linked to familial AD 
(Mo/HuAPP695swe) and a mutant human presenilin 1 (PSEN1dE9), which is also linked to 
familial AD (Hardy, 1997). The double transgenic increases the ratio of Aβ1-42:Aβ1-40 as 
compared to mice carrying the APPswe mutation alone (Jankowsky et al., 2004). Both mutations 
are under the control of the mouse prion protein promoter, which directs transgene expression 
largely to central nervous system neurons.  PSAPP mice show detectable Aβ deposits by 4 
months of age and an overall increase in levels of soluble and insoluble levels of two Aβ 
isoforms (Aβ1-40 and Aβ1-42) by twelve months of age, with Aβ1-42 being the predominantly 
expressed Aβ species (Garcia-Alloza et al., 2006). In Figure 3.1, we demonstrate an increase in 
6E10 antibody immunoreactivity (directed against the N-terminus of human Aβ peptide; 
biotinylated, SIG-39340; Covance, Emeryville, CA) in the PSAPP genotype in comparison to 
wild type. Behaviorally, by 6 months mutant mice have learning and memory deficits compared 
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to wild-type littermates (Gimbel et al., 2010, Phillips et al., 2011). All studies were approved by 
the University of Pittsburgh Institutional Animal Care and Use Committee.  
3.3.1.2 C57BL/6NJ. Primary neuronal culture experiments were performed on newborn (P0) 
C57BL/6NJ mice (The Jackson Laboratory, Bar Harbor, Maine). 
 
 
Figure 3.1 Representative 6E10 Western blot of 6-month-old wild type brain tissue versus PSAPP. A marked 
increase in APP expression is observed within the PSAPP animals. 
3.3.2 LC-SRM/MS 
3.3.2.1 Sample preparation. Tissue homogenates were prepared from fresh frozen PSAPP and 
wild-type mouse cortex. Total protein was extracted using SDS extraction buffer (0.125 M Tris – 
HCl (pH 7), 2% SDS, and 10% glycerol) at 70°C. Using bicinchoninic acid assay (Micro 
BCATM Protein Assay, Pierce) protein concentration was measured. 20 ug of total protein from 
the whole brain homogenate was mixed with Lysine 13C6 Stable Isotope Labeled Neuronal 
Proteome Standard (13C6 STD; 20 ug) for on gel trypsin digestion. Samples were run on a single 
10 well 4-12% BisTris gel with two SeeBlue® Plus2 Pre-stained Protein Standards. On-gel 
trypsin digestion was performed as previously described (MacDonald et al., 2012) with samples 
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being run 4 cm into the gel and divided into two fractions (above and below 65kd). The samples 
were randomly distributed in a block design across three 10-well gels with each gel containing 
seven samples, one pooled internal control, and two lane markers.  
3.3.2.2 LC-SRM/MS. VILIP-1 peptides were selected for analysis based on the presence of a 
lysine, the amino acid labeled in the 13C6STD. Five peptide sequences were identified from the 
VILIP-1 protein for quantification as indicated as underlined text in the following VILIP-1 
amino acid sequence:  
 
MGKQNSKLAPEVMEDLVKSTEFNEHELKQWYKGFLKDCPSGRLN
LEEFQQLYVKFFPYGDASKFAQHAFRTFDKNGDGTIDFREFICALSITSRG
SFEQKLNWAFNMYDLDGDGKITRVEMLEIIEAIYKMVGTVIMMKMNEDG
LTPEQRVDKIFSKMDKNKDDQITLDEFKEAAKSDPSIVLLLQCDIQK 
 
LC-SRM/MS analyses were conducted as previously described. (MacDonald et al., 2012) In 
brief, SRMs were monitored using a TSQ Quantiva triple stage quadrupole mass spectrometer 
(Thermo Scientific) with an UltiMate 3000 Nano LC Systems (Thermo scientific). 2 μl (~1 μg 
protein) of sample was loaded/desalted on a PepMap100 Nano-Trap column (Thermo scientific) 
at 8 μl/min for 2 min and separated on a Reprosil-pur 3 µm PicoChip column (New Objective) at 
400 nl/min over a 20 min gradient from 2-35% mobile phase B (Acetonitrile containing 0.1% 
formic acid). SRM transitions were timed using 1.5 min retention windows.  Transitions were 
monitored, allowing for a cycle time of 1 sec, resulting in a dynamic dwell time, never falling 
below 2 msec.  The MS instrument parameters were as follows: capillary temperature 275 °C, 
spray voltage 1100 V, and a collision gas of 1.4 mTorr (argon).  The resolving power of the 
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instrument was set to 0.7 Da (Full Width Half Maximum) for the first and third quadrupole. 
Using Skyline, integrated peak areas for both “light” PSAPP peptides and the “heavy” 13C6STD 
peptides were calculated for each of the five VILIP-1 peptide sequences. The light:heavy 
integrated area ratio was calculated to obtain peptide measures using multiple transitions per 
peptide. A sample chromatogram is shown in Figure 3.2.  
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Figure 3.2 Representative mass chromatogram of Vilip-1 LNLEEFQQLYVK product ions for the light (A) and 
heavy (B) peptide SRM measures. 
3.3.3 Cell Culture 
3.3.3.1 Primary neuronal culture generation. Primary neuronal cultures were generated as 
previously described (Beaudoin et al., 2012) with modifications. Mouse cortical neurons were 
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prepared from newborn (P0) mice. Pups were euthanized by decapitation and heads were placed 
in dissection medium (1X Hank’s Balanced Salt Solution (Ca2+ and Mg2+ free; Gibco; Catalog #: 
14185), 100X sodium pyruvate (Sigma-Aldrich; Catalog #: P-2256), 20% glucose (Sigma-
Aldrich; Catalog #: G-6152), 1 M HEPES (Sigma-Aldrich; Catalog #: H0887)). Skin on top of 
the head was gently dissected to expose the skull and using fine scissors, the skull was opened by 
making an incision at the base of the brain. The two halves of the skull were separated and 
removed exposing the brain. The brain was pinched off from the base in a scooping motion and 
transferred to a fresh dish of dissection media kept on ice. Under the dissecting scope, a sagittal 
cut was made down the midline of the brain, separating the two halves. The midbrain and 
thalamic tissues were then removed leaving the intact hemisphere containing the cortex and the 
hippocampus. Meninges were removed from each hemisphere by gently peeling them off. 
Forceps were then used to dissect out the hippocampus from the neighboring cortical tissue. 
Using a pipette, cortical tissue was collected and placed in an Eppendorf tube with 500 μL of 
dissection media. Following the competition of dissection of all brains, the tissue was 
resuspended in 500 μL of fresh dissection media and 50 μL of 2.5% trypsin solution (Gibco; 
Catalog #: 15090046) and incubated at 37°C in a water bath for 20 minutes. After 20 minutes, 20 
μL of DNase (Thermo Scientific; Catalog #: EN0525) was added and tissue was incubated at 
room temperature for 5 minutes. Following incubation, the media was aspirated and washed 
twice with 1 mL of dissection medium followed by two washes with temperature-equilibrated 
(37°C) plating medium (Minimum Essential Medium with Earle’s salts, Gibco, Catalog #: 
41090-036), 100 mM pyruvic acid (Sigma-Aldrich; Catalog #: P-2256), 20% glucose, 10% 
Horse serum (Gibco; Catalog #: 26050-070)). Tissue was then carefully triturated between ten to 
fifteen times to dissociate cells. Cell numbers were estimated using exclusion of trypan blue 
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(Sigma-Aldrich; Catalog #: T8154) staining and a hemocytometer. In 60 mm dishes with five 
poly-d-lysine (PDL) coated glass coverslips (neuVitro; Catalog #: GG-18-pdl), neurons were 
plated at 100,000 cells/dish. Cortical neurons were maintained in Neurobasal Medium (Gibco; 
Catalog #: 21103-049), supplemented with 2% B27 Supplement (Gibco; Catalog #: 17504-44), 
penicillin/streptomycin (100 U/mL and 100 mg/mL, respectively; Gibco; Catalog #: 15145-014), 
and 2 mM glutamine (Sigma-Aldrich; Catalog #: G3126) with replacement of one half of the 
media in each well every 3 days. Neurons were incubated at 37 °C, with 5% CO2.  
3.3.3.2 Aβ Exposure. Human amyloid β-peptide (1-42) (Tocris, Bristol, UK; Catalog #: 1428) is 
considered to be the predominant and most toxic Aβ-peptide species in Alzheimer disease 
patients. The Aβ1-42 amino acid sequence is: 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA. 100 μg of Aβ1-42 was 
solubilized at 1 mg/mL in 50 mM Tris buffer (PH 7.0) creating a 221.5 μM Aβ1-42 stock solution 
and vortexed vigorously for 1 minute. Next, 225.7 μL of solublized stock Aβ1-42 was added to 1 
mL of B27 maintenance media and vortexed again for 1 minute before adding the solution to the 
4 mL of conditioned media present in the dish with the coverslips, bringing the final 
concentration to10 μM Aβ1-42.  Our Aβ1-42 stock solution preparation was determined to be 
largely dimeric with some higher molecular weight oligomeric species (Figure 3.3). Primary 
mouse cortical cultures (DIV 8 or 10) were incubated in Aβ1-42 or media only for 24 hours. 
Directly following Aβ1-42 exposure, primary cortical neurons were immersion-fixed in cold 4% 
paraformaldehyde for 20 minutes, and stored in HBSS at 4°C until immunohistochemistry.  
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Figure 3.3 Aβ1-42 preparation was largely dimeric with some higher molecular weight oligomeric species. 
3.3.3.3 Immunohistochemistry. Monoclonal Vilip-1 antibody, 3A8.1 (kind gift of Jack 
Ladenson, Washington University, St. Louis, MO), was raised against Vilip-1 protein with a 
combination of DNA and protein injections (Laterza et al., 2006). Polyclonal rabbit anti-MAP2 
(antiserum 266 raised against MAP2; kind gift of Shelley Halpain, UCSD, San Diego, CA) 
primarily recognizes the high molecular weight MAP2 doublet (MAP2a and MAP2b) and is 
unaffected by phosphorylation state of the protein (Halpain and Greengard, 1990). Fixed cells 
were permeabilized with 0.2% Triton for 10 minutes and rinsed three times for 3 minutes each in 
Hank’s Balanced Salt Solution (HBSS). Cells were then incubated for 20 minutes in HBSS 
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containing 2% normal goat serum, followed by a 45 minute incubation at room temperature in 
HBSS containing 1% normal goat serum, a 1:500 dilution of Vilip-1 antibody, and a 1:500 
dilution of 266 antibody. Next cells were incubated for 45 minutes at room temperature in the 
dark in HBSS containing 1% normal goat serum, 1:500 dilution of goat anti-rabbit secondary 
antibody conjugated to Alexa Fluor 405 (Invitrogen), and a 1:500 dilution of goat anti-mouse 
secondary antibody conjugated to Alexa Fluor 568 (Invitrogen). Coverslips were mounted onto 
glass slides with Vectashield hardset (Vector Laboratories, Burlingame, CA). 
3.3.3.4 Microscopy. Data acquisition was performed on an Olympus (Center Valley, PA) BX51 
WI upright microscope equipped with an Olympus spinning disk confocal (SDCM) using an 
Olympus PlanAPO N 60X 1.40 NA super corrected oil immersion objective. The SDCM was 
equipped with an ORCA-R2 camera (Hamamatsu, Bridgewater, NJ), MBF CX9000 front-
mounted digital camera (MicroBrightField, Inc., Natick, MA), BioPrecision2 XYZ motorized 
stage with linear XYZ encoders (Ludl Electronic Products Ltd., Hawthorne, NY), excitation and 
emission filterwheels (Ludl Electronic Products Ltd.), and equipped with a Sedat Quad 89000 
filter set (Chroma Technology Corp., Bellows Falls, VT). The microscope was controlled by 
Stereo Investigator (MicroBrightField, Inc.) and SlideBook (Intelligent Imaging Innovations) 
software and samples were illuminated using a Lumen 220 metal halide lamp (Prior Scientific, 
Rockland, MA). 
Using Stereo Investigator software, the glass coverslip was first outlined and a systematic 
random sampling grid was then randomly rotated and applied. 3-dimensional image stacks, 
consisting of image planes of 512 X 512 pixels (~3,058 μm2) that were separated by 0.1 μm, 
were acquired throughout the thickness of the cell starting at the slide. At each plane, data were 
collected using the following filters: 488 nm channel- excitation 490 ± 10 nm/emission 528 ±19 
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nm, and 568 nm channel-excitation 555 ± 14 nm/emission 617 nm ± 37 nm. Exposure times 
were set at 1,000 milliseconds for Vilip-1 (568 nm channel) for all sites and optimized at each 
site for the MAP2 (488 nm channel) for both experiments. Vilip-1 exposure times were 
standardized in order to compare intensity values across image stacks, whereas MAP2 intensity 
was optimized to ensure best visualization of the cell for the masking procedure described below. 
There were no instances of pixel saturation in any stack. In two independent experiments, 
between ten and twelve sites were imaged per coverslip (2 coverslips per condition: Aβ and 
media). 
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3.3.3.5 Image processing. In SlideBook, two-dimensional sum-projection images were made of 
each three-dimensional image stack. Next, a binary mask of the MAP2 channel was created by 
manual threshold segmentation and used to assess Vilip-1 fluorescence intensity values (Figure 
3.4).  
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Figure 3.4 Multichannel view of neuron labeled with MAP2 (A), Vilip-1 (B), the merged image (C), and the MAP2 
threshold mask (D). Representative Vilip-1 immunofluorescence in an Aβ treated cell (E) versus a control media 
only cell (F). Scale bars represent 10 μm.  
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3.3.4 Statistical analysis 
All light:heavy ratios were log2 transformed for statistical analysis.  Comparison of Vilip-1 
peptide levels between Vilip-1 heterozygous animals and wild-type animals used independent 
samples T-tests.  
Comparison of sum VILIP-1 fluorescence intensity levels between 10 μM Aβ1-42 and 
media conditions for two independent culture experiments used independent samples T-tests. All 
Vilip-1 intensity measurements used in the analyses were normalized to the mean sum Vilip-1 
intensity control condition (media only) within an experiment to account for assay variability. 
3.4 RESULTS 
3.4.1 VILIP-1 levels in a mouse model of Aβ overexpression  
In a comparison of 5 PSAPP and 5 wild-type 6 month old mice, Vilip-1 levels were not 
significantly different between groups for any of the peptides (Figure 3.5; Table 3.1). 
 
Table 3.1 Summary of Vilip-1 peptide expression in PSAPP and WT cortical brain tissue (PSAPP: n = 5; WT n = 5)  
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Figure 3.5 Log2-transformed expression ratios of VILIP-1 peptides in whole brain homogenate comparing PSAPP 
(n = 5) and wild-type (n=5) mice. No peptide levels differed significantly between groups. 
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3.4.2 VILIP-1 levels following Aβ exposure in culture 
We examined Vilip-1 levels in neurons in following a 24 hour 10 μM Aβ1-42 exposure. Vilip-1 
levels in the Aβ1-42 exposed group (n = 40) did not differ significantly from the control neurons 
in media only (n = 42) (Figure 3.6). 
 
Figure 3.6 Vilip-1 immunoreactivity (sum Vilip-1 fluorescence intensity) in C57BL/6NJ primary cortical neuronal 
cultures normalized to the average control Vilip-1 sum fluorescence intensity in each experiment. Aβ and media 
conditions are not significantly different (p = 0.219). Two independent experiments are represented.  
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3.5 DISCUSSION 
Here we provide evidence that Vilip-1 expression is unaltered in the presence of Aβ in two 
model systems: an animal model of Aβ overexpression and primary cortical neuronal cultures 
treated with Aβ peptide. These congruent findings from different experimental modalities 
suggest that Aβ is unlikely to lead to elevated neuronal Vilip-1 in AD. 
Several lines of evidence have suggested an association between Vilip-1 and Aβ in the 
pathogenesis of AD.  First, studies looking at cerebrospinal fluid (CSF) Vilip-1 levels and 
amyloid load using positron emission tomography imaging with Pittsburgh Compound-B, an 
histological dye that easily crosses the blood-brain barrier and binds amyloid, have demonstrated 
a positive correlation between these markers in preclinical AD (Tarawneh et al., 2012). 
Additionally, combining CSF Vilip-1 levels with CSF Aβ1-42 (Vilip-1/Aβ1-42) levels has also been 
shown to predict the rate of cognitive decline in AD (Tarawneh et al., 2012). Second, an 
immunohistochemistry study looking at Vilip-1 in AD brain tissue also found a qualitative 
association of Vilip-1 with neuritic plaques in the neocortex (Braunewell et al., 2001a). Third, 
we have shown using mRNA microarray analysis that VSNL1, the gene that encodes Vilip-1 
protein, is co-expressed with amyloid precursor protein (APP) throughout normal aging 
(Appendix B) (Lin et al., 2015).  
While collectively the above data is suggestive of a link between Aβ and Vilip-1, in this 
study we provide the first functional evaluation of this relationship, finding that Aβ does not 
drive Vilip-1 expression using two model systems. Our findings are consistent with our 
observation in Chapter 1.0 that VILIP-1 levels did not correlate with soluble Aβ1-42 or Aβ1-40 
levels within human brain tissue in the superior frontal gyrus. Unlike studies using human 
subjects, the current use of both in vivo and in vitro models has the advantage of focusing on the 
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impact of Aβ in isolation. For example, neither model is characterized by the other predominant 
AD neuropathology, neurofibrillary tangles (Kurt et al., 2003). Nor is the PSAPP mouse model 
characterized by prominent neuronal loss (Irizarry et al., 1997, Takeuchi et al., 2000). Finally 
neither model has been associated with any of the other frequent comorbid neuropathologies 
found in AD subjects, such as vascular lesions, Lewy bodies, and TAR DNA-binding protein 43 
(TDP-43) aggregates.  
One limitation of this study is that primary cortical cultures were only exposed to one 10 
μM concentration of Aβ1-42. We used this relatively high concentration of peptide to ensure that 
we would have robust biological effects (as confirmed in our evaluation of neuronal death, see 
Chapter 3.0). While the Aβ1-42 isoform is widely considered the most toxic Aβ species (Klein et 
al., 1999, Sanchez et al., 2011, Pauwels et al., 2012) and we used a primarily dimeric preparation 
with some higher molecular weight species that are known to induce pathological changes in 
culture (Shankar et al., 2008, O'Nuallain et al., 2010), it is unknown whether lower 
concentrations of Aβ1-42 would elicit a different response in Vilip-1 expression.  
Another potential study limitation is the age at which PSAPP and wild-type mice were 
examined using LC-SRM/MS. While we have demonstrated that these animals have a clear 
elevation in APP expression at 6 months (Figure 3.1), it is possible that Vilip-1 levels could be 
altered at a later time point (e.g. 12 months) due to greater amyloid load. However, this seems an 
unlikely scenario given that neuronal cultures exposed to high levels of Aβ did not differ 
significantly from untreated neurons. 
While Aβ does not appear to drive increased Vilip-1 expression, this does not exclude 
Vilip-1 from being engaged by Aβ-induced molecular alterations that ultimately result in 
neuronal death. As shown in Chapter 1.0 in human brain tissue, decreases in Vilip-1 are present 
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in regions with prominent neuronal loss. Further investigation into whether Vilip-1 actively 
participates in the process of Aβ-induced neuronal death will be addressed in Chapter 3.0. 
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4.0  THE EFFECT OF VILIP-1 EXPRESSION ON AΒ-INDUCED NEURONAL 
DEATH  
4.1 ABSTRACT 
Through mechanisms that are not yet entirely clear, Aβ oligomers perturb neuronal Ca2+ 
homeostasis and initiate a cascade of pathological events in the cell that ultimately results in 
neuronal death. In Chapter 1.0, we observed significantly reduced Vilip-1 levels in brain regions 
associated with significant neuronal loss. In this study, we investigated the effect of manipulating 
Vilip-1 levels on Aβ-induced neuronal death in primary cortical neuronal cultures using 
fluorescence microscopy. We found that the extent of Vilip-1 expression did not influence 
neuronal death, indicating that Vilip-1 unlikely mediates Aβ-induced neuronal loss.  
4.2 INTRODUCTION 
A substantial body of evidence exists supporting the theory that Aβ oligomers disrupt neuronal 
Ca2+ homeostasis. Several studies have demonstrated that exogenous exposure of cultured 
neurons to synthetic Aβ oligomers results in a sustained elevation in intracellular Ca2+ levels 
(Mattson et al., 1992, Guo et al., 1999, Demuro et al., 2005). Similarly, multiphoton imaging in 
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mouse models of Aβ overexpression has shown Ca2+ overload in neurites and dendritic spines as 
a function of amyloid plaque proximity (Kuchibhotla et al., 2008).  
Importantly, dendritic spine loss, neuron death, and subsequent cognitive impairments in 
AD may arise from pathologic disruption of Ca2+ homeostasis by soluble Aβ. Previous in vivo 
and in vitro work has shown that Aβ-induced activation of Ca2+-dependent phosphatase 
calcineurin is sufficient to induce dendritic spine loss and neurite dystrophy (Kuchibhotla et al., 
2008, Wu et al., 2010). Additionally, application of exogenous Aβ to primary neuronal cultures 
has been shown to trigger Ca2+-influx-induced apoptosis through generation of reactive oxygen 
species (Ekinci et al., 2000). 
Neuronal Ca2+-sensing (NCS) protein, visinin like protein 1 (Vilip-1) has previously been 
implicated as a potential mediator in neuronal death. As described in Chapter 1.0, in AD, we 
observed significantly diminished levels of the protein within the entorhinal cortex, a brain 
region characterized by prominent neuronal loss. However, in a brain region with comparatively 
little neuronal loss, the superior frontal gyrus (SF), Vilip-1 levels were unaltered in the same 
subjects. Further evidence supporting an association of Vilip-1 and neuronal loss is that we saw 
similar reductions as observed in the ERC of AD subjects within the SF of frontotemporal lobar 
degeneration (FTLD) individuals, which is a region primarily effected by widespread neuronal 
loss.  
In vitro studies have also provided evidence for a role of Vilip-1 in neuronal death. One 
previous report found that Vilip-1 overexpression in pheochromocytoma cells (PC12) lead to 
increased Ca2+-mediated cell death (Schnurra et al., 2001). Additionally, overexpression of the 
highly homologous NCS family member hippocalcin has been shown to facilitate cell survival in 
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the face of a Ca2+ challenge, suggesting this family of NCS proteins could hold different 
functional roles in modulating cell death (Mercer et al., 2000). 
 
In this study we used fluorescence microscopy to evaluate Aβ-induced neuronal death in primary 
cortical neuronal cultures that differ by extent of Vilip-1 expression. We found that Vilip-1 
levels did not impact neuronal death, indicating that Vilip-1 is unlikely to play a role in Aβ-
mediated neuronal death.  
4.3 METHODS 
4.3.1 VSNL1tm1(KOMP)Vlcg mouse model 
Primary cortical culture experiments were carried out using heterozygous and wild-type newborn 
(P0) mice. Transgenic VSNL1tm1(KOMP)Vlcg were generated by the Knockout Mouse 
Program (KOMP) using embryonic stem cells provided by the International Knockout Mouse 
Consortium by inserting the ZEN-UB1 Velocigene cassette (beta-galactosidase coding sequence 
from E. coli LacZ gene) into the VSNL1 gene, deleting exon 2 spanning Chromosome 
12:11,393,779-11,393,606. The construct was introduced into C57BL/6N-derived VGB6 
embryonic stem cells and correctly targeted embryonic stem cells were injected into B6(Cg)-
TyrC-2J/J blastocysts. The resulting chimeric males were bred to C57Bl/6NJ females. 
Homozygous knockout of the VSNL1 gene is embryonic lethal. Vilip-1 is expressed in the 
neocortex, among other brain regions, at postnatal day zero (http://www.informatics.jax.org). 
Heterozygous VSNL1tm1(KOMP)Vlcg  are viable and fertile, demonstrating approximately 
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50% reduction in Vilip-1 protein levels (Figure 4.1). Heterozygous and wildtype P0 mice were 
generated by crossing heterozygous VSNL1tm1(KOMP)Vlcg male mice with C57BL/6NJ 
females. All studies were approved by the University of Pittsburgh Institutional Animal Care and 
Use Committee.  
 
Figure 4.1 Vilip-1 levels in heterozygous and wild-type mice. (A). An example blot from the comparison of 
subjects with wild-type (+/+) and Vilip-1 heterozygous (+/-) mice (B) Quantification of wild-type (WT) and 
heterozygous (Het) Vilip-1 levels. 
4.3.2 Cell culture 
Primary neuronal cultures were generated as previously described (Beaudoin et al., 2012) with 
modifications. Mouse cortical neurons were prepared from newborn (P0) mice. Importantly, 
throughout the entire preparation, individual mouse brains were kept, processed, and plated 
separately to ensure that genotypes were not mixed. Tail samples for genotyping were collected 
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at the time of decapitation. Pups were euthanized by decapitation and heads were placed in 
dissection medium (1X Hank’s Balanced Salt Solution (Ca2+ and Mg2+ free; Gibco; Catalog #: 
14185), 100X sodium pyruvate (Sigma-Aldrich; Catalog #: P-2256), 20% glucose (Sigma-
Aldrich; Catalog #: G-6152), 1 M HEPES (Sigma-Aldrich; Catalog #: H0887)). Skin on top of 
the head was gently dissected to expose the skull and using fine scissors, the skull was opened by 
making at incision at the base of the brain. The two halves of the skull were separated and 
removed exposing the brain. The brain was pinched off from the base in a scooping motion and 
transferred to a fresh dish of dissection media kept on ice. Under the dissecting scope, a sagittal 
cut was made down the midline of the brain, separating the two halves. The midbrain and 
thalamic tissues were then removed leaving the intact hemisphere containing the cortex and the 
hippocampus. Meninges were removed from each hemisphere by gently peeling them off and the 
hippocampus was dissected out from the neighboring cortical tissue with forceps. Using a 
pipette, cortical tissue was collected and placed in an Eppendorf tube with 500 μL of dissection 
media on ice. Following the competition of dissection of all brains, the tissue was resuspended in 
500 μL of fresh dissection media and 50 μL of 2.5% trypsin solution (Gibco; Catalog #: 
15090046) and incubated at 37°C in a water bath for 20 minutes. After 20 minutes, 20 μL of 
DNase was added and tissue was incubated at room temperature for 5 minutes. Following 
incubation, the media was aspirated and washed twice with 1 mL of dissection medium followed 
by two washes with temperature-equilibrated (37°C) plating medium (Minimum Essential 
Medium with Earle’s salts (Gibco, Catalog #: 41090-036), 100 mM pyruvic acid (Sigma-
Aldrich; Catalog #: P-2256), 20% glucose, 10% horse serum (Gibco; Catalog #: 26050-070)). 
Tissue was then carefully triturated between ten to fifteen times to dissociate cells. Cell numbers 
were estimated using exclusion of trypan blue (Sigma-Aldrich; Catalog #: T8154) staining and a 
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hemocytometer. In 60 mm dishes with five poly-d-lysine (PDL) coated glass coverslips 
(neuVitro; Catalog #: GG-18-pdl), neurons were plated at 100,000 cells/dish. Cortical neurons 
were maintained in Neurobasal Medium (Gibco; Catalog #: 21103-049), supplemented with 2% 
B27 Supplement (Gibco; Catalog #: 17504-44), penicillin/streptomycin (100 U/mL and 100 
mg/mL, respectively; Gibco; Catalog #: 15145-014), and 2 mM glutamine (Sigma-Aldrich; 
Catalog #: G3126) with replacement of one half of the media in each dish every 3 days. Neurons 
were incubated at 37 °C, with 5% CO2.  
4.3.3 Aβ Exposure 
Human amyloid β-peptide (1-42) (1428; Tocris, Bristol, UK) is considered to be the predominant 
and most toxic Aβ-peptide species in Alzheimer disease patients. The Aβ1-42 amino acid 
sequence is: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA. 100 μg of 
Aβ1-42 was solubilized at 1 mg/mL in 50 mM Tris buffer (PH 7.0) creating a 221.5 μM Aβ1-42 
stock solution and vortexed vigorously for 1 minute. Next, 225.7 μL of solublized stock Aβ1-42 
was added to 1 mL of B27 maintenance media and vortexed again for 1 minute before adding the 
solution to the 4 mL of conditioned media present in the dish with the coverslips, bringing the 
final concentration to10 μM Aβ1-42.  Our Aβ1-42 stock solution preparation was determined to be 
largely dimeric with some higher molecular weight oligomeric species  (Chapter 3.0, Figure 
3.3). Primary mouse cortical cultures (DIV 8 or 10) were incubated in Aβ1-42 or media only for 
24 hours. Directly following Aβ1-42 exposure, primary cortical neurons were immersion-fixed in 
cold 4% paraformaldehyde for 20 minutes, and stored in HBSS at 4°C until 
immunohistochemistry.  
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4.3.4 Immunohistochemistry 
Histochemical detection of apoptotic cell death in primary cortical neurons was accomplished 
with the In Situ Cell Death Detection Kit, Fluorescein (11684795910; Roche, Indianapolis, IN). 
This kit features the TUNEL reaction, which predominantly labels apoptotic-generated DNA 
strand breakage through the use of terminal deoxynucleotidyl transferase (TdT) that catalyzes the 
polymerization of labeled modified nucleotides to free DNA 3’-OH termini in a template-
independent fashion.  Cortical neurons were labeled with Guinea pig polyclonal anti-NeuN 
antibody (ABN90; Millipore, Temecula, CA), which recognizes the N-terminus of the DNA-
binding, neuron-specific nuclear protein (NeuN). 
Fixed cells were incubated in the In Situ Cell Death Detection Kit TUNEL reaction 
mixture for 60 minutes at 37 °C in the dark. Next cells were rinsed in Hank’s Balanced Salt 
Solution (HBSS) and permeabilized with 0.2% Triton for 10 minutes. Cells were then incubated 
for 20 minutes in HBSS containing 2% normal goat serum, followed by a 45-minute incubation 
at room temperature in the dark in HBSS containing 1% normal goat serum and a 1:500 dilution 
of NeuN antibody. Cells were then incubated for 45 minutes at room temperature in the dark in 
HBSS containing 1% normal goat serum and a 1:500 dilution of goat anti-guinea pig secondary 
antibody conjugated to Alexa Fluor 568 (Invitrogen). Coverslips were mounted onto glass slides 
with Vectashield hardset (Vector Laboratories, Burlingame, CA). 
4.3.5 Microscopy 
Data acquisition was performed on an Olympus (Center Valley, PA) BX51 WI upright 
microscope equipped with an Olympus spinning disk confocal (SDCM) using an Olympus 
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PlanAPO N 10X 0.40 NA air objective. The SDCM was equipped with an ORCA-R2 camera 
(Hamamatsu, Bridgewater, NJ), MBF CX9000 front-mounted digital camera (MicroBrightField, 
Inc., Natick, MA), BioPrecision2 XYZ motorized stage with linear XYZ encoders (Ludl 
Electronic Products Ltd., Hawthorne, NY), excitation and emission filterwheels (Ludl Electronic 
Products Ltd.), and equipped with a Sedat Quad 89000 filter set (Chroma Technology Corp., 
Bellows Falls, VT). The microscope was controlled by Stereo Investigator (MicroBrightField, 
Inc) and SlideBook (Intelligent Imaging Innovations) software (MicroBrightField, Inc.) and 
samples were illuminated using a Lumen 220 metal halide lamp (Prior Scientific, Rockland, 
MA). 
Using Stereo Investigator software, the glass coverslip was first outlined and a systematic 
random sampling grid was then randomly rotated and applied. Each two-dimensional image 
consisted of an image plane that was 512 X 512 pixels (~3,058 μm2). At each plane, data were 
collected using the following filters: excitation 490 ± 10 nm/emission 528 ±19 nm and excitation 
555 ± 14 nm/emission 617 nm ± 37 nm. Exposure times were set at 1,000 milliseconds for both 
the TUNEL (488 nm), and NeuN (568 nm) channels.  
4.3.6 Image processing 
Intensity histograms for each channel were manually adjusted to the mode of the histogram for 
the low setting and a standard value for the high setting for each channel that was optimized for 
visualization. TUNEL-positive, NeuN-positive and objects positive for both TUNEL and NeuN 
(Tunel-NeuN-positive) were manually counted at each site (Figure 4.2). 
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Figure 4.2 Primary cortical cultures labeled for TUNEL (A) and NeuN (B). Channels are merged in Panel C. 
Arrows represent TUNEL-NeuN-positive objects. Arrowheads represent NeuN cells that are TUNEL-negative. 
Scale bars represent 10 μm.  
4.3.7 Statistical analysis 
Apoptotic neuronal counts were normalized by taking the number of Tunel-NeuN-positive 
objects per site and dividing by the average number of NeuN objects per site within condition 
and experiment. Normalization helped account for varying total cell numbers across coverslips. 
Comparisons of normalized cell death counts between experimental conditions, genotypes, and 
the interaction between genotype and condition were made using two-way ANOVA.  
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4.4 RESULTS 
4.4.1 Alterations in Vilip-1 heterozygous neuron death following Aβ exposure 
In a comparison of Vilip-1 heterozygous neurons to wild-type neurons following Aβ1-42 
exposure, genotype did not significantly affect neuronal death (p = 0.977). Aβ1-42 exposure in the 
wild-type group resulted in a 48% increase in cell death over the media control condition (p = 
0.005). Heterozygous cells had a 60% increase in cell death after Aβ1-42 exposure (p = 0.001) 
(Figure 2). There was no significant interaction of genotype x condition (p = 0.700). 
 
 
Figure 4.3 Normalized cell death counts across two independent experiments ([# of TUNEL-NeuN + objects per 
site/average # NeuN objects per site within condition and experiment]/average # of NeuN objects in the WT media 
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condition). WT Aβ and Vilip-1 Het Aβ conditions were not significantly different (p = 0.819).  * p < 0.05. Bars 
indicate SEM. 
4.5 DISCUSSION 
In primary cortical cultures of Vilip-1 heterozygous and wild type mice, we found that 
reductions in Vilip-1 did not alter the amount of Aβ-induced neuronal death. This finding 
provides evidence that Vilip-1 is unlikely a mediator of Aβ-induced neuronal loss. Additionally, 
it suggests that lower levels of Vilip-1 may not be neuroprotective.  
Previous work has revealed a potential role for Vilip-1 in cell death. As described in 
Chapter 1.0, we observed reductions in Vilip-1 protein levels in disease within brains regions 
characterized by prominent neuronal loss: the entorhinal cortex (ERC) of AD subjects and in the 
superior frontal gyrus (SF) of frontotemporal lobar degeneration (FTLD). However, in a region 
with comparatively less neuronal death – the SF of AD subjects – Vilip-1 expression was 
unaltered, suggesting a potential link between the NCS protein and neuronal loss. In addition, a 
previous study has further suggested a more functional role for Vilip-1 in cell death showing that 
expression of Vilip-1 in PC12 increased sensitivity to Ca2+-mediated cell death (Schnurra et al., 
2001). Despite these potential connections to neuronal loss, our findings in primary cortical 
neuronal cultures that differ by extent of Vilip-1 expression show unaltered neuronal death 
levels, indicating that Vilip-1 unlikely plays a role in Aβ-mediated neuronal death.  
A major factor contributing to discrepancy between our finding and the previous study is 
the use of different cell types. We used primary cortical neurons that naturally express Vilip-1 
(Figure 4.1), whereas PC12 cells (a cell line derived from the rat adrenal gland) do not express 
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Vilip-1 and were transfected for analysis (Braunewell et al., 2001b). Thus, in our study we 
compared naturally occurring Vilip-1 levels to a reduction in heterozygous animals and the 
previous report by Schnurra and colleagues assessed overexpression of the protein in PC12 cells.  
Additionally, in our study we directly tested Aβ-induced neuronal death and the prior 
PC12 cell report investigated cell death following Ca2+ challenge via the Ca2+ ionophore 
ionomycin. The extent of mechanistic overlap between these two cytotoxic challenges is 
currently unclear. While the particular manner by which Aβ oligomers perturb neuronal Ca2+ 
homeostasis and increase neurotoxicity is complex and still a matter of debate, there are a 
number of theories.  Aβ oligomers have been shown to fuse with lipid bilayers creating annular 
structures that function as artificial pores or channels in the membrane, allowing for increased 
cation flux into the cell (Arispe et al., 1993). They also have been shown to induce membrane-
associated oxidative stress leading to Ca2+ influx (Butterfield, 2002). Others have postulated that 
Aβ can stimulate the release of Ca2+ from internal stores through altering the sensitivity of 
inositol triphosphate receptor (IP3R) and ryanodine receptor (RyR) channels in the endoplasmic 
reticulum (Stutzmann et al., 2004, Bezprozvanny and Mattson, 2008). As for ionomycin, it is 
thought to act primarily through the release from internal calcium stores (Himmel et al., 1990, 
Morgan and Jacob, 1994).  While it is widely accepted that Aβ does perturb Ca2+ homeostasis in 
neurons, a potential caveat is that we did not measure changes in Ca2+ following Aβ exposure. 
Different amounts of calcium may have impacted the apoptotic-pathway in the condition of 
reduced Vilip-1 levels.  
As previously described in Chapter 2.0, a limitation of this study is the single 10 μM 
concentration exposure of neurons to Aβ1-42. At lower concentrations of Aβ, neuronal death 
levels in the heterozygous cultures may be altered due to reduced Vilip-1 and therefore we may 
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not be seeing an effect due to the high levels of toxicity in the cultures.  In addition to Aβ 
concentration, the Aβ exposure time length could impact the neuronal death response. We 
selected a 24-hour Aβ exposure to ensure that we observed neuronal death but shorter or longer 
time frames may also impact the apoptotic process in the presence of reduced levels of Vilip-1. 
Another possible caveat is the stage of neuronal death that we assessed. In this study we 
used the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) reaction that 
detects DNA fragmentation by labeling free DNA 3’-OH termini of nucleic acids to assess 
apoptosis. This assay measures late stages of apoptosis after extensive DNA degradation has 
occurred to the cell. However, use of an earlier apoptotic marker, such as caspase-3 would have 
provided more information about cells at risk for progression to apoptotic cell death. Previous 
work in culture has demonstrated that the caspase-3 apoptotic-pathway is activated by Aβ 
(Takuma et al., 2004). We attempted to label neurons with caspase-3, however the antibody 
failed to label cells even at high concentrations.  Future work could focus on a different early 
apoptotic marker, such as YO-PRO-1 Iodide, a DNA marker for cells with a compromised 
plasma membrane. 
A technical factor to keep in consideration is that our methodology of exogenously 
exposing rodent neuronal cultures to Aβ does not recapitulate all of the pathological aspects of 
AD. Mouse models of Aβ overexpression have demonstrated hyperphosphorylation of mouse tau 
but not aggregation into neurofibrillary tangles as human tau does in disease. Additionally, these 
mice do not exhibit neuronal loss (Games et al., 1995, Stancu et al., 2014). Also, other 
pathologies in addition to tau aggregation, such as Lewy bodies, are not present in these Aβ 
models. Thus, it is possible that Aβ-induced neuronal death in human brain engages additional 
pathways not assessed in this mouse neuronal culture system. 
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Accepting the caveats associated with the Aβ1-42 exposure parameters and cell culture 
model discussed above, our findings suggest, in combination with evidence presented in 
Chapters 1.0 and 2.0, that Vilip-1 is not an active participant in AD-related cell death, but rather 
a passive bystander that decreases in the brain as a consequence of neuronal loss. Furthermore, 
when considering the findings of increased CSF Vilip-1 in AD patients, that Vilip-1 is likely 
released upon neuronal death, accumulating in the CSF. 
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5.0  GENERAL DISCUSSION 
5.1 5.1 SUMMARY OF FINDINGS 
Alzheimer disease (AD) is a prevalent, progressive neurodegenerative disorder that is 
characterized clinically by declining memory, progressive loss of cognitive ability, and 
behavioral impairments that result from pathogenic protein accumulation, synapse impairment, 
and widespread neuronal loss that culminates in end-organ (brain) failure. The fundamental 
neurobiological mechanisms underlying neuron death in AD are not yet fully understood, 
however amassing evidence implicates soluble Aβ oligomers as a primary neurotoxic agent in 
AD. Aβ oligomers are thought to exact their detrimental effects on the brain by initiating a 
cascade of neurotoxic events involving neuronal Ca2+ dysregulation, synaptic impairment and 
dysfunction, loss of dendritic spines, tau phosphorylation and aggregation, and ultimately 
neuronal death. In addition to understanding the neurobiology behind AD, a research priority has 
been working on identifying AD biomarkers in order to accurately detect early pathologic 
processes in hopes of early intervention.  Recently, Vilip-1 protein has been identified as a 
peripheral biomarker of AD and is predictive of the rate of cognitive decline. It is unknown to 
what extent Vilip-1 contributes to AD pathogenesis, particularly through Aβ-mediated pathways. 
The goal of this dissertation was to determine how Vilip-1 is altered in the AD brain and using in 
vivo and in vitro model systems, determine whether it is an active participant in Aβ-mediated 
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neuronal death or merely an innocent bystander in the process that ends up being discarded into 
the CSF. We demonstrated that Vilip-1 is reduced within brain regions characterized by 
prominent neuronal loss in both AD and frontotemporal lobar degeneration (FTLD) (Chapter 
2.0). We reported that Vilip-1 expression is not driven by Aβ (Chapter 3.0). Finally, we 
examined Aβ-initiated neuron death in neurons with differing levels of Vilip-1 protein and found 
that neuron death was unaffected by the extent of Vilip-1 expression (Chapter 4.0).  In the 
following sections, we will review the findings of the experimental chapters and discuss the 
broader implications for these Vilip-1 findings in AD. We will also address the caveats 
associated with model systems of AD and the experimental challenges associated with neuronal 
culture systems.    
5.2 UTILITY OF VILIP-1 AS A PERIPHERAL AD BIOMARKER: DIFFERENTIAL 
ACCESS FOR MEDIAL TEMPORAL LOBE STRUCTURES 
5.2.1 CSF regional proximity 
As discussed in the General Introduction (Chapter 1.0), Vilip-1 has recently been identified as an 
AD-specific, prognostic, peripheral biomarker of cognitive decline and disease severity. CSF and 
plasma Vilip-1 levels are elevated in mild cognitive impairment and AD compared to normal 
control subjects (Lee et al., 2008, Tarawneh et al., 2011, Mroczko et al., 2015). In addition, 
higher CSF Vilip-1 concentrations correlate with reduced Mini Mental State Examination 
(MMSE) scores and are predictive of a more rapid deterioration in cognitive performance 
(Tarawneh et al., 2012, Fagan et al., 2014, Mroczko et al., 2015).  Notably, a number of studies 
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indicates that Vilip-1 CSF concentrations are elevated as part of an AD-specific phenomenon, as 
other non-AD neurodegenerative disorders like Lewy Body dementia, progressive supranuclear 
palsy, and FTLD do not exhibit changes in CSF Vilip-1 compared to normal controls (Tarawneh 
et al., 2011, Luo et al., 2013).  While AD demonstrates elevated CSF Vilip-1 concentrations, our 
findings indicate that Vilip-1 levels are reduced only in brain regions associated with prominent 
neuronal loss: the entorhinal cortex (ERC), but not the superior frontal gyrus (SF), in AD and the 
SF in FTLD. The disparity between CSF and postmortem brain tissue findings suggest that 
Vilip-1 released from ERC neurons upon neuronal death may have a more direct influence on the 
CSF compartment sampled by lumbar puncture compared to SF neurons.  
While alterations in CSF fluid dynamics in AD are not fully understood, there are likely a 
number of contributing factors. First, proximity of the affected brain region to the ventricular 
system could impact protein diffusion and penetration into the CSF. In a dual neuroimaging-CSF 
study investigating how brain Aβ deposition is reflected in the CSF, researchers correlated tracer 
carbon-11-labeled Pittsburgh Compound B (PiB), which binds cerebral plaque and non-plaque 
amyloid deposits in the brain, with CSF Aβ1-42 concentrations in 30 patients with probable AD. 
Grimmer and colleagues found that the relationship between CSF Aβ concentrations and amyloid 
load in the brain were strongest within brain regions surrounding the ventricles, suggesting that 
CSF protein levels may chiefly reflect pathology localized to brain regions in the vicinity of the 
ventricular system (Grimmer et al., 2009).  Additional support of this idea comes from a study 
investigating region-specific uptake of CSF-administered radiocarbon labeled glutamate (14C-
glutamate) in rats.  Results showed that the cerebral cortex had the lowest uptake of 14C-
glutamate as it is farthest from the CSF ventricular system (Al-Sarraf and Philip, 2003).  
Notably, this idea of access via proximity of the affected brain region to the ventricle is 
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consistent with the anatomy of our observed Vilip-1 reductions in brain regions with significant 
neuronal loss. The hippocampus, which is anatomically juxtaposed to the ERC, is located in the 
temporal cortex, medial to the inferior horn of the lateral ventricle. The hippocampal-CSF 
interface runs the entire length of lateral ventricle in each hemisphere of the brain, while the 
frontal cortex is located relatively far from the ventricular system (Johanson et al., 2005). In 
addition to proximity, MRI studies have demonstrated the breakdown of the ventricular lining in 
AD, rendering it more accessible to proteins in the local interstitium (Scheltens et al., 1995), 
which could include Vilip-1 released upon neuronal death in the ERC. The possibility of 
additional AD-specific mechanisms for ERC Vilip-1 penetration exists, however, based on the 
currently available data, both proximity and thinning of the ventricular lining provide the most 
parsimonious explanations for this phenomenon. Altogether, these data suggest that Vilip-1 may 
be a good marker of neuronal integrity for neurodegeneration in affected brain regions within 
close proximity to the ventricles, like the ERC in AD but not the SF in FTLD.  
5.2.2 Plasma and blood brain barrier permeability 
Vilip-1 levels are also increased in the plasma of AD patients compared to normal control 
subjects, which could be impacted by regional blood-brain barrier (BBB) vulnerability 
(Tarawneh et al., 2011). A number of factors have the ability to influence BBB integrity 
including aging and early stages of neurodegenerative disease. A recent MRI study looking at 
regional BBB breakdown during normal aging and mild cognitive impairment (MCI) found that 
BBB deterioration begins with the hippocampus in normal aging and worsens with MCI 
(Montagne et al., 2015).  Additionally, integrity in cortical regions remains intact throughout 
both normal aging and MCI aging, demonstrating a regional disparity that is exacerbated with 
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cognitive decline (Montagne et al., 2015). This regional pattern for BBB integrity is consistent 
with the observed regional discrepancies between reduced Vilip-1 levels in regions associated 
with prominent neuronal loss (ERC in AD; SF in FTLD), but not other cortical regions in AD 
(SF), and AD Vilip-1 biomarker positivity in plasma. While the specific mechanisms underlying 
BBB vulnerability in AD are not fully understood, these studies demonstrate that regional 
differences exist within the capacity of the tissue to mediate BBB permeability changes, and 
present a possible mechanism for Vilip-1 plasma elevations observed in AD patients.  
5.3 VILIP-1: POTENTIAL AS A NOVEL BIOLOGICAL INDICATOR OF 
NEURONAL INTEGRITY AND LOSS IN BRAIN TISSUE 
At autopsy, AD patients show gross cortical atrophy, predominantly affecting the medial 
temporal lobes, while the primary motor, sensory, and visual cortices are left relatively intact 
(Serrano-Pozo et al., 2011). However, stereological studies have demonstrated that while there is 
significant neuronal loss at early to moderate stages of disease in medial temporal structures, like 
the hippocampus and entorhinal cortex, the extent of neuron loss in the neocortex is 
comparatively less robust (Regeur et al., 1994, Gomez-Isla et al., 1996). 
In the ERC, we observed decreased levels of Vilip-1 in AD subjects compared to normal 
controls (Chapter 2.0). Consistent with this observation, microtubule-associated protein 2 
(MAP2) levels were severely decreased in AD subjects compared to normal controls in this 
region. In the brain, MAP2 is a neuron-specific protein like Vilip-1 (Bernstein et al., 1999). 
MAP2 functions in microtubule stability and plasticity and is vulnerable to cytotoxic insults on 
the cell. Loss of MAP2 immunoreacitvity is considered an early indicator of neuronal damage 
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and has been shown to occur following neuronal insults such as ischemia, brain injury, and 
notably, Aβ exposure (Fifre et al., 2006). In the SF of AD subjects, Vilip-1 levels were 
unchanged compared to normal controls. MAP2 levels in the SF were decreased compared to 
normal controls, however the magnitude of reduction was considerably less than the measured 
loss in the ERC, consistent with stereological reports of limited neuron loss in the SF even at 
moderate stages of disease (Regeur et al., 1994).  
Interestingly, Vilip-1 levels in FTLD subjects were significantly decreased compared to 
both AD and normal control subjects in the SF. In contrast to AD, FTLD is characterized by 
severe cerebral atrophy that is relatively selective for the frontal and anterior temporal lobes and 
that is accompanied by neuronal loss in these regions (Mackenzie et al., 2009, Rabinovici and 
Miller, 2010). In our study, FTLD subjects also showed substantially decreased MAP2 levels in 
the SF compared to normal controls. The magnitude of the reduction was similar to the level of 
reduction observed in the ERC of AD subjects and consistent with extensive neuronal loss in the 
SF in FTLD. Importantly, in the SF, FTLD subjects had significantly decreased Vilip-1 levels 
compared to AD subjects. Taken together, our data suggest that Vilip-1 levels coincide well with 
established patterns of neuronal loss in both AD and FTLD cases, making its potential as a 
biologic indicator of neuronal loss promising.  
In addition to observed Vilip-1 elevation in the CSF of AD, Vilip-1 has also been shown 
to be elevated in the CSF of a rat model of stroke (Laterza et al., 2006, Stejskal et al., 2011). The 
rat model of stroke involves occluding the middle cerebral artery either temporarily or 
permanently, which results in massive neuronal injury (Longa et al., 1989). While CSF 
alterations in stroke patients have yet to be demonstrated, if ischemic damage is widespread 
enough, including areas located within the medial temporal lobe, it is unsurprising that Vilip-1 
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concentrations would increase in the CSF as observed in the rat model. Stroke findings further 
indicate a role for Vilip-1 in determining degree of neuronal integrity, both in CSF and brain 
tissue.  
While the current gold standard for determination of unbiased estimates of neuron counts 
is design-based stereology, use of Vilip-1 as a biological indicator of neuronal integrity and loss 
in brain tissue may prove beneficial for several reasons. Stereology employs mathematical 
principles and systematic random sampling to provide estimates of the number of objects within 
a three-dimensional region of interest from two-dimensional information (Geuna and Herrera-
Rincon, 2015). While the stereological approach provides highly accurate cell counts, there are 
limitations to this technique. Chiefly, the process of counting cells in human tissue sections is 
highly time consuming. Often immunohistochemical stains must be performed prior to the study 
to identify characteristic chemical profiles or cytoarchitectural features of the region of interest. 
In addition, if multiple brain regions are being considered, independent counting procedures 
must be performed for each individual region (Geuna and Herrera-Rincon, 2015, Herculano-
Houzel et al., 2015). Other challenges such as tissue shrinkage, distinguishing between neurons 
and glia, appropriate sample size to ensure representative counts, and human error also factor 
into this technique. Identifying a novel, less labor-intensive marker, like Vilip-1 or perhaps an 
approach incorporating Vilip-1 and MAP2, for accurately measuring neuronal integrity and 
determining relative amounts of neuronal loss in brain tissue would be beneficial in human brain 
tissue studies, particularly in scenarios where constraints on tissue availability and equipment 
exist.  
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5.4  IMPLICATIONS FOR THE RELATIONSHIP OF VILIP-1 WITH AD 
PATHOLOGY AND PSYCHOSIS PHENOTYPE 
In AD, soluble Aβ oligomers play a central etiological role in the pathogenesis of the disease. 
Widely considered the most toxic form of Aβ, soluble oligomers are hypothesized to initiate a 
pathological cascade of neurotoxic events involving Ca2+ dysregulation, synaptic disruption, and 
tau hyperphosphorylation and aggregation that culminate in neuron death. As described in 
Appendix B, VSNL1 coexpresses with genes associated with AD throughout normal aging, in 
particular the amyloid APP gene, which encodes the transmembrane protein that is cleaved to 
form Aβ peptide (Lin et al., 2015). In addition to the association with APP, Vilip-1 has been 
shown to abnormally localize with neuritic plaques in AD brain tissue (Braunewell et al., 2001a). 
Given these associations, we hypothesized that Aβ-induced pathology drives Vilip-1 expression. 
In Chapter 2.0 we investigated this hypothesis in two model systems: a transgenic mouse model 
of Aβ-overexpression and exogenous Aβ exposure in primary cortical neuronal cultures. Vilip-1 
expression levels were unaltered in both systems by the presence of Aβ peptide. While these 
results suggest that Vilip-1 expression is not driven by Aβ, it does not exclude Vilip-1 from 
potentially having a role in other major AD pathophysiological processes, such as tau 
hyperphosphorylation and aggregation in a manner that could contribute in various ways to 
disease phenotype.  
Notably, increased hyperphosphorylation of tau is a characteristic of a prevalent, 
heritable, and more severely progressive phenotype of AD, AD with psychosis (AD+P). 
Distinguished by the presence of hallucinations and delusions, AD+P occurs frequently, in 
upwards of 40% of AD cases. Familial aggregation is observed in AD+P with an estimated 
heritability of any occurrence of psychotic symptoms in AD of 30%, which increases to 61% for 
  82 
multiple/recurrent symptoms (Bacanu et al., 2005).  A substantial body of evidence indicates that 
the presence of psychotic symptoms in AD is linked to both greater cognitive impairment and 
more rapid cognitive decline (Ropacki and Jeste, 2005).  
Although data on the link between Aβ pathology burden and AD+P are conflicting, 
studies have indicated a consistent connection between psychosis and increased indices of tau 
pathology in the neocortex (Murray et al., 2014b). For example, we recently reported on 
phosphorylated tau in the prefrontal cortex of 45 AD cases with and without psychosis using 
immunohistochemistry. Intraneuronal tau concentration was higher in AD+P subjects, while the 
extent of phosphorylated tau spread throughout the DLPFC was unchanged. In addition, 
phosphorylated tau concentrations correlated inversely with scores on the MMSE and the Digit 
Span Backwards test that evaluates executive function and depends in part on the DLPFC 
(Murray et al., 2014a). These findings suggest that tau phosphorylation may be accelerated in 
AD+P. 
In conjunction with increased levels of hyperphosphorylated tau and decreased neuronal 
integrity attributed to AD+P, genetic studies evaluating putative psychosis risk genes in AD have 
identified an association of VILIP-1 with AD+P (Hollingworth et al., 2012). Qualitative 
immunohistochemistry data from human AD brain has also shown Vilip-1 immunoreactivity 
associates with extracellular tangles in the cortex (Braunewell et al., 2001a). Finally, Vilip-1-
transfected PC12 cells exposed to an ionomycin Ca2+ challenge demonstrated an increase in tau 
phosphorylation, suggesting that Vilip-1 may enhance this process (Schnurra et al., 2001). As 
described in Chapter 2.0, our data indicates that neither total tau levels nor phosphorylated tau 
levels were correlated with Vilip-1 in the SF of AD subjects. Additionally, history of psychosis 
was not significantly associated with SF Vilip-1 levels.  
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While our data suggest that it is unlikely that Vilip-1 is a critical component in further 
propagating disease related processes in either AD with or without psychosis, the possibility of 
an interaction between Vilip-1 and tau pathology needs to be further evaluated in alternative 
model systems. Neither the in vitro or B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax (PSAPP) 
in vivo models used in this dissertation are ideal for the evaluation of tau pathology as they do 
not recapitulate all of the neurofibrillary tangle pathology observed in AD (detailed in Chapter 
5.6 Methodological Considerations). Thus examining a model with more complete tau 
pathology and manipulating Vilip-1 levels in an Aβ environment would provide additional 
insight into a potential role for Vilip-1 in the pathogenesis of AD. One example might involve 
knocking down Vilip-1 expression in neurons from transgenic mutant tau mice and exposing the 
cultures to soluble Aβ to determine if reducing the protein expression is protective against 
neuron death in a model involving both major neuropathological components associated with 
AD. 
5.5 A ROLE FOR VILIP-1 IN AΒ-MEDIATED DISEASE PATHOLOGY? 
5.5.1 Neuron death 
Several lines of evidence support the amyloid cascade hypothesis in which Aβ oligomers initiate 
a set of events that perturb neuronal Ca2+ homeostasis and ultimately kill neurons. However, the 
full extent of neuropathological mechanisms engaged in the Aβ-mediated apoptotic process are 
not yet fully understood and remain a matter of investigation. Vilip-1, a neuronal calcium 
sensing protein, has previously been implicated as a potential mediator in neuronal death. Vilip-1 
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overexpression in PC12 cells has been shown to increase cell vulnerability to Ca2+-mediated cell 
death (Schnurra et al., 2001). In contrast, another NCS family member, hippocalcin, which is 
highly homologous to Vilip-1, is neuroprotective against Ca2+-mediated death in neural cell lines 
(Mercer et al., 2000). Together these data suggest that Vilip-1 may play a functional role in 
mediating Aβ-initiated neuronal death, specifically we hypothesized that downregulation of 
Vilip-1 expression would be neuroprotective against Aβ-mediated neuron death. Using primary 
cortical cultures of Vilip-1 heterozygous and wild type mice, we found that the extent of Vilip-1 
expression did not influence neuronal death, indicating that Vilip-1 unlikely mediates Aβ-
induced neuronal loss.  
Further clarification of the complex cascade of events involving Aβ-induced apoptosis 
will provide additional insight into whether differential pathways of activation exist and if Vilip-
1 potentially participates in a disease mechanism our experiment did not fully recapitulate. 
Currently, Aβ induction of apoptosis can occur through a number of hypothesized calcium 
dyshomeostasis mechanisms including artificial membrane pore formation (Arispe et al., 1993), 
oxidative stress buildup at the cell membrane (Butterfield, 2002), and altering internal calcium 
stores through endoplasmic reticulum channels (Stutzmann et al., 2004, Bezprozvanny and 
Mattson, 2008). This Ca2+ dysregulation is thought to lead to caspase activation, which can 
initiate an apoptosis cascade (Sharma and Rohrer, 2004, Tantral et al., 2004). However, the 
extent to which Aβ-induced caspase activation definitely leads to neuronal death, as opposed to 
primarily remodeling dendrites and spines, is currently debated (Hyman, 2011). While we were 
unsuccessful in our attempt to measure caspase-3 expression following Aβ treatment as 
described in Chapter 4.0, understanding the response of more specific aspects involved in this 
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complex cascade of apoptotic events would identify additional pathways affected by altering 
Vilip-1 levels, albeit to an extent that does not result in a change in neuron death.  
5.5.2 Synaptic Plasticity 
While our current data suggest that Vilip-1 does not participate in the Aβ-mediated neuronal 
death cascade, this NCS protein may have a role in Aβ-synaptic plasticity changes. Vilip-1, like 
other NCS subfamily members, seems to be involved in modifying receptor recycling 
(Braunewell and Klein-Szanto, 2009). With a higher affinity for Ca2+ than calmodulin, Vilip-1 
binds Ca2+ inducing a conformational change that exposes a hydrophobic myristoyl group 
allowing Vilip-1 to translocate and interact with cellular membranes and target proteins 
(Burgoyne and Weiss, 2001, Spilker and Braunewell, 2003). Specifically, Vilip-1 has been 
shown to interact with α4β2 nicotinic acetylcholine receptors and several types of receptors 
involved in cyclic guanosine monophosphate (cGMP) signaling, modulating surface expression 
and function (Braunewell et al., 2001b, Lin et al., 2002, Braunewell and Klein-Szanto, 2009). 
Another NCS protein family member, hippocalcin, appears to modify receptor trafficking via 
GluR endocytosis and promote NMDAR-dependent LTD (LTDNMDAR). Expression of a 
dominant negative hippocalcin that cannot detect Ca2+ occludes LTD (Palmer et al., 2005). 
Although the effects of VILIP-1 on GluR, NMDAR, and LTP/LTD are largely unknown, Vilip-
1’s highly homologous structure to hippocalcin suggests a role in a similar LTDNMDAR 
mechanism. LTD mechanisms (in conjunction with LTP) are widely thought to mediate dendritic 
spine size and stability (Yang et al., 2008), and thus cognitive function (Kasai et al., 2010).  
However, quantitative Western blot data from our lab suggests that Vilip-1 may not play a 
prominent role in LTDNMDAR mechanisms as reducing expression levels does not change 
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expression of key synaptic proteins. In particular, no significant alteration in the expression of 
synaptophysin, spinophilin, postsynaptic density protein 95(PSD-95), glutamate receptor 1 and 2 
(GluR1, GluR2), N-methyl D-aspartate receptor subtypes 1 and 2B (NR1, NR2b), or glutamate 
decarboxylase 65 (GAD65) was observed between Vilip-1 heterozygous and wild-type mice 
(data not shown). Future studies examining spine loss in Vilip-1 heterozygous/PSAPP mice, or 
in primary neuronal culture derived from Vilip-1 heterozygous and wild type mice exposed to 
Aβ, would provide further insight into a potential role for Vilip-1 in pathologic synapse 
alterations.  
5.6 METHODOLOGICAL CONSIDERATIONS 
5.6.1 Mouse models of Aβ deposition 
Many transgenic mouse lines model aspects of AD, but as with other complex psychiatric 
diseases, there is no one model that accurately recapitulates the neuropathology of the human 
disease in its entirety (Chin, 2011).  However, the most widely used genetically engineered 
mouse models generate major neuropathological hallmarks of AD, like amyloid plaques and 
neurofibrillary tangles, and provide insight into mechanisms underlying the disease.  
As described in Chapter 3.0, we selected the PSAPP mouse model for our study 
investigating whether Aβ drives Vilip-1 expression. This double transgenic model expresses 
chimeric mouse/human amyloid precursor protein carrying two mutations linked to familial AD: 
the Swedish mutation (Mo/HuAPP695swe) and mutant human presenilin 1 (PSEN1dE9) (Hardy, 
1997). The double transgenic increases the ratio of Aβ1-42:Aβ1-40 as compared to mice carrying 
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the APPswe mutation alone (Jankowsky et al., 2004). Both mutations are under the control of the 
mouse prion protein promoter, which results in primarily central nervous system transgene 
expression. At 4 months of age, the PSAPP mouse model presents with detectable Aβ deposits. 
By 12 months of age there is a global increase in levels of soluble and insoluble levels of two Aβ 
isoforms (Aβ1-40 and Aβ1-42), with Aβ1-42 being the predominantly expressed Aβ species (Garcia-
Alloza et al., 2006).  
Aβ-based mouse models, like PSAPP, recapitulate many of the key features of AD 
including production of neurotoxic Aβ species and subsequent amyloid plaque deposition, 
synapse loss, tau phosphorylation, dystrophic neurites, reactive gliosis, and cognitive deficits. 
However, neurofibrillary tangles and neuron loss are notably absent (Kurt et al., 2003, Chin, 
2011).  While familial AD mutations involving APP and/or presenilin always develop into 
typical AD with amyloid plaques and neurofibrillary tangles, it is unknown why these same 
mutations expressed within mouse models fail to display a more complete set of 
neuropathological disease attributes, such as the presentation of detectable tangles.  
Tau appears to be a critical component of the Aβ-initiated neurodegeneration cascade, as 
demonstrated by knockout studies. Complete removal of tau in neuronal cultures exposed to 
exogenous Aβ prevented characteristic neurite degeneration (Rapoport et al., 2002) and Aβ-
induced impairment of long-term potentiation (LTP) (Shipton et al., 2011). In addition, reducing 
endogenous levels of tau in APP overexpressing transgenic mice prevented cognitive deficits 
(Roberson et al., 2007).  However the extents to which neurofibrillary tangles and subsequent 
neuron loss play a role are not fully realized in models in which only mutant APP and/or 
presenilin are overexpressed. A few mouse models contain both amyloid and tau-related 
mutations, which can be useful for investigating the interaction between Aβ and tau. However, 
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since there are no known AD-specific tau mutations, these mice express familial tau mutations 
associated with FTLD (Gotz et al., 2007). Understanding the underlying mechanisms between 
Aβ-cascade initiation and tau aggregation through other model systems, like primary neuronal 
culture from transgenic mutant tau mice exposed to Aβ, may lead to new insights into how 
transgenic mouse models can more completely recapitulate the more complex nuances of AD 
neuropathology. 
 
5.2.1 Challenges and strategies for neuronal culture and Aβ treatment 
 
Over the past century, neuronal culture has advanced our fundamental understanding of 
nervous system function. Evolving from the hanging drop culture technique, which first 
demonstrated that cells could be maintained outside of the body, to better mimicking the brain 
and gaining precise spatiotemporal fluidic control by pioneering neuron growth in three-
dimensional microenvironments, in vitro studies are pushing boundaries and providing new 
insight across all fields in neuroscience (Millet and Gillette, 2012). A variety of neuronal culture 
techniques are in use today, each with their own benefits and challenges. Disparities observed 
between different approaches can present certain challenges in reproducing results and reviewing 
data across laboratories and experiments. This section will discuss some of the strengths and 
limitations associated with the primary cortical neuronal culture methodology employed in this 
dissertation and the strategies used to overcome encountered challenges.   
5.6.1.1 Variability associated with primary cortical neuronal cultures. The first major 
consideration in culture system selection is the type of cells being cultured. A number of options 
exist including neuronal cell line models, primary hippocampal and cortical neuronal cultures, 
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and hippocampal organotypic slice cultures, among others. We selected primary cortical cultures, 
a well-established system for investigating Aβ-induced neuronal toxicity. In addition, in AD with 
psychosis neuroimaging and postmortem studies have shown impairments associated with 
psychotic symptoms in neocortical regions (particularly in DLPFC), but not in hippocampus. 
Primary cortical cultures have several advantages over available immortalized neuronal cell 
lines. These include the natural production of Vilip-1, our protein of interest, and that they are 
not tumor derived, more accurately recapitulating in vivo neuronal properties. Additionally, they 
more accurately recapitulate the in vivo environment of the brain by providing a population of 
neurons that extend axons and dendrites, and create functional synapses between the cells. 
However, the lack of immortality limits the number of neurons obtained from each animal 
cortex.   
Initially we employed the use of a bilaminar co-culture system consisting of primary 
cortical neurons and glia. This approach involves late embryonic stage neurons being plated on a 
glass coverslip, which are then inverted over a glial feeder cell layer (Shimizu et al., 2011). 
While this technique is ideal for examining cell morphology as it can sustain extremely low-
density cultures, it is technically challenging. Individual paraffin feet must be crafted onto the 
coverslip and be of equal size to ensure even diffusion of glial survival factors across all cells on 
the coverslip and prevent coverslips from sliding on top of each other. Additionally, an issue 
arose with glial adherence to the tissue culture dish following inversion of neuronal coverslips, 
which was caused by switching the cells from glial maintenance media to neuronal media. 
Ultimately, we switched our approach to a more widely employed technique yielding more 
consistent results, that of primary cortical culture supplementation with B27 reagent.  
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B27 is a serum-free supplement that is designed to promote the growth and maintenance 
of low or high density mixed cortical neuronal cultures. While sufficient for the originally 
intended purpose of maintaining neurons, its proprietary formulation later presented unforeseen 
problems in attempts to measure protein release into the media. B27 inhibited the lactate 
dehydrogenase (LDH) cell death reaction that is used to measure the cytosolic enzyme upon 
release into the medium following cell membrane breakdown following apoptosis. LDH levels 
would have served as another neuronal integrity measure in conjunction with our neuron-specific 
nuclear protein (NeuN)/TUNEL cell counts. Additionally, future work investigating Vilip-1 
protein release upon neuronal death via western blot or LC-SRM/MS is complicated as an 
unknown component of the B27 supplement reacts with the bicinchoninic acid assay used to 
measure protein concentration in a sample. To further pursue these avenues, new serum-free 
media supplements may need to be investigated. 
While neuron-glia interactions in the central nervous system are important for normal 
function, presence of both cell-types in mixed cortical cultures presents some additional 
limitations in terms of cell discrimination. To circumvent this issue and ensure our neuronal 
death counts did not include glia, we developed an assay using NeuN antibody paired with 
TUNEL staining. NeuN has been vetted as a neuron-specific nuclear protein in vertebrates and is 
widely expressed across neuronal types with a few exceptions including cerebellar Purkinje cells, 
olfactory bulb mitral cells, and retinal photoreceptor cells (Mullen et al., 1992). However, these 
exceptions did not present an issue with the use of primary cortical cultures in our experiments. 
Other methodological modifications we made to limit assay variability and improve 
neuronal survival included plating higher neuron densities, switching the cell attachment and 
adhesion substrate from poly-L-lysine, which can be digested by cells, to coverslips coated with 
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poly-D-lysine, and replacing L-glutamine with GlutaMAX, a reagent that is a stabilized form of 
L-glutamine that better withstands degradation and better supports the energy demands of cells. 
5.6.1.2  Aβ. In addition to the variability associated with culture systems, a number of factors 
influence the design of an Aβ-treatment experiment. First, amyloid peptide application can either 
be exogenously applied or endogenously produced from overexpression of mutant APP. For 
exogenous application, synthetic Aβ forms are most commonly utilized, however naturally 
secreted peptides from human AD brains can be extracted. Aβ peptides exist in a number of 
conformations that produce varying levels of toxicity including: monomers, dimers, oligomers, 
or fibrils. Additionally Aβ exists in variety of lengths, with Aβ1-40, 1-42, 1-43, and 25-35 being 
the most commonly studied. Finally, Aβ fibrils may aggregate into plaques. In vivo, plaques may 
actually serve as reservoirs for Aβ oligomers in which there is a constant interconversion 
between nonfibrillar and fibrillar forms of Aβ in the plaque surround (Koffie et al., 2009, 
Kirkwood et al., 2013). The kinetics and structure of Aβ in culture can be difficult to discern, 
particularly after the peptide preparation goes into culture as these self-aggregating peptides are 
influenced by factors such as pH and temperature (Valerio et al., 2008, Zhang et al., 2013).  Aβ 
concentration and exposure time length also factor into study design because exposing neurons 
to lower concentrations and/or shorter exposure times can exact more subtle effects on dendritic 
spines than higher concentrations and/or longer exposure times, which can result in neuron 
death.  
We used a commercially available synthetic form of human Aβ1-42, which is the 
predominant form of the peptide found in the human AD brain (Mann et al., 1996). As described 
in Chapter 3.0, we demonstrated that we applied primarily dimeric and some higher molecular 
weight Aβ species to our culture system, which have shown to have significant toxic effects on 
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cells (Ono et al., 2009). Cultures were exposed for 24 hours to ensure induction of neuronal 
death. 
Many factors impact the design of an Aβ-exposure culture experiment with the list 
including but not limited to: cell type, cell density, culture supplementation, Aβ type, Aβ 
concentration, and Aβ exposure duration. However despite the number of factors that can impact 
an experiment, as research continues to uncover more about how Aβ induces toxicity in AD, 
these variables can be honed into a more precise model. 
5.7 CONCLUSIONS AND FUTURE DIRECTIONS 
In summary, this dissertation begins to address the critical gap in knowledge associated with the 
role of Vilip-1 in AD. Identified as an AD-specific peripheral biomarker and further implicated 
in the disease process by genetic and immunohistochemical studies, to date evidence for a 
functional role of Vilip-1 in the pathogenesis of AD is limited. Studies conducted in this 
dissertation highlight two important points about the potential utility of Vilip-1 protein as a 
marker of neuronal integrity. First, Vilip-1 appears to be a general marker for neuronal loss in 
brain tissue instead of part of an AD-specific pathological process, however due to differential 
access to the CSF and plasma for structures in the medial temporal lobe, which are particularly 
affected in AD, it is a reliable biomarker for the disease in comparison to other 
neurodegenerative disorders that impact different brain regions. Second, Vilip-1 may have value 
as a marker for relative amounts of neuronal loss in human brain tissue, which would save 
resources and time in studies that require a general evaluation of the measure. 
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Future mechanistic in vivo and in vitro studies investigating the potential roles of Vilip-1 
in other AD-associated neuropathologies such as tau hyperphosphorylation or its impact on other 
aspects of neurodegeneration, like synaptic plasticity and spine loss, will aid in the development 
of a more comprehensive picture of whether Vilip-1 plays a functional role in AD. Based on the 
findings in this dissertation Vilip-1 does not present as a promising therapeutic target for 
intervening in Aβ-mediated neuronal loss, however, it cannot be fully ruled out in the 
neuropathogenesis of AD until more extensive work evaluating multiple aspects of the disease is 
completed. 
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A.1 ABSTRACT 
Dendritic spines are the site of the majority of excitatory synapses, the loss of which correlates 
with cognitive impairment in patients with Alzheimer disease. Substantial evidence indicates that 
amyloid-β (Aβ) peptide, either insoluble fibrillar Aβ deposited into plaques or soluble non-
fibrillar Aβ species, can cause spine loss but the concurrent contributions of fibrillar Aβ and non-
fibrillar Aβ to spine loss has not been previously assessed. We used multiple-label 
immunohistochemistry to measure spine density, size, and f-actin content surrounding plaques in 
the cerebral cortex in the PSAPP mouse model of Aβ deposition. Our approach allowed us to 
measure fibrillar Aβ plaque content and an index of non-fibrillar Aβ species concurrently. We 
found that spine density was reduced within 6 μm of the plaque perimeter, remaining spines were 
more compact, and f-actin content per spine was increased. Measures of fibrillar Aβ plaque 
content were associated with reduced spine density near plaques, whereas measures of non-
fibrillar Aβ species were associated with reduced spine density and size, but not altered f-actin 
content. These findings suggest that strategies to preserve dendritic spines in AD patients may 
need to address both non-fibrillar and fibrillar forms of Aβ and that non-fibrillar Aβ may exert 
spine toxicity through pathways not mediated by depolymerization of f-actin. 
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A.2 INTRODUCTION 
Alzheimer disease (AD) is the most common form of dementia and is characterized clinically by 
progressive loss of memory and cognitive function and progressive impairments in behavior. A 
number of neurodegenerative changes underlie these clinical manifestations. Two 
neuropathologic hallmarks of AD are extracellular amyloid plaques composed of amyloid-β (Aβ) 
peptide and intracellular neurofibrillary tangles, consisting of hyperphosphorylated microtubule-
associated protein tau (Selkoe, 2004, Ballatore et al., 2007). Other pathologic changes include 
widespread cortical synapse loss, neuronal loss, and reactive gliosis (Ingelsson et al., 2004). Of 
these pathologic alterations, loss of synapses is the best structural correlate of cognitive 
impairments in AD (DeKosky and Scheff, 1990, Scheff et al., 2007). Genetic, in vitro, and in 
vivo studies have implicated soluble Aβ as a primary cause of the synapse loss in AD (Walsh 
and Selkoe, 2007). 
In cerebral cortex, dendritic spines are the site of the majority of excitatory synapses. 
Substantial evidence indicates that progressive loss of dendritic spines in AD is due to effects of 
Aβ, either insoluble fibrillar Aβ deposited into amyloid plaques, or non-fibrillar Aβ species 
lacking amyloid structure, the latter including soluble oligomers and protofibrils (Walsh et al., 
2005). In organotypic slice culture, both exogenous exposure to soluble Aβ and overexpression 
of endogenous Aβ by neurons dramatically reduce dendritic spine density (Hsieh et al., 2006, 
Shankar et al., 2007). Transcranial multiphoton imaging studies in transgenic mouse models of 
AD have shown that dendrites passing through or near fibrillar Aβ plaques undergo spine loss  
(Tsai et al., 2004, Spires et al., 2005). Transgenic mouse model studies have also revealed that 
fibrillar Aβ plaques are surrounded by a halo of oligomeric Aβ and have reported a loss of 
excitatory synapses within this halo region (Koffie et al., 2009). Confocal microscopy in the 
  97 
PSAPP mouse model and in AD autopsy brain tissue has confirmed reduced densities of 
dendritic spines in proximity to fibrillar Aβ plaques (Grutzendler et al., 2007). While 
informative, these studies did not address the relative contributions to dendritic spine loss of 
fibrillar Aβ in plaques and concurrently measured non-fibrillar (soluble) Aβ species. 
Current understanding of dendritic spine maintenance and elimination has focused mainly 
on the regulation of the spine f-actin network. Long-term potentiation (LTP) is a form of 
activity-dependent synaptic plasticity that is widely believed to be the cellular basis for learning 
and memory. Enlargement of single spines has been shown to be associated with LTP 
(Matsuzaki et al., 2004), and requires polymerization of g-actin into f-actin (Okamoto et al., 
2004). Conversely, long-term depression (LTD), another form of activity-dependent plasticity, 
has been shown to induce dendritic spine shrinkage and elimination via f-actin depolymerization 
(Nagerl et al., 2004, Okamoto et al., 2004, Zhou et al., 2004). Studies conducted in rodent 
hippocampus have demonstrated that soluble Aβ oligomers can enhance LTD and inhibit LTP, 
suggesting that Aβ-induced spine loss engages mechanisms that reduce f-actin content in spines. 
(Wang et al., 2002, Shankar et al., 2008). 
In the present study, we used a novel multiple-label immunohistochemical approach in 
the PSAPP transgenic mouse model of Aβ deposition to measure spine density, size, and f-actin 
content surrounding plaques in the cerebral cortex. In addition, our approach allowed us to 
concurrently measure fibrillar Aβ plaque content and an index of non-fibrillar Aβ species, 
examining their relationship to spine parameters. We found that dendritic spine density was 
reduced and remaining spines were more compact within 6 μm of the plaque perimeter, with a 
concomitant increase in f-actin content per spine. Measures of fibrillar Aβ plaque content were 
associated with reduced spine density near plaques, while measures of non-fibrillar Aβ species 
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were associated with reduced spine density, size, and shape complexity, but not with altered f-
actin content. 
A.3 MATERIALS AND METHODS 
A.3.1 Transgenic Animals 
Double transgenic PSAPP mice were generated by mating male APP Tg2576 (K670N/M671L) 
mice (Hsiao et al., 1996) (Taconic Farms, Germantown, NY) with female M146L PS1 mice 
(mutant PS1, line 6.2, University of South Florida) (Duff et al., 1996). The Tg 2576 mice were 
derived from a C57B6/SJL × C57B6 background; the M146L PS1 animals were derived from a 
Swiss-Webster/B6D2F1 × B6D2F1 background (Holcomb et al., 1998). Food and water were 
available ad libitum and a 12/12-hour light/dark cycle was maintained. All studies were approved 
by the University of Pittsburgh Institutional Animal Care and Use Committee. All mice were 
male to circumvent concerns about estrous cycling. 
A.3.2 Tissue Preparation and Immunohistochemistry 
PSAPP mice were anesthetized with isoflurane and perfused transcardially with phosphate buffer 
followed by cold 4% paraformaldehyde. Brains were removed, immersion-fixed in cold 4% 
paraformaldehyde for 24 hours and cryoprotected in a series of 15% and 30% sucrose solutions. 
Sections were cut coronally at 40 μm on a freezing sledge microtome and stored at −20°C in 
cryoprotectant solution (Watson et al., 1986). A single section was selected for analysis from 
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each of 4 12-week-old, 3 15-week-old, and 4 18-week-old mice, matched for rostral-caudal level 
using cytoarchitectonic features (~bregma −2.30 mm [(Paxinos G, 2004)]). 
Histochemical staining of fibrillar Aβ plaques was performed using X-34, a highly 
fluorescent Congo red derivative, which binds peptides and proteins in fibrillar β-pleated sheet 
conformations (“amyloid”) with a high affinity (Ikonomovic et al., 2006). Because 
immunoreactivity of fibrillar Aβ plaques to anti-Aβ antibodies is weak unless a formic acid pre-
treatment is used to break up the fibrillar β-pleated sheet structure (Ikonomovic et al., 2006), we 
used 3 different antibodies, each in the absence of formic acid pre-treatment, to visualize non-
fibrillar Aβ. The 6E10 antibody (biotinylated, SIG-39340; Covance, Emeryville, CA) is directed 
against the N-terminus of human Aβ peptide. The 4G8 antibody (biotinylated, SIG-39240, 
Covance) is directed against Aβ amino acids 17–24. Western blot analyses provide clear 
evidence that 6E10 and 4G8 are reactive with soluble monomeric and oligomeric species of Aβ 
(Kayed et al., 2010, Zempel et al., 2010). Because both of these antibodies may cross-react with 
the Aβ precursor protein (APP), we also used the anti-Aβx-40 antibody (AB5074P; Millipore, 
Temecula, CA), which is directed against the neo-epitope at amino acid 40 of the Aβ peptide and 
has human and mouse species reactivity. This antibody predominantly labels Aβ 1-40, and does 
not label longer Aβ forms (e.g. 1-42) or full-length APP (Kamal et al., 2001). Histochemical 
staining of dendritic spines was accomplished with the f-actin binding mushroom toxin 
phalloidin, conjugated to Alexa Fluor 568 (A12380; Invitrogen, Eugene, OR) (Capani et al., 
2001). Although a direct, linear relationship specifically between phalloidin fluorescence 
intensity and f-actin concentration has not been firmly established, we have previously shown 
that detected fluorescence intensity is directly related to the intensity of fluorescent microspheres 
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embedded in thick sections, and can be used to measure protein concentration accurately 
(Sugiyama et al., 2005, Fish et al., 2008). 
Free-floating tissue sections were incubated in 1% NaBH4 for 30 minutes followed by a 
3-hour incubation at room temperature in phosphate buffered saline (PBS) containing 5% normal 
human serum, 5% goat serum, and 0.3% Triton X-100, and then incubated with PBS containing 
5% normal human serum, 5% goat serum, and a 1:1000-dilution of biotinylated 6E10 antibody, a 
1:1000 dilution of biotinylated 4G8 antibody, or a 1:100 dilution of anti-Aβx-40 antibody for 24 
hours at 4°C. Next tissue sections were incubated for 24 hours at 4°C in PBS containing 5% 
normal human serum, 5% goat serum, phalloidin conjugated to Alexa Fluor 568 at a 
concentration of 1.5 μL/mL and either a 1:500 dilution of streptavidin conjugated to Alexa Fluor 
488 (Invitrogen) or 1:500 goat anti-rabbit secondary antibody conjugated to Alexa Fluor 488 
(Invitrogen). All tissue sections were then mounted on slides and after drying for 1 hour the 
sections were rehydrated for 5 minutes in PBS. Sections were incubated for 10 minutes in 100 
μM stock solution of X-34, and then dipped in distilled water and incubated in 0.2% sodium 
hydroxide made in 80% unbuffered ethanol for 2 minutes; they were then soaked in distilled 
water for 10 minutes. Sections were coverslipped with Vectashield hard set (Vector Laboratories, 
Burlingame, CA). Final mean section thickness was 10.45 ± 4.409 μm (SD). Sections were 
processed and analyzed in 2 separate immunohistochemistry runs. 
A.3.3 Microscopy 
Data acquisition was performed on an Olympus (Center Valley, PA) BX51 WI upright 
microscope equipped with an Olympus spinning disk confocal (SDCM) using an Olympus 
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PlanAPO N 60X 1.42 N.A. oil immersion objective. The SDCM was equipped with an ORCA-
R2 camera (Hamamatsu, Bridgewater, NJ), MBF CX9000 front mounted digital camera 
(MicroBrightField, Inc., Natick, MA), BioPrecision2 XYZ motorized stage with linear XYZ 
encoders (Ludl Electronic Products Ltd., Hawthorne, NY), excitation and emission filter wheels 
(Ludl Electronic Products Ltd), and equipped with a Sedat Quad 89000 filter set (Chroma 
Technology Corp., Bellows Falls, VT). The microscope was controlled by Stereo Investigator 
software (MicroBrightField, Inc.) and illuminated using a Lumen 220 metal halide lamp (Prior 
Scientific, Rockland, MA). 
Using Stereo Investigator software, the cerebral cortex of each tissue section was first 
outlined and a systematic random sampling grid was then randomly rotated and applied to each 
tissue section (Figure, Supplemental Digital Content 1, http://links.lww.com/NEN/A474). At 
each site, defined by the intersection of the grid with the cortical gray matter, the investigator 
determined if a visible single plaque (defined by the presence of X-34-positive staining) was 
present within the 512 × 512 field of view at high power. When a single plaque was present it 
was then recentered in the field of view and, if it fit within the 512 × 512 pixels window of 
uniform fluorescence illumination, it was used for quantification, that is, an image stack was 
collected. 
Each 3-dimensional image stack consisted of image planes of 512 × 512 pixels (~ 3058 
μm2) that were separated by 0.25 μm and acquired throughout the tissue section starting at the 
slide. At each plane, data were collected using the following filters: excitation 403 ± 6 
nm/emission 457 ± 25 nm, excitation 490 ± 10) nm/emission 528 ± 19 nm, and excitation 555 ± 
14 nm/emission 617 nm ± 37 nm. Exposure times (150 seconds, 1000 seconds, and 1100 
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seconds, respectively) were maintained for all experiments and there were no instances of pixel 
saturation in any stack. 
A.3.4 Image Processing 
To control for differences in background fluorescence intensity across animals, sections, and 
image stacks, the mode of the histogram was identified and subtracted. The choice of this 
approach reflected several considerations. First, because labeled objects of interest (i.e. dendritic 
spines) represent a minority of the voxels, the modal value is reflective of the background. 
Second, this approach is without the potential for operator bias. Third, non-specific background 
fluorescence is variable between sites and across samples (Luther et al., 2004), particularly in 
tissue sections. 
Following background subtraction, the phalloidin channel was transformed to enhance 
automated detection of dendritic spines. Specifically, the final output was a subtraction of 
Gaussian filter channels of 2 different standard deviations of the Gaussian distribution s(σ) ([σ = 
0.7] − [σ = 2.0]). Figure Supplemental Digital Content 2, http://links.lww.com/NEN/A475, 
 demonstrates this concept with a 500-nm fluorescent bead. Data segmentation of the Gaussian 
filter transformation of the phalloidin channel to create binary mask objects was performed as 
previously described (Fish et al., 2008) except that threshold settings were evenly spaced (50 
grey levels; Figure A.1.A). This approach provides for quantification of large numbers of 
phalloidin-labeled objects, with little contribution of non-specific fluorescent signal (Figure, 
Supplemental Digital Content 3, http://links.lww.com/NEN/A476). Image channels for non-
fibrillar Aβ, fibrillar Aβ plaques and phalloidin, but not the Gaussian filter transformation 
channel, were deconvolved using the constrained iterative algorithm included in SlideBook 5.13. 
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After deconvolution, a region of interest containing the entire fibrillar Aβ plaque was manually 
defined and a threshold segmentation set at 50 grayscale units above background was applied to 
the X-34 channel intensity to generate a binary mask object of the plaque. Twelve contiguous 3-
dimensional concentric shells were constructed around the outer edge of the fibrillar Aβ plaque 
(Figure A.1.B). Each shell was created using the mask dilation command in SlideBook, which 
allowed each shell mask, starting with the mask of the plaque, to be increased in radial size by 
exactly 2 μm from the prior mask. The prior mask was then subtracted from this larger mask to 
create each shell. The coordinates of the centroid for each phalloidin channel mask object were 
used to assign each mask object to a single shell, allowing for the analysis of dendritic spine 
density, morphology, and relative fluorescence intensity at known distances from the fibrillar Aβ 
plaque. 
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Figure A.1 Approach to image processing. (A.1–A.3) Image processing. Raw single plane image of dendritic 
spines labeled with phalloidin (red), amyloid-β (Aβ)-Immunoreactivity (green), and fibrillar Aβ plaque (blue) (A.1). 
The raw image was processed using the constrained iterative (CI) algorithm deconvolution for the Aβ-
Immunoreactivity (green) and fibrillar Aβ plaque (blue) and the Gaussian filter transformation for dendritic spines 
(red). Dendritic spines are now clearly defined punctate structures and the amyloid and Aβ-Immunoreactive 
structures are refined (A.2). Generation of a binary mask (blue) using Iterative threshold segmentation of the 
Gaussian filter transformation (red) from the image seen in (A.2) shows the precision of dendritic spine coverage 
achieved using this processing technique. For extraction of relative fluorescence intensity within spines, the mask 
shown is overlayed on the CI deconvolved phalloidin channel (A.3). (B.1–B.3) Three-dimensional shells 
surrounding a plaque. A single plane from a CI deconvolved image with dendritic spines (red), Aβ-
Immunoreactivity (green), and fibrillar Aβ plaque (blue) (B.1). Outline of the first 4 (of 12) shells used in the 
analysis; each is expanded by 2 μm from the edge of the fibrillar Aβ plaque overlayed on (A) (B.2). Three-
dimensional surface rendering of lower half of the same image stack with a representative shell shown in dark blue 
(B.3). 
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A.3.5 Statistical Methods 
Initial comparison of spine parameters as a function of distance (0 to 6 μm and greater than 6 
μm) from the fibrillar Aβ plaque for the 134 measured plaques used linear mixed models with a 
first order autoregressive covariance structure. Subject level effects were animal, with repeated 
measures of plaque and shell. Fixed effects were fibrillar Aβ plaque volume, mean X-34 
fluorescence intensity within the plaque, total non-fibrillar Aβ intensity within the shell, 
immunohistochemistry run, and (to control for any possible effects of the small difference in 
ages between mice) age group. For analysis of the impact of plaque and non-fibrillar Aβ effects 
on dendritic spine density, linear mixed models with a first order autoregressive covariance 
structure were used to analyze each concentric shell. Plaque was a repeated measure within 
animal, with fixed effects of fibrillar Aβ plaque volume, mean X-34 fluorescence intensity 
within the plaque, total non-fibrillar Aβ intensity within the shell, immunohistochemistry run, 
and age group. Spine density in each shell, i.e. at each distance from the plaque, was the 
dependent variable. Based on the results of the preceding linear mixed models, further analyses 
of spine density, morphology and total f-actin content per spine were conducted for shells within 
0 to 6 μm of the plaque perimeter. These analyses used mixed models, with repeated measures 
within animals of plaque and shell, and fixed effects of fibrillar Aβ plaque volume, mean X-34 
fluorescence intensity within the plaque, total non-fibrillar Aβ intensity within each shell, 
immunohistochemistry run, and age group. Additional models in which final section thickness 
was entered to evaluate whether section shrinkage during processing might have influenced the 
associations did not alter the results except where indicated. All intensity measurements used in 
the analyses were normalized across immunohistochemistry run to account for assay variability. 
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A.4 RESULTS 
A.4.1 Detection of Aβ-Immunoreactivity Surrounding Fibrillar Aβ Plaques 
Anti-Aβ antibodies 6E10, 4G8, and anti-Aβx-40 revealed a similar pattern of label 
concentrated in the immediate surrounding area of the X-34-positive fibrillar Aβ plaque (Figure 
A.2.A). Three-dimensional surface renderings also demonstrated accumulation of Aβ-
immunoreactivity around X-34-positive fibrillar Aβ plaques (Figure A.2.B). Figure A.3 
graphically depicts the distribution of 6E10 antibody label as a function of distance from the 
plaque with the highest Aβ-immunoreactivity located adjacent to the plaque. 
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Figure A.2 Plaques dual-labeled with X-34 and anti- amyloid-β (Aβ) antibodies. (A) X-34 positive fibrillar Aβ 
plaques (red) and Aβ-Immunoreactivity detected with anti-Aβ antibodies (green). The antibodies, 6E10, 4G8, and 
anti-Aβx-40 label the N-terminus, amino acids 17–24, and the C-terminus neo-epitope of Aβ, respectively. Several 
examples shown for each antibody reveal a similar pattern of label external to the outside edge of the fibrillar Aβ 
plaque, and in the immediate surrounding areas. (B) Three-dimensional surface rendering of a plaque dual-labeled 
with X-34 and 6E10. The 3 rotated views illustrate the accumulation of Aβ-Immunoreactivity labeled with 6E10 
(green) adjacent to and in the area surrounding an X-34-labeled fibrillar Aβ plaque (red). 
  108 
 
 
Figure A.3 Amyloid-β (Aβ) immunoreactivity (total 6E10 fluorescence intensity) within each 3-dimensional shell 
as a function of distance from the plaque. The means of 134 plaques analyzed are shown. The majority of the Aβ-
Immunoreactivity is concentrated within the first few μm of the fibrillar Aβ plaque. Bars indicate SEM. 
A.4.2 Spine Density, Spine Morphology, and Mean Phalloidin Fluorescence Intensity Per 
Spine Vary as a Function of Distance from Fibrillar Aβ Plaques 
Decreased dendritic spine density around fibrillar Aβ plaques was qualitatively observed with 
near complete spine ablation in the area occupied by the X-34-positive fibrillar Aβ plaque  
(Figure, Supplemental Digital Content 4, http://links.lww.com/NEN/A477), with reduced spine 
densities apparent out to a distance of 6 μm from the perimeter of the plaque (Figure A.4). 
Quantitative analyses of a total of 830,634 spines in the PSAPP mouse cortex confirmed that 
spine density was lower within this 6-μm perimeter of the Aβ plaque (Figure A.4; Table A.1). In 
contrast, we analyzed spine densities in 16-week-old male C57BL6/J mice (Figure Supplemental 
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Digital Content 5, http://links.lww.com/NEN/A478). A phantom plaque was created in the 
middle of each image stack and 12 concentric shells were constructed as in the PSAPP mice and 
spine densities were calculated. There was no significant difference of spine density between any 
of the shells in the C57BL6/J mice. 
 
 
Figure A.4 Mean spine density as a function of distance from the plaque. (A, B) Aβ-Immunoreactivity fluorescence 
intensity (A) and fibrillar Aβ plaque mean X-34 fluorescence intensity (B) are shown separated into low (●), 
medium (), and high (■) tertiles to demonstrate graphically the effects evaluated in Table 2.] 
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Table A.1 Summary of Dendritic Spine Characteristics as a Function of Distance from the Plaque (n = 134) 
 
In addition to reductions in spine density within the 6-μm perimeter of the Aβ plaque, spine 
volume was lower in this region and spine surface area was reduced, resulting in a reduction in 
spine shape complexity (Table 1). Despite these changes in spine morphology, there was no 
decrease in mean phalloidin intensity per spine. In fact there was a significant increase in these 
values within the 6-μm perimeter, indicating an increased concentration of f-actin within these 
spines. 
A.4.3 Relationships of Spine Density, Spine Morphology, and Mean Phalloidin 
Fluorescence Intensity Per Spine with Fibrillar Aβ Plaque Volume, Aβ Plaque Mean X-34 
Fluorescence Intensity, and Non-Fibrillar Aβ 6E10 Fluorescence Intensity 
Linear mixed models showed that a decrease in spine density was independently associated with 
greater fibrillar Aβ plaque mean X-34 fluorescence intensity the first 6 μm from the plaque and 
with greater total Aβ-immunoreactivity (6E10 fluorescence intensity) within the first 2 μm of the 
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plaque edge (Table A.2; Figure A.4). No significant effect was seen due to fibrillar Aβ plaque 
volume. 
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Table A.2 Stepwise linear regressions of spine densities starting within the fibrillar Aβ plaque and extending to a 
distance of 24 μm from the plaque perimeter 
 
Decreases in spine volume and surface area were significantly associated with non-
fibrillar Aβ 6E10 fluorescence intensity within 6 μm of the fibrillar Aβ plaque edge (Table A.3). 
Interestingly, the relative amount of f-actin as indexed by phalloidin fluorescence intensity 
measured per spine did not change as a function of Aβ-immunoreactivity (Table A.3). There 
were no significant associations of fibrillar Aβ plaque mean X-34 fluorescence intensity with 
spine morphology or relative amount of f-actin. 
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Table A.3 Association of Spine Morphologic Measures with β-Amyloid and Plaque Features 
 
A.5 DISCUSSION 
A.5.1 Spine Density and Morphology Alterations are Present Surrounding Fibrillar Aβ 
Plaques 
We observed significant decreases in spine density within the first 6 μm beyond the perimeter of 
fibrillar Aβ plaque due to independent contributions of fibrillar Aβ plaque content and content of 
Aβ-immunoreactivity. A study by Spires et al utilizing 21- to 25-month-old Tg2576 mice 
similarly reported that distance from plaque perimeter correlates with deficits in spine density 
(Spires et al., 2005). In that study, plaque area (similar to plaque volume in the current report) 
was also not correlated with spine loss (Spires et al., 2005); however, the investigators found that 
the correlation between distance from the plaque and reduced spine density extended up to 20 
μm. This discrepancy likely reflects the differences in mouse strain, in the ages and degree of 
plaque pathology of these animals, and/or differences in imaging methodologies between that 
and the current study. 
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In addition to reductions in spine density, we found decreases in surface area and shape 
complexity, and a trend towards decreased spine volume surrounding plaques. These findings 
suggest that spine physiology could be altered even before their disappearance. Soluble Aβ 
species have been shown to engage LTD and inhibit LTP pathways (Wang et al., 2002, Shankar 
et al., 2008), processes that typically leads to spine loss via spine f-actin depolymerization 
(Okamoto et al., 2004). It was therefore somewhat surprising that when investigating the relative 
amount of f-actin, as indexed by total phalloidin fluorescence measured per spine, we did not 
observe net reductions in spines close to plaques. In fact, we saw an increase in phalloidin total 
intensity within smaller, more spherical spines. Thus, the mechanism of spine morphology 
changes, at least initially, and does not appear to be through net depletion of f-actin, but through 
restructuring of the cytoarchitecture. Actin filaments in the spine head are very dynamic and 
there are several mechanisms by which actin polymerization and depolymerization are regulated 
to influence the spatial arrangement of f-actin in spines. For example Arp2/3 binds to existing 
actin filaments to nucleate new filaments and facilitate branching (Wilson et al., 2007). Another 
actin-regulating molecule, myosin II, binds and contracts actin filaments and is required for 
proper spine morphology (Korobova and Svitkina, 2010). Drebrin is an actin-binding protein 
localized in spines that is thought to inhibit the actin-myosin interaction and subsequently alter 
spine morphology (Hayashi et al., 1996). Still other proteins, such as cofilin, are responsible for 
proper spine head morphology, play an active role in actin dynamics (Bamburg and Bloom, 
2009), and result in pathologic changes in actin in response to soluble Aβ (Davis et al., 2011). 
Thus, one or more of these molecular mechanisms may be acting to alter spine morphology in a 
manner independent of f-actin loss. 
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A.5.2 Relative Contributions of Fibrillar and Non-Fibrillar Aβ Species to Spine 
Alterations Surrounding Fibrillar Aβ Plaques 
Previous in vitro studies with synthetic Aβ have reported that fibrillar Aβ forms, such as those 
found in Aβ plaques, are neurotoxic (Lorenzo and Yankner, 1994, Iversen et al., 1995). Other 
studies have implicated soluble Aβ as the primary contributor to synaptotoxicity (Lue et al., 
1999, Walsh et al., 2002). Because both forms can exist in equilibrium there is some controversy 
regarding which is primarily responsible for pathologic effects (Zempel et al., 2010). We 
observed a halo of Aβ immunoreactivity in the immediate surround of the X-34 positive fibrillar 
Aβ plaque. We interpret this Aβ-immunoreactivity as an index enriched for the content of non-
fibrillar soluble Aβ species in the plaque surround. This interpretation is based on several aspects 
of our approach and findings. Although the 3 antibodies used in the present study target different 
portions of the Aβ peptide (i.e. the N-terminus, mid portion, and C-terminus), they produced 
comparable patterns of Aβ immunoreactivity around the X-34 positive fibrillar Aβ plaque, which 
suggests that we are in fact labeling Aβ forms rather than full-length APP (which is not detected 
by anti-Aβx-40) or another related metabolic fragment. Second, there is clear evidence that at 
least antibodies 6E10 and 4G8 label non-fibrillar soluble species of Aβ (Kayed et al., 2010, 
Zempel et al., 2010). Third, soluble Aβ binds locally to synaptic structures (Koffie et al., 2009) 
and to various components of the extracellular matrix (Valle-Delgado et al., 2010), either of 
which would facilitate in situ fixation, although some non-fibrillar soluble Aβ would likely be 
lost by diffusion. Fourth, in the absence of formic acid pre-treatment, we saw little evidence of 
colocalization of anti-Aβ labeling with X-34 staining, the latter of which is highly selective for 
fibrillar, β-pleated sheet conformations (Ikonomovic et al., 2006). While some anti-Aβ binding 
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to fibrillar Aβ in plaques may still occur, our approach would have enriched the relative 
contribution of non-fibrillar Aβ species to the total measured Aβ-immunoreactivity. Fifth, we 
observed effects likely to reflect the toxicity of Aβ at distances up to 6 μm beyond the edge of 
the fibrillar Aβ plaque, consistent with diffusion of soluble species. 
The interpretation that Aβ-immunoreactivity indexes non-fibrillar Aβ species is also 
consistent with the observed dissociation of Aβ-immunoreactivity and fibrillar Aβ plaque content 
with measures of spine morphology, in contrast to the finding that each is associated with spine 
loss. This dissociation suggests that fibrillar and non-fibrillar Aβ may lead to spine loss via 
distinct pathways. For example, dendrites passing through or in close proximity to fibrillar Aβ 
plaques demonstrate a number of abnormalities, including atrophy, tortuosity, varicosities, and 
local loss of spines in the affected segments (Spires et al., 2005, Grutzendler et al., 2007). Thus, 
fibrillar Aβ plaques may lead to spine loss via toxic effects on dendrites, perhaps via effects on 
tau, which accumulates in dendrites and can interfere with microtubule functions necessary for 
spine growth and maintenance (Gu and Zheng, 2009, Ittner and Gotz, 2011). In contrast, soluble 
Aβ species have been shown to bind directly to synaptic structures and may induce spine loss by 
altering post-synaptic signal transduction pathways (Shankar et al., 2008, Koffie et al., 2009). 
A.5.3 Potential Limitations of this Study 
Because fibrillar and non-fibrillar Aβ exist in equilibrium, there may be no in vivo (or in vitro) 
approach that can conclusively determine their independent effects when both are concurrently 
present. However, our data are consistent with a model in which Aβ fibrils in plaques are 
themselves toxic to spines, and serve as a reservoir for toxic soluble forms of non-fibrillar Aβ, 
with a concentration gradient that falls with distance from the plaque edge. Transgenic mouse 
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models aspire to capture some or all aspects of often uniquely human diseases, such as AD. The 
PSAPP mouse model demonstrates robust amyloid plaque deposition, well-characterized 
synaptic loss, and cognitive deficits that correlate with presence of oligomeric Aβ species 
(Urbanc et al., 2002), making it an excellent model to examine effects resulting from Aβ 
accumulation, a process that appears to correspond to the earliest stages of AD (Jack et al., 
2011). However, the PSAPP model lacks the neurofibrillary tangle formation and neuronal loss 
that are seen as AD progresses (Urbanc et al., 2002). This discrepancy between the PSAPP 
model and human neuropathology enhance confidence in the interpretation that our findings are 
secondary to Aβ, but render uncertain whether the associations identified in the current study are 
ultimately present in humans. This could be addressed by extending our multiple wavelength 
imaging and quantification approach to human postmortem tissue but this application is not 
straightforward due to tissue autofluorescence and high plaque densities in AD tissue. 
Another potential limitation to this study derives from our approach to spine imaging. We 
utilized phalloidin labeling to estimate spine volume, surface area and shape. Electron 
microscopy studies have shown that actin is the major cytoskeleton component in spines and 
plays a pivotal role in spine size and shape (Landis and Reese, 1983). Thus, phalloidin labeling 
presents a good overall estimate of spine shape and size; however, dendritic spines also contain 
other components, such as postsynaptic machinery and membrane bound organelles, that 
contribute to their shape and volume to some degree (Sheng and Hoogenraad, 2007). We imaged 
our sections via spinning disk confocal microscopy. This approach has several advantages 
relative to other fluorescent imaging methodologies for quantification in synaptic structures 
(Sweet et al., 2010). Nevertheless, our approach shares with other confocal techniques 
limitations in the z-axis resolution. While this limitation is mitigated by the Gaussian filter 
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transformation we applied during image processing, it may still have caused us to underestimate 
spine density by failing to discriminate spines closely apposed in the z-axis. Because we found 
reduced density of spines in the same region where spines were more compact, any such 
potential limitation would have biased against our detected effect rather than having contributed 
to it. Moreover, whereas alternate techniques such as array tomography may enhance z-axis 
resolution, they suffer from the same disadvantages for fluorescence intensity quantification 
(relative to spinning disk) as we have described for other laser scanning confocal techniques 
(Sweet et al., 2010). 
Finally, our working assumption was that amyloid plaques are embedded randomly 
throughout all parenchymal structures, and thus sampled a large number of plaques. However, 
reduced spine density could be due to cell bodies around plaques if plaques preferentially form in 
areas of high cell body density. 
A.5.4 Implications for AD 
Accepting the caveats associated with the PSAPP model discussed above, our findings have 
significance for therapeutic strategies in AD. We found that dendritic spine degeneration and loss 
in cerebral cortex were independently associated with both fibrillar Aβ plaque content and with 
an index of non-fibrillar, presumptively soluble, Aβ species. These findings argue strongly that 
therapeutic strategies should consider targeting both forms of Aβ concurrently. Additionally, the 
novel findings that spine morphology was altered in relation to an index of non-fibrillar Aβ 
content, but not associated with reduced relative f-actin content per spine, suggests an effect of 
non-fibrillar Aβ on pathways that signal to actin-regulating molecules outside canonical LTD 
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pathways. The specific pathways remain to be elucidated and may represent novel targets for 
therapy of AD. 
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B.1 ABSTRACT 
The visinin-like 1 (VSNL1) gene encodes visinin-like protein 1, a peripheral biomarker for 
Alzheimer disease (AD). Little is known, however, about normal VSNL1 expression in brain and 
the biologic networks in which it participates. Frontal cortex gray matter obtained from 209 
subjects without neurodegenerative or psychiatric illness, ranging in age from 16 to 91, was 
processed on Affymetrix GeneChip 1.1 ST and Human SNP Array 6.0. VSNL1 expression was 
unaffected by age and sex, and not significantly associated with SNPs in cis or trans. VSNL1 
was significantly co-expressed with genes in pathways for calcium signaling, AD, long-term 
potentiation, long-term depression, and trafficking of AMPA receptors. The association with AD 
was driven, in part, by correlation with amyloid precursor protein (APP) expression. These 
findings provide an unbiased link between VSNL1 and molecular mechanisms of AD, including 
pathways implicated in synaptic pathology in AD. Whether APP may drive increased VSNL1 
expression, VSNL1 drives increased APP expression, or both are downstream of common 
pathogenic regulators will need to be evaluated in model systems. 
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B.2 INTRODUCTION 
Alzheimer disease (AD) is the most prevalent form of dementia in the United States. It is 
characterized clinically by declining memory, progressive loss of cognitive ability, and 
behavioral changes. The incidence of AD increases rapidly with increasing age (Mayeux and 
Stern, 2012). This suggests a role of brain aging in risk for AD, although the basis of this age-
dependence is not established. Neuropathologically, the hallmarks of AD are deposition of 
extracellular amyloid plaques that are predominantly composed of amyloid-β (Aβ) peptide and 
intracellular neurofibrillary tangles (NFTs) comprised of hyperphosphorylated microtubule-
associated protein tau (Selkoe, 2004, Ballatore et al., 2007). Other pathologic changes include 
synapse and neuron loss, and reactive gliosis (Ingelsson et al., 2004). 
Among these pathologies, the strongest correlate of cognitive impairment in individuals 
with AD is loss of synapses across neocortical regions (Terry et al., 1991, Scheff and Price, 
2003), with excitatory synapses onto dendritic spines particularly affected (Baloyannis et al., 
2007, Grutzendler et al., 2007). Substantial evidence now indicates that aggregation of Aβ into 
soluble oligomers is a primary source of synaptotoxicity in AD (Lue et al., 1999, Naslund et al., 
2000, Selkoe, 2002, Walsh and Selkoe, 2007, Selkoe, 2008, Koffie et al., 2011). Although 
studies continue to elucidate how Aβ acts to eliminate dendritic spines, there is evidence that 
soluble Aβ inhibits mechanisms of long-term potentiation and/or engages mechanisms of long-
term depression, including reducing NMDA receptor dependent Ca2+ influx, mGlutamate 
receptor (mGluR) activation, and low level caspase-3 activation (Selkoe, 2008, Koffie et al., 
2011). The final common mechanism for these pathways converge on altered endocytotic 
recycling of GluR, resulting in reduced synaptic expression of GluR1 and GluR2 containing 
AMPA receptors and synaptic NMDA receptor (Hsieh et al., 2006). 
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Recently, several studies have identified visinin-like protein 1 (Vilip1), a protein encoded 
by the visinin-like 1 (VSNL1) gene, as a biomarker of AD. Vilip1 concentrations in 
cerebrospinal fluid and plasma are elevated in AD subjects relative to normal controls (Lee et al., 
2008, Tarawneh et al., 2011) and to non-AD dementia subjects (Tarawneh et al., 2011). Higher 
levels of cerebrospinal fluid Vilip1 also predicted a faster rate of cognitive decline (Tarawneh et 
al., 2012). Other biomarkers for AD, such as cerebrospinal fluid measures of Aβ, tau, and 
phospho-tau (Jack et al., 2010), are strongly implicated in the pathogenesis of AD by genetic, 
post-mortem, animal model, and in vitro studies. To date, the evidence for Vilip1 is much more 
limited. We reported that genetic variations in VSNL1 were associated with risk for psychosis in 
AD (Hollingworth et al., 2012), a phenotype characterized by more rapid cognitive deterioration 
than seen in AD subjects without psychosis (Ropacki and Jeste, 2005, Murray et al., 2014b). 
Qualitative studies have reported that Vilip1 can be detected in association with neuritic plaques 
and NFTs in neocortex of AD subjects (Braunewell et al., 2001a), and may contribute to 
phosphorylation of tau and Ca2+-mediated cell death (Schnurra et al., 2001). 
Vilip1 is a highly brain expressed member of the visinin-like protein subfamily of 
neuronal calcium sensors (Burgoyne and Weiss, 2001). Vilip1, like other subfamily members 
appears to modify receptor recycling (Braunewell and Klein-Szanto, 2009). For example, the 
closely related subfamily member, hippocalcin, is necessary for NMDA receptor dependent 
long-term depression via GluR endocytosis (Palmer et al., 2005, Amici et al., 2009). Whether 
Vilip1 has effects on synaptic plasticity processes implicated in synapse loss in AD, such as 
GluR recycling, long-term potentiation, and long-term depression, is not known. However, 
Vilip1 has a higher affinity for Ca2+ than calmodulin, suggesting it may respond to the lower 
Ca2+ levels, which induce long-term depression (Burgoyne and Weiss, 2001). 
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The above findings are consistent with the hypothesis that VSNL1/Vilip1 may contribute 
to the risk for AD, possibly via age-dependent alterations in expression or by affecting processes 
that contribute to synapse or neuronal loss. To date, however, very little is known about normal 
VSNL1 expression in brain, whether it is modulated by genetic variation, and the brain-related 
biologic co-expression networks in which VSNL1 participates. To begin to address these 
questions, we assessed VSNL1 expression in two regions of frontal cortex obtained from 209 
subjects spanning the adult age range, and without evidence of psychiatric or neurodegenerative 
illness. We found that VSNL1 expression was present throughout the adult life span and was 
unaffected by age, sex, and common genetic variants in cis and trans. VSNL1 co-expression 
networks included KEGG pathways for calcium signaling, AD, and pathways implicated in 
synaptic pathology in AD. 
B.3 METHODS AND MATERIALS 
B.3.1 Subjects 
All of the brain specimens were collected during autopsies conducted at the Allegheny County 
Office of the Medical Examiner with permission obtained from the subjects’ next-of-kin. The 
protocol used to obtain consent was approved by the University of Pittsburgh Institutional 
Review Board (IRB) and Committee for Oversight of Research Involving the Dead. An 
independent committee of experienced clinicians made consensus DSM-IV diagnoses for each 
subject, using information obtained from clinical records and structured interviews with 
surviving relatives. These procedures were IRB approved. Samples from a total of 212 subjects 
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without any DSM-IV diagnosis (i.e., including no diagnosis of a cognitive disorder) were 
obtained for use in this study. 
B.3.2 Tissue Processing 
Upon brain collection, ~2 cm coronal blocks from the right hemisphere were cut through the 
rostro-caudal extent of the brain and stored at −80°C. The RNA integrity (RIN) of each brain 
was assessed by chromatography (Agilent Bioanalyzer, Santa Clara, CA, USA). Samples were 
obtained from two prefrontal cortex (PFC) regions: Brodmann areas (BA) 11 and 47. These areas 
were selected based on prior findings showing robust age-related changes in gene expression that 
were highly correlated with other PFC regions (e.g., BA9) (Erraji-Benchekroun et al., 2005). 
Gray matter samples containing all six layers and excluding white matter were harvested from 
three to four consecutive 20 μm sections and stored in Trizol reagent. 
B.3.3 RNA Arrays 
Total RNA was extracted from frozen BA11 and BA47 samples stored in TRIZOL and 
were processed for microarray analysis using GeneChip Human Gene 1.1 ST from Affymetrix 
according to manufacturer’s protocol (http://www.affymetrix.com). Gene expression data were 
extracted using Expression Console build 1.2.1.20. The normalization method is based on 
quantile normalization to eliminate batch effects. Data from arrays were processed by RMA 
method. Gene expression probes were processed at gene-level and taken in log2 scale for further 
analysis. After normalization, 33,297 gene-level probes remained. Three samples were removed 
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from study, one due to poor array quality, one due to outlier effect, and one due to XXY 
genotype, resulting in a final sample size of 209 subjects (Table B.1). 
 
 
Table B.1 Demographic and technical characteristics of human subjects. 
 
B.3.4 Genotyping 
DNA samples for 204 of the subjects were available, and processed on Affymetrix SNP 6.0 
arrays, assessing genotype at 906,600 SNPs. Genotype calls were generated using Affymetrix 
Genotyping Console version 4.1.3. For intensity quality control (QC), we used Contrast QC, 
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which is the per sample QC test in the Affymetrix SNP 6.0 intensity array; two samples were 
removed after QC, leaving a final sample of 202 subjects for genotype measures. Birdseed v2 
algorithm was used for genotyping, using the EM algorithm to drive a maximum likelihood fit of 
a two dimensional Gaussian mixture model. 
B.3.5 Statistical Analysis 
Age-dependent expression 
Linear regression models were fitted to assess the association between VSNL1 expression level 
and demographic factors (age, sex, race). These models included as covariates the technical 
factors brain pH and RIN, as both were significantly associated with VSNL1 
expression: p = 7.21e-09 (BA11) and 1.94e-04 (BA47) for pH association and p = 3.66e-12 
(BA11) and 1.16e-08 (BA47) for RIN association. There was no significant association of 
VSNL1 expression with post-mortem interval (PMI, p = 0.26 and 0.36 in BA11 and BA47, 
respectively) and thus PMI was not included in the models. 
 
eQTL mapping 
eQTL analysis was performed in the 169 Caucasian subjects for whom genotype data were 
available. PCA analysis did not indicate population substructure within this cohort. All subjects 
had call rates >98%. SNPs were filtered out using the following criteria: (i) sample missing rate 
>10%, (ii) Minor allele frequency (MAF) <5%, and (iii) p value of Hardy–Weinberg equilibrium 
(HWE) test <10−3. SNPs were defined as in cis if they were located within 50 kbp of VSNL1. 
All other SNPs were defined as in trans. 
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The eQTL model adjusted for age, pH, and RIN values (each was significantly associated 
with gene expression in both BA11 and BA47) since the effects of those covariates may 
confound eQTL findings. The eQTL model with three covariates for a given genotype was: 
 
in which: Gij: gene expression of gene i of subject j; αi: intercept term of gene i; γi: effect of the 
selected genotype to gene i based on additive model; Xj: genotype of subject i, 0 (homozygous 
major alleles), 1 (heterozygous calls), and 2 (homozygous minor alleles); βik: the effect of 
covariates k; k = 1 (age), 2 (pH), and 3 (RIN) in gene i; Sjk: the value of covariate k of 
subject j; k = 1 (age), 2 (pH), and 3 (RIN); 
 
We used the “Matrix eQTL” R package, a recent computationally efficient package for eQTL 
analysis (Shabalin, 2012), to detect the desired trans-eQTLs. We applied the adaptive weighted 
(AW) Fisher’s method (Li and Tseng, 2011) for meta-analysis to combine eQTL p-values from 
two brain regions (BA11 and BA47). The AW Fisher’s method has the advantage to distinguish 
study homogeneity and heterogeneity by assigning 0 or 1 study (brain region) weights for each 
eQTL. Detected eQTLs from the meta-analysis can have three possible resulting weights: (1,1) 
meaning detected eQTL in both brain regions; (1,0) showing detected eQTL in BA11 but not in 
BA47 and vice versa for (0,1) weight. In order to avoid heterogeneity of eQTL findings across 
brain regions, we selected only eQTLs that were identified in both brain regions with (1,1) 
weights in the AW Fisher’s method. 
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B.3.6 Co-expression pathway analyses 
To reveal the co-expression structure of VSNL1, we selected the top 400 positively and 
negatively correlated genes in both brain regions. The minimum observed correlation among the 
selected genes was 0.64, and the associated p-values suggest the corresponding false discovery 
rate (FDR) is <1e-04. Pathway analysis was performed via over representation analysis based on 
Fisher’s exact test using pathway information retrieved from KEGG, BIOCARTA, and 
REACTOME databases. The Benjamini Hochberg procedure was used to control FDR for 
pathways (Benjamini and Hochberg, 1995). 
B.4 RESULTS 
B.4.1 VSNL1 expression 
There were no significant associations of VSNL1 expression in either BA11 or BA47 with age, 
race, or gender (Figure B.1). 
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Figure B.1 VSNL1 expression as a function of age, race, and sex. The correlation of VSNL1 expression levels with 
age are shown in the first panels for each area. The second and third panels show the density of expression levels as 
a function of race and sex. No associations were significant. BA, Brodmann area. 
B.4.2 VSNL1 eQTL analysis 
There was no significant association of VSNL1 expression with 40 genotyped SNPs located in 
the cis-regulatory region (Table S1 in Supplementary Material). Examination of the association 
of VSNL1 expression with SNPs in trans revealed 27 SNPs with suggestive evidence of 
association (p < 10−6, Figure B.2; Table S2 in Supplementary Material). However, no SNPs 
reached the threshold for genome wide significance (p < 10−8). 
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Figure B.2 Manhattan plot of SNP associations with VSNL1 expression. Associations are shown for each region, 
and for the weighted average of the two regions in the meta-analysis. BA, Brodmann area. 
B.4.3 VSNL1 co-expression networks 
We next evaluated VSNL1 co-expression. Although VSNL1 expression was itself not age 
dependent, many of its potential co-expression partners show age-dependent alterations in 
expression, including genes related to neurodegeneration (Erraji-Benchekroun et al., 2005, 
Glorioso et al., 2011). Therefore, we separately evaluated co-expression in subjects under and 
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over 50 years of age. The 400 genes with the greatest positive and negative correlations with 
VSNL1 expression in each age group are shown in Table S3 in Supplementary Material. 
The KEGG, BIOCARTA, and REACTOME pathways showing the most significant 
loading for genes positively and negatively correlated with VSNL1 expression are shown in 
Tables B.2 and B.3, respectively (all pathways are shown in Table S4 in Supplementary 
Material). In subjects under 50, VSNL1 was positively correlated with genes in the KEGG 
pathway for AD and the BIOCARTA pathway for P35 signaling in AD (P35Alzheimers). The 
association with the KEGG pathway was driven by correlations with amyloid precursor protein 
(APP), ATP2A2, CALM1, CDK5, CHP, GSK3B, ITPR1, NDUFAB1, NDUFV2, PPP3CA, 
PPP3CB, and UQCRH. The association with the P35Alzheimers pathway was driven by three of 
the same genes (APP, CDK5, and GSK3B) as well as PPP2CA. In subjects over 50, the co-
expression of VSNL1 with these AD pathways was weakened, with CDK5, CHP, and 
NDUFAB1 no longer among the top co-expressed genes. 
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Table B.2 Top pathways identified by genes showing positive correlations with VSNL1 expression. 
 
 
  134 
 
 
Table B.3 Top pathways identified by genes showing negative correlations with VSNL1 expression. 
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Other neuronal calcium sensor family members have been shown to mediate processes 
dependent on glutamate receptor trafficking, such as long-term potentiation and long-term 
depression (Palmer et al., 2005, Amici et al., 2009, Saab et al., 2009). Although the protein 
product of VSNL1, Vilip1, is known to alter availability of α4,β2-nicotinic acetylcholine 
receptors at the cell membrane via affects on endocytic trafficking (Lin et al., 2002), a similar 
effect on glutamate receptors has not been shown. It is of some interest, therefore, that among the 
top pathways identified by genes positively correlated with VSNL1 expression are the KEGG 
pathway for long-term potentiation and REACTOME pathways for trafficking of AMPA 
receptors. These associations include positive correlations with several AMPA receptor subunits: 
GRIA1, GRIA2, and GRIA3. Although not among the top pathways identified, there was also a 
significant positive correlation of VSNL1 expression with the KEGG pathway for long-term 
depression in both age groups (Table S4 in Supplementary Material). 
B.5 DISCUSSION 
We evaluated the hypothesis that VSNL1 may contribute to the development of AD by 
assessing whether VSNL1 demonstrated age-dependent expression and by determining the brain-
related biologic co-expression networks in which VSNL1 participates. VSNL1 expression was 
present throughout the adult life span, but was not correlated with subject age. VSNL1 co-
expression networks included AD pathways and pathways implicated in synaptic pathology in 
AD, including long-term potentiation, long-term depression, and trafficking of AMPA receptors. 
These latter findings provide an unbiased link in support of the hypothesis that VSNL1/Vilip1 
may participate in molecular mechanisms of AD. 
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We found that VSNL1 is expressed throughout the adult lifespan in human frontal cortex 
and is independent of subject age. We, and others, have previously reported that there is a 
substantial overlap between genes demonstrating age-related changes in expression and genes 
involved in the pathogenesis of neurodegenerative illnesses, including AD (Glorioso and Sibille, 
2011). The lack of changes in VSNL1 expression with age in our subjects suggests that any 
contribution of VSNL1 to the development of AD is not via this age-dependent mechanism. 
However, this does not preclude that VSNL1 expression could vary with age in other brain 
regions relevant to AD pathogenesis, such as the hippocampus. Also, it remains possible that 
post-transcriptional processing of VSNL1 into Vilip1 protein may vary with age. Evaluating that 
alternative will require future study of brain Vilip1 levels in an aging cohort. 
We had previously identified an association between genetic variation in VSNL1 and the 
psychotic phenotype of AD (Hollingworth et al., 2012). Because one important mechanism by 
which genetic variants may affect risk for neurodegenerative disease is to alter the transcription 
of their gene products in brain (Zou et al., 2012), we evaluated whether VSNL1 expression in 
frontal cortex is associated within or nearby the VSNL1 locus. We did not detect an association 
of VSNL1 expression with any of the tested SNPs. However, the possibility that nearby SNPs, 
other than the ones tested, affect VSNL1 expression cannot be excluded. To assess this 
likelihood, we used data from the 1000 Genomes project to estimate what proportion of all 
common variants (minor allele frequency ≥5%) in VSNL1 were correlated with the SNPs tested 
in our analysis. Only 70% of the common variants were tagged by one or more of our SNPs with 
an r2 ≥ 0.8. The 30% of poorly tagged common variants includes the most strongly-associated 
SNP in our GWAS, rs4038131. It is also possible that genetic variants, including those evaluated 
in the current study, may alter VSNL1 expression only in the presence of neurodegenerative 
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pathology. However, it should be noted that recent tests of SNPs in the AD risk genes ABCA7, 
BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A6A, MS4A6E, and PICALM for associations 
with the expression of their respective genes in brain tissue from AD and healthy control subjects 
have been largely negative (Allen et al., 2012, Karch et al., 2012). 
Although the focus of our study was on risk for AD, genetic variants in VSNL1, altered 
brain VSNL1 mRNA expression, and altered brain levels of Vilip1 protein have been reported in 
schizophrenia (Beveridge et al., 2008, Martins-de-Souza et al., 2009, Braunewell et al., 2011). Of 
particular relevance to the current report was the finding that microRNA miR-181b, which is 
elevated in schizophrenia, can downregulate VSNL1 expression in model systems and correlates 
with reduced VSNL1 expression in the superior temporal gyrus in subjects with schizophrenia 
(Beveridge et al., 2008). We were able to replicate the negative correlation between VSNL1 
expression and expression of pre-miR-181b genes in our normal aging cohort in both BA11 and 
BA47 (Figure S1 in Supplementary Material). However, how this normative regulation of 
VSNL1 by miR-181b might be changed in the presence of AD pathology and/or genetic 
variation in VSNL1, and in particular whether they may interact to underlie the association of 
VSNL1 genetic variation with psychosis in AD, is not known. 
VSNL1 was co-expressed with genes in several distinct pathways. This included co-
expression with genes identified with AD pathways and genes involved in mediating synaptic 
plasticity mechanisms such as long-term potentiation, long-term depression, and trafficking of 
AMPA receptors. These findings support a role for Vilip1 in these processes, as co-expressed 
genes tend to be related functionally (Oldham et al., 2008). However, the specific nature of any 
functional relationship cannot be readily inferred, as co-expression can arise from many sources 
(Gaiteri et al., 2014). For example, gray matter homogenates are a mixture of many cell types. 
  138 
Multiple genes that are specifically enriched in a single cell type, e.g. microglia, may be 
identified as co-expressed (Oldham et al., 2008, Hawrylycz et al., 2012). Alternatively, genes 
may share a mechanism regulating their transcription such as a transcription factor in common 
(Allocco et al., 2004), proximity within the linear sequence of DNA leading to synchronous 
transcription (Ebisuya et al., 2008), or colocalization within the spatial configuration of 
chromosomes (Homouz and Kudlicki, 2013). Similarly, epigenetic control of transcription via 
histone acetylation and methylation can lead to co-expression of neighboring genes (Horvath et 
al., 2012). Finally, mRNA degradation via microRNA binding may also lead multiple targets of a 
given microRNA to demonstrate correlated expression (Gennarino et al., 2012). 
In summary, VSNL1 is co-expressed with functional groups and gene transcripts in AD 
pathways, including APP itself and pathways implicated in synaptic pathology in AD. These 
findings provide an unbiased link between VSNL1 and molecular mechanisms of AD. However, 
whether increased expression of APP may drive increased VSNL1 expression, increased VSNL1 
expression drives increased APP expression, or both are concurrently altered downstream of 
another factor will need to be evaluated in model systems. For example, evaluation of VSNL1 
expression in transgenic mouse models of AD, or evaluation of APP expression after knockdown 
of VSNL1 would be indicated. Similarly, whether altering VSNL1 expression modifies synaptic 
pathology in AD would benefit from testing within in vitro and/or genetic mouse models. 
 
 
 
 
 
 
  139 
BIBLIOGRAPHY 
 
(2014) 2014 Alzheimer's disease facts and figures. Alzheimers Dement 10:e47-92. 
Acker CM, Forest SK, Zinkowski R, Davies P, d'Abramo C (2013) Sensitive quantitative assays 
for tau and phospho-tau in transgenic mouse models. Neurobiol Aging 34:338-350. 
Al-Sarraf H, Philip L (2003) Increased brain uptake and CSF clearance of 14C-glutamate in 
spontaneously hypertensive rats. Brain Res 994:181-187. 
Allen M, Zou F, Chai HS, Younkin CS, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, 
Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, 
Bisceglio G, Georgescu C, Schultz D, Rakhshan F, Kolbert CP, Jen J, Haines JL, Mayeux 
R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Petersen RC, Graff-Radford NR, 
Dickson DW, Younkin SG, Ertekin-Taner N, Apostolova LG, Arnold SE, Baldwin CT, 
Barber R, Barmada MM, Beach T, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird 
TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buros J, Buxbaum JD, Cairns 
NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, 
Corneveaux J, Cotman CW, Crane PK, Cruchaga C, Cummings JL, De Jager PL, DeCarli 
C, DeKosky ST, Demirci FY, Diaz-Arrastia R, Dick M, Dombroski BA, Duara R, Ellis 
WD, Evans D, Faber KM, Fallon KB, Farlow MR, Ferris S, Foroud TM, Frosch M, 
Galasko DR, Gallins PJ, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, 
Gilman S, Giordani B, Glass JD, Goate AM, Green RC, Growdon JH, Hakonarson H, 
Hamilton RL, Hardy J, Harrell LE, Head E, Honig LS, Huentelman MJ, Hulette CM, 
Hyman BT, Jarvik GP, Jicha GA, Jin LW, Jun G, Kamboh MI, Karlawish J, Karydas A, 
Kauwe JS, Kaye JA, Kennedy N, Kim R, Koo EH, Kowall NW, Kramer P, Kukull WA, 
Lah JJ, Larson EB, Levey AI, Lieberman AP, Lopez OL, Lunetta KL, Mack WJ, Marson 
DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, 
McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Montine TJ, 
Morris JC, Myers AJ, Naj AC, Nowotny P, Parisi JE, Perl DP, Peskind E, Poon WW, 
Potter H, Quinn JF, Raj A, Rajbhandary RA, Raskind M, Reiman EM, Reisberg B, Reitz 
C, Ringman JM, Roberson ED, Rogaeva E, Rosenberg RN, Sano M, Saykin AJ, 
Schneider JA, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, 
Spina S, St George-Hyslop P, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, 
Tsuang DW, Van Deerlin VM, Vardarajan BN, Vinters HV, Vonsattel JP, Wang LS, 
Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL (2012) Novel late-onset 
Alzheimer disease loci variants associate with brain gene expression. Neurology 79:221-
228. 
Allocco DJ, Kohane IS, Butte AJ (2004) Quantifying the relationship between co-expression, co-
regulation and gene function. BMC Bioinformatics 5:18. 
Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of 
Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 
8:429-431. 
  140 
Amici M, Doherty A, Jo J, Jane D, Cho K, Collingridge G, Dargan S (2009) Neuronal calcium 
sensors and synaptic plasticity. Biochem Soc Trans 37:1359-1363. 
Arispe N, Rojas E, Pollard HB (1993) Alzheimer disease amyloid beta protein forms calcium 
channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl 
Acad Sci U S A 90:567-571. 
Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation 
sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta 
Neuropathol 103:26-35. 
Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA (2005) 
Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry 13:624-627. 
Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's 
disease and related disorders. Nat Rev Neurosci 8:663-672. 
Baloyannis SJ, Costa V, Mauroudis I, Psaroulis D, Manolides SL, Manolides LS (2007) 
Dendritic and spinal pathology in the acoustic cortex in Alzheimer's disease: 
morphological and morphometric estimation by Golgi technique and electron 
microscopy. Acta Otolaryngol 127:351-354. 
Bamburg JR, Bloom GS (2009) Cytoskeletal pathologies of Alzheimer disease. Cell Motil 
Cytoskeleton 66:635-649. 
Beaudoin GM, 3rd, Lee SH, Singh D, Yuan Y, Ng YG, Reichardt LF, Arikkath J (2012) 
Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. 
Nat Protoc 7:1741-1754. 
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate – a practical and 
powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 
57:289-300. 
Bernstein HG, Baumann B, Danos P, Diekmann S, Bogerts B, Gundelfinger ED, Braunewell KH 
(1999) Regional and cellular distribution of neural visinin-like protein 
immunoreactivities (VILIP-1 and VILIP-3) in human brain. J Neurocytol 28:655-662. 
Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, Tran N, Dedova I, 
Cairns MJ (2008) Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. 
Hum Mol Genet 17:1156-1168. 
Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of 
Alzheimer's disease. Trends Neurosci 31:454-463. 
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer 
disease-associated neurofibrillary pathology using paraffin sections and 
immunocytochemistry. Acta Neuropathol 112:389-404. 
  141 
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathol 82:239-259. 
Brackmann M, Schuchmann S, Anand R, Braunewell KH (2005) Neuronal Ca2+ sensor protein 
VILIP-1 affects cGMP signalling of guanylyl cyclase B by regulating clathrin-dependent 
receptor recycling in hippocampal neurons. J Cell Sci 118:2495-2505. 
Braunewell K, Riederer P, Spilker C, Gundelfinger ED, Bogerts B, Bernstein HG (2001a) 
Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins 
(vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr 
Cogn Disord 12:110-116. 
Braunewell KH, Brackmann M, Schaupp M, Spilker C, Anand R, Gundelfinger ED (2001b) 
Intracellular neuronal calcium sensor (NCS) protein VILIP-1 modulates cGMP signalling 
pathways in transfected neural cells and cerebellar granule neurones. J Neurochem 
78:1277-1286. 
Braunewell KH, Dwary AD, Richter F, Trappe K, Zhao C, Giegling I, Schonrath K, Rujescu D 
(2011) Association of VSNL1 with schizophrenia, frontal cortical function, and 
biological significance for its gene product as a modulator of cAMP levels and neuronal 
morphology. Transl Psychiatry 1:e22. 
Braunewell KH, Klein-Szanto AJ (2009) Visinin-like proteins (VSNLs): interaction partners and 
emerging functions in signal transduction of a subfamily of neuronal Ca2+ -sensor 
proteins. Cell Tissue Res 335:301-316. 
Burgoyne RD, Weiss JL (2001) The neuronal calcium sensor family of Ca2+-binding proteins. 
Biochem J 353:1-12. 
Busciglio J, Lorenzo A, Yeh J, Yankner BA (1995) beta-amyloid fibrils induce tau 
phosphorylation and loss of microtubule binding. Neuron 14:879-888. 
Bussiere T, Giannakopoulos P, Bouras C, Perl DP, Morrison JH, Hof PR (2003) Progressive 
degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons 
predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal 
cortex area 9. J Comp Neurol 463:281-302. 
Butterfield DA (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: 
implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic 
Res 36:1307-1313. 
Cahill ME, Xie Z, Day M, Photowala H, Barbolina MV, Miller CA, Weiss C, Radulovic J, 
Sweatt JD, Disterhoft JF, Surmeier DJ, Penzes P (2009) Kalirin regulates cortical spine 
morphogenesis and disease-related behavioral phenotypes. Proc Natl Acad Sci U S A 
106:13058-13063. 
Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL, 3rd, 
Schneider JA, Grinberg LT, Halliday G, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, 
  142 
Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, 
Trojanowski JQ, Mann DM (2007) Neuropathologic diagnostic and nosologic criteria for 
frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal 
Lobar Degeneration. Acta Neuropathol 114:5-22. 
Cairns NJ, Brannstrom T, Khan MN, Rossor MN, Lantos PL (2003) Neuronal loss in familial 
frontotemporal dementia with ubiquitin-positive, tau-negative inclusions. Exp Neurol 
181:319-326. 
Capani F, Deerinck TJ, Ellisman MH, Bushong E, Bobik M, Martone ME (2001) Phalloidin-
eosin followed by photo-oxidation: a novel method for localizing F-actin at the light and 
electron microscopic levels. J Histochem Cytochem 49:1351-1361. 
Chaumont S, Compan V, Toulme E, Richler E, Housley GD, Rassendren F, Khakh BS (2008) 
Regulation of P2X2 receptors by the neuronal calcium sensor VILIP1. Sci Signal 1:ra8. 
Chin J (2011) Selecting a mouse model of Alzheimer's disease. Methods Mol Biol 670:169-189. 
Davis RC, Marsden IT, Maloney MT, Minamide LS, Podlisny M, Selkoe DJ, Bamburg JR 
(2011) Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited 
by maintaining cofilin-phosphorylation. Mol Neurodegener 6:10. 
Dehmelt L, Halpain S (2005) The MAP2/Tau family of microtubule-associated proteins. 
Genome Biol 6:204. 
DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: 
correlation with cognitive severity. Ann Neurol 27:457-464. 
Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG (2005) Calcium dysregulation and 
membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid 
oligomers. J Biol Chem 280:17294-17300. 
Demuro A, Parker I, Stutzmann GE (2010) Calcium signaling and amyloid toxicity in Alzheimer 
disease. J Biol Chem 285:12463-12468. 
Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager 
D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) 
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 
383:710-713. 
Ebisuya M, Yamamoto T, Nakajima M, Nishida E (2008) Ripples from neighbouring 
transcription. Nat Cell Biol 10:1106-1113. 
Ekinci FJ, Linsley MD, Shea TB (2000) Beta-amyloid-induced calcium influx induces apoptosis 
in culture by oxidative stress rather than tau phosphorylation. Brain Res Mol Brain Res 
76:389-395. 
  143 
Erraji-Benchekroun L, Underwood MD, Arango V, Galfalvy H, Pavlidis P, Smyrniotopoulos P, 
Mann JJ, Sibille E (2005) Molecular aging in human prefrontal cortex is selective and 
continuous throughout adult life. Biol Psychiatry 57:549-558. 
Esbjorner EK, Chan F, Rees E, Erdelyi M, Luheshi LM, Bertoncini CW, Kaminski CF, Dobson 
CM, Kaminski Schierle GS (2014) Direct observations of amyloid beta self-assembly in 
live cells provide insights into differences in the kinetics of Abeta(1-40) and Abeta(1-42) 
aggregation. Chem Biol 21:732-742. 
Fagan AM (2014) CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, 
Diagnosis, and Clinical Trial Design. Advances in Geriatrics 2014. 
Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins 
RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, 
Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM 
(2014) Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's 
disease. Sci Transl Med 6:226ra230. 
Fifre A, Sponne I, Koziel V, Kriem B, Yen Potin FT, Bihain BE, Olivier JL, Oster T, Pillot T 
(2006) Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during 
soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of 
calpain and caspase-3. J Biol Chem 281:229-240. 
Fish KN, Sweet RA, Deo AJ, Lewis DA (2008) An automated segmentation methodology for 
quantifying immunoreactive puncta number and fluorescence intensity in tissue sections. 
Brain Res 1240:62-72. 
Gaiteri C, Ding Y, French B, Tseng GC, Sibille E (2014) Beyond modules and hubs: the 
potential of gene coexpression networks for investigating molecular mechanisms of 
complex brain disorders. Genes Brain Behav 13:13-24. 
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, 
Donaldson T, Gillespie F, et al. (1995) Alzheimer-type neuropathology in transgenic 
mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527. 
Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, 
Greenberg SM, Bacskai BJ, Frosch MP (2006) Characterization of amyloid deposition in 
the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24:516-524. 
Gennarino VA, D'Angelo G, Dharmalingam G, Fernandez S, Russolillo G, Sanges R, Mutarelli 
M, Belcastro V, Ballabio A, Verde P, Sardiello M, Banfi S (2012) Identification of 
microRNA-regulated gene networks by expression analysis of target genes. Genome Res 
22:1163-1172. 
Geuna S, Herrera-Rincon C (2015) Update on stereology for light microscopy. Cell Tissue Res. 
  144 
Gierke P, Zhao C, Brackmann M, Linke B, Heinemann U, Braunewell KH (2004) Expression 
analysis of members of the neuronal calcium sensor protein family: combining 
bioinformatics and Western blot analysis. Biochem Biophys Res Commun 323:38-43. 
Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM 
(2010) Memory impairment in transgenic Alzheimer mice requires cellular prion protein. 
J Neurosci 30:6367-6374. 
Glorioso C, Oh S, Douillard GG, Sibille E (2011) Brain molecular aging, promotion of 
neurological disease and modulation by sirtuin 5 longevity gene polymorphism. 
Neurobiol Dis 41:279-290. 
Glorioso C, Sibille E (2011) Between destiny and disease: genetics and molecular pathways of 
human central nervous system aging. Prog Neurobiol 93:165-181. 
Gomez Ravetti M, Rosso OA, Berretta R, Moscato P (2010) Uncovering molecular biomarkers 
that correlate cognitive decline with the changes of hippocampus' gene expression 
profiles in Alzheimer's disease. PLoS One 5:e10153. 
Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT 
(1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's 
disease. Ann Neurol 41:17-24. 
Gomez-Isla T, Price JL, McKeel DW, Jr., Morris JC, Growdon JH, Hyman BT (1996) Profound 
loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J 
Neurosci 16:4491-4500. 
Gotz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, Schonrock N, Ittner LM (2007) A 
decade of tau transgenic animal models and beyond. Brain Pathol 17:91-103. 
Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, 
Wester HJ, Kurz A, Drzezga A (2009) Beta amyloid in Alzheimer's disease: increased 
deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol 
Psychiatry 65:927-934. 
Grutzendler J, Helmin K, Tsai J, Gan WB (2007) Various dendritic abnormalities are associated 
with fibrillar amyloid deposits in Alzheimer's disease. Ann N Y Acad Sci 1097:30-39. 
Gu J, Zheng JQ (2009) Microtubules in Dendritic Spine Development and Plasticity. Open 
Neurosci J 3:128-133. 
Guo Q, Sebastian L, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP (1999) 
Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice 
to amyloid beta-peptide toxicity: central roles of superoxide production and caspase 
activation. J Neurochem 72:1019-1029. 
Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the 
Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112. 
  145 
Halpain S, Greengard P (1990) Activation of NMDA receptors induces rapid dephosphorylation 
of the cytoskeletal protein MAP2. Neuron 5:237-246. 
Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20:154-159. 
Hartigan JA, Johnson GV (1999) Transient increases in intracellular calcium result in prolonged 
site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-
dependent pathway. J Biol Chem 274:21395-21401. 
Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, van de Lagemaat 
LN, Smith KA, Ebbert A, Riley ZL, Abajian C, Beckmann CF, Bernard A, Bertagnolli D, 
Boe AF, Cartagena PM, Chakravarty MM, Chapin M, Chong J, Dalley RA, Daly BD, 
Dang C, Datta S, Dee N, Dolbeare TA, Faber V, Feng D, Fowler DR, Goldy J, Gregor 
BW, Haradon Z, Haynor DR, Hohmann JG, Horvath S, Howard RE, Jeromin A, Jochim 
JM, Kinnunen M, Lau C, Lazarz ET, Lee C, Lemon TA, Li L, Li Y, Morris JA, Overly 
CC, Parker PD, Parry SE, Reding M, Royall JJ, Schulkin J, Sequeira PA, Slaughterbeck 
CR, Smith SC, Sodt AJ, Sunkin SM, Swanson BE, Vawter MP, Williams D, Wohnoutka 
P, Zielke HR, Geschwind DH, Hof PR, Smith SM, Koch C, Grant SG, Jones AR (2012) 
An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 
489:391-399. 
Hayashi K, Ishikawa R, Ye LH, He XL, Takata K, Kohama K, Shirao T (1996) Modulatory role 
of drebrin on the cytoskeleton within dendritic spines in the rat cerebral cortex. J 
Neurosci 16:7161-7170. 
Herculano-Houzel S, von Bartheld CS, Miller DJ, Kaas JH (2015) How to count cells: the 
advantages and disadvantages of the isotropic fractionator compared with stereology. 
Cell Tissue Res. 
Himmel HM, Riehle R, Stieler K, Siess M (1990) Effects of the divalent cation ionophore 
ionomycin on the performance of isolated guinea-pig atria. Basic Res Cardiol 85:247-
256. 
Hogg RC, Raggenbass M, Bertrand D (2003) Nicotinic acetylcholine receptors: from structure to 
brain function. Rev Physiol Biochem Pharmacol 147:1-46. 
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller 
R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin 
S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice 
carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 
4:97-100. 
Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, Stretton A, Jones N, Gerrish 
A, Chapman J, Ivanov D, Moskvina V, Lovestone S, Priotsi P, Lupton M, Brayne C, Gill 
M, Lawlor B, Lynch A, Craig D, McGuinness B, Johnston J, Holmes C, Livingston G, 
Bass NJ, Gurling H, McQuillin A, Holmans P, Jones L, Devlin B, Klei L, Barmada MM, 
Demirci FY, DeKosky ST, Lopez OL, Passmore P, Owen MJ, O'Donovan MC, Mayeux 
  146 
R, Kamboh MI, Williams J (2012) Genome-wide association study of Alzheimer's 
disease with psychotic symptoms. Mol Psychiatry 17:1316-1327. 
Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's disease: the challenge of the second 
century. Sci Transl Med 3:77sr71. 
Homouz D, Kudlicki AS (2013) The 3D organization of the yeast genome correlates with co-
expression and reflects functional relations between genes. PLoS One 8:e54699. 
Horvath S, Zhang Y, Langfelder P, Kahn RS, Boks MP, van Eijk K, van den Berg LH, Ophoff 
RA (2012) Aging effects on DNA methylation modules in human brain and blood tissue. 
Genome Biol 13:R97. 
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) 
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. 
Science 274:99-102. 
Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R (2006) AMPAR 
removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 
52:831-843. 
Huh JW, Raghupathi R, Laurer HL, Helfaer MA, Saatman KE (2003) Transient loss of 
microtubule-associated protein 2 immunoreactivity after moderate brain injury in mice. J 
Neurotrauma 20:975-984. 
Hyman BT (2011) Caspase activation without apoptosis: insight into Abeta initiation of 
neurodegeneration. Nat Neurosci 14:5-6. 
Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis 
of Alzheimer disease from the National Institute on Aging and the Reagan Institute 
Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer 
disease. J Neuropathol Exp Neurol 56:1095-1097. 
Ikonomovic MD, Abrahamson EE, Isanski BA, Debnath ML, Mathis CA, Dekosky ST, Klunk 
WE (2006) X-34 labeling of abnormal protein aggregates during the progression of 
Alzheimer's disease. Methods Enzymol 412:123-144. 
Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, 
Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky 
ST (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case 
of Alzheimer's disease. Brain 131:1630-1645. 
Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, 
Hyman BT, Irizarry MC (2004) Early Abeta accumulation and progressive synaptic loss, 
gliosis, and tangle formation in AD brain. Neurology 62:925-931. 
Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT (1997) Abeta 
deposition is associated with neuropil changes, but not with overt neuronal loss in the 
  147 
human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 
17:7053-7059. 
Ittner LM, Gotz J (2011) Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat 
Rev Neurosci 12:65-72. 
Iversen LL, Mortishire-Smith RJ, Pollack SJ, Shearman MS (1995) The toxicity in vitro of beta-
amyloid protein. Biochem J 311 ( Pt 1):1-16. 
Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, 
Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's 
pathological cascade. Lancet Neurol 9:119-128. 
Jack CR, Jr., Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein 
MA, Petersen RC, Weiner MW, Knopman DS (2011) Evidence for ordering of 
Alzheimer disease biomarkers. Arch Neurol 68:1526-1535. 
James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA (2014) Contribution of 
Alzheimer disease to mortality in the United States. Neurology 82:1045-1050. 
Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee 
MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins 
specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for 
augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159-170. 
Janocko NJ, Brodersen KA, Soto-Ortolaza AI, Ross OA, Liesinger AM, Duara R, Graff-Radford 
NR, Dickson DW, Murray ME (2012) Neuropathologically defined subtypes of 
Alzheimer's disease differ significantly from neurofibrillary tangle-predominant 
dementia. Acta Neuropathol 124:681-692. 
Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ (2011) Soluble amyloid beta-protein 
dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and 
neuritic degeneration. Proc Natl Acad Sci U S A 108:5819-5824. 
Johanson CE, Duncan JA, Stopa EG, Baird A (2005) Enhanced prospects for drug delivery and 
brain targeting by the choroid plexus-CSF route. Pharm Res 22:1011-1037. 
Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS (2001) Kinesin-mediated 
axonal transport of a membrane compartment containing beta-secretase and presenilin-1 
requires APP. Nature 414:643-648. 
Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM (2012) Expression of novel 
Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS One 
7:e50976. 
Kasai H, Fukuda M, Watanabe S, Hayashi-Takagi A, Noguchi J (2010) Structural dynamics of 
dendritic spines in memory and cognition. Trends Neurosci 33:121-129. 
  148 
Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, Albay R, 3rd, Pensalfini A, Yeung 
S, Head E, Marsh JL, Glabe C (2010) Conformation dependent monoclonal antibodies 
distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. 
Mol Neurodegener 5:57. 
Kirkwood CM, Ciuchta J, Ikonomovic MD, Fish KN, Abrahamson EE, Murray PS, Klunk WE, 
Sweet RA (2013) Dendritic spine density, morphology, and fibrillar actin content 
surrounding amyloid-beta plaques in a mouse model of amyloid-beta deposition. J 
Neuropathol Exp Neurol 72:791-800. 
Klein AM, Kowall NW, Ferrante RJ (1999) Neurotoxicity and oxidative damage of beta amyloid 
1-42 versus beta amyloid 1-40 in the mouse cerebral cortex. Ann N Y Acad Sci 893:314-
320. 
Koffie RM, Hyman BT, Spires-Jones TL (2011) Alzheimer's disease: synapses gone cold. Mol 
Neurodegener 6:63. 
Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, 
Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL (2009) 
Oligomeric amyloid beta associates with postsynaptic densities and correlates with 
excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106:4012-4017. 
Koppel J, Acker C, Davies P, Lopez OL, Jimenez H, Azose M, Greenwald BS, Murray PS, 
Kirkwood CM, Kofler J, Sweet RA (2014) Psychotic Alzheimer's disease is associated 
with gender-specific tau phosphorylation abnormalities. Neurobiol Aging 35:2021-2028. 
Korobova F, Svitkina T (2010) Molecular architecture of synaptic actin cytoskeleton in 
hippocampal neurons reveals a mechanism of dendritic spine morphogenesis. Mol Biol 
Cell 21:165-176. 
Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ (2008) Abeta 
plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural 
and functional disruption of neuronal networks. Neuron 59:214-225. 
Kurt MA, Davies DC, Kidd M, Duff K, Howlett DR (2003) Hyperphosphorylated tau and paired 
helical filament-like structures in the brains of mice carrying mutant amyloid precursor 
protein and mutant presenilin-1 transgenes. Neurobiol Dis 14:89-97. 
Landis DM, Reese TS (1983) Cytoplasmic organization in cerebellar dendritic spines. J Cell Biol 
97:1169-1178. 
Larson ME, Lesne SE (2012) Soluble Abeta oligomer production and toxicity. J Neurochem 120 
Suppl 1:125-139. 
Laterza OF, Modur VR, Crimmins DL, Olander JV, Landt Y, Lee JM, Ladenson JH (2006) 
Identification of novel brain biomarkers. Clin Chem 52:1713-1721. 
  149 
Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, Gao F, Ohlendorf M, 
Ladenson JH (2008) The brain injury biomarker VLP-1 is increased in the cerebrospinal 
fluid of Alzheimer disease patients. Clin Chem 54:1617-1623. 
Li C, Pan W, Braunewell KH, Ames JB (2011) Structural analysis of Mg2+ and Ca2+ binding, 
myristoylation, and dimerization of the neuronal calcium sensor and visinin-like protein 1 
(VILIP-1). J Biol Chem 286:6354-6366. 
Li J, Tseng G (2011) An adaptively weighted statistic for detecting differential gene 
expression when combining multiple transcriptomic studies. Ann Appl Stat 5:994. 
Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of 
amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal 
glutamate uptake. Neuron 62:788-801. 
Lin CW, Chang LC, Tseng GC, Kirkwood CM, Sibille EL, Sweet RA (2015) VSNL1 Co-
Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and 
Alzheimer's Disease Pathways. Front Psychiatry 6:30. 
Lin L, Jeanclos EM, Treuil M, Braunewell KH, Gundelfinger ED, Anand R (2002) The calcium 
sensor protein visinin-like protein-1 modulates the surface expression and agonist 
sensitivity of the alpha 4beta 2 nicotinic acetylcholine receptor. J Biol Chem 277:41872-
41878. 
Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery 
occlusion without craniectomy in rats. Stroke 20:84-91. 
Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW (1993) Apoptosis is 
induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci 
U S A 90:7951-7955. 
Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, Snitz B, Saxton J, McDade E, 
Kamboh MI, DeKosky ST, Reynolds CF, 3rd, Klunk WE (2013) The long-term effects of 
conventional and atypical antipsychotics in patients with probable Alzheimer's disease. 
Am J Psychiatry 170:1051-1058. 
Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is 
inhibited by congo red. Proc Natl Acad Sci U S A 91:12243-12247. 
Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R (2001) A gene expression profile of 
Alzheimer's disease. DNA Cell Biol 20:683-695. 
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers 
J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in 
Alzheimer's disease. Am J Pathol 155:853-862. 
Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang 
Y, Wu F, He H, Ning Y (2013) CSF levels of the neuronal injury biomarker visinin-like 
  150 
protein-1 in Alzheimer's disease and dementia with Lewy bodies. J Neurochem 127:681-
690. 
Luther E, Kamentsky L, Henriksen M, Holden E (2004) Next-generation laser scanning 
cytometry. Methods Cell Biol 75:185-218. 
MacDonald ML, Ciccimaro E, Prakash A, Banerjee A, Seeholzer SH, Blair IA, Hahn CG (2012) 
Biochemical fractionation and stable isotope dilution liquid chromatography-mass 
spectrometry for targeted and microdomain-specific protein quantification in human 
postmortem brain tissue. Mol Cell Proteomics 11:1670-1681. 
Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, 
Trojanowski JQ, Mann DM, Lee VM (2011) A harmonized classification system for 
FTLD-TDP pathology. Acta Neuropathol 122:111-113. 
Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, 
Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh 
S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2009) 
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: 
consensus recommendations. Acta Neuropathol 117:15-18. 
Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, 
Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh 
S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2010) 
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar 
degeneration: an update. Acta Neuropathol 119:1-4. 
Mann DM, Iwatsubo T, Ihara Y, Cairns NJ, Lantos PL, Bogdanovic N, Lannfelt L, Winblad B, 
Maat-Schieman ML, Rossor MN (1996) Predominant deposition of amyloid-beta 42(43) 
in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated 
with mutations in the amyloid precursor protein gene. Am J Pathol 148:1257-1266. 
Mark RJ, Hensley K, Butterfield DA, Mattson MP (1995) Amyloid beta-peptide impairs ion-
motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and 
cell death. J Neurosci 15:6239-6249. 
Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, Maccarrone 
G, Turck CW, Dias-Neto E (2009) Alterations in oligodendrocyte proteins, calcium 
homeostasis and new potential markers in schizophrenia anterior temporal lobe are 
revealed by shotgun proteome analysis. J Neural Transm 116:275-289. 
Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H (2004) Structural basis of long-term 
potentiation in single dendritic spines. Nature 429:761-766. 
Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992) beta-Amyloid 
peptides destabilize calcium homeostasis and render human cortical neurons vulnerable 
to excitotoxicity. J Neurosci 12:376-389. 
  151 
Mayeux R, Stern Y (2012) Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 
2. 
McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, 
Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del 
Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, 
Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka 
K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina 
JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada 
M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the 
DLB Consortium. Neurology 65:1863-1872. 
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical 
diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the 
auspices of Department of Health and Human Services Task Force on Alzheimer's 
Disease. Neurology 34:939-944. 
Mercer EA, Korhonen L, Skoglosa Y, Olsson PA, Kukkonen JP, Lindholm D (2000) NAIP 
interacts with hippocalcin and protects neurons against calcium-induced cell death 
through caspase-3-dependent and -independent pathways. EMBO J 19:3597-3607. 
Miller JA, Oldham MC, Geschwind DH (2008) A systems level analysis of transcriptional 
changes in Alzheimer's disease and normal aging. J Neurosci 28:1410-1420. 
Millet LJ, Gillette MU (2012) Over a century of neuron culture: from the hanging drop to 
microfluidic devices. Yale J Biol Med 85:501-521. 
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van 
Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease 
(CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's 
disease. Neurology 41:479-486. 
Mondragon-Rodriguez S, Perry G, Luna-Munoz J, Acevedo-Aquino MC, Williams S (2014) 
Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in 
Alzheimer's disease and Down syndrome. Neuropathol Appl Neurobiol 40:121-135. 
Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs 
RE, Liu CY, Amezcua L, Harrington MG, Chui HC, Law M, Zlokovic BV (2015) Blood-
brain barrier breakdown in the aging human hippocampus. Neuron 85:296-302. 
Morgan AJ, Jacob R (1994) Ionomycin enhances Ca2+ influx by stimulating store-regulated 
cation entry and not by a direct action at the plasma membrane. Biochem J 300 ( Pt 
3):665-672. 
Mroczko B, Groblewska M, Zboch M, Muszynski P, Zajkowska A, Borawska R, Szmitkowski 
M, Kornhuber J, Lewczuk P (2015) Evaluation of visinin-like protein 1 concentrations in 
the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic 
biomarker of Alzheimer's disease. J Alzheimers Dis 43:1031-1037. 
  152 
Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid beta-protein: synaptic and network 
dysfunction. Cold Spring Harb Perspect Med 2:a006338. 
Mullen RJ, Buck CR, Smith AM (1992) NeuN, a neuronal specific nuclear protein in vertebrates. 
Development 116:201-211. 
Murray PS, Kirkwood CM, Gray MC, Fish KN, Ikonomovic MD, Hamilton RL, Kofler JK, 
Klunk WE, Lopez OL, Sweet RA (2014a) Hyperphosphorylated tau is elevated in 
Alzheimer's disease with psychosis. J Alzheimers Dis 39:759-773. 
Murray PS, Kirkwood CM, Gray MC, Ikonomovic MD, Paljug WR, Abrahamson EE, Henteleff 
RA, Hamilton RL, Kofler JK, Klunk WE, Lopez OL, Penzes P, Sweet RA (2012) beta-
Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis. 
Neurobiol Aging 33:2807-2816. 
Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA (2014b) Psychosis in Alzheimer's 
disease. Biol Psychiatry 75:542-552. 
Nagerl UV, Eberhorn N, Cambridge SB, Bonhoeffer T (2004) Bidirectional activity-dependent 
morphological plasticity in hippocampal neurons. Neuron 44:759-767. 
Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) 
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive 
decline. JAMA 283:1571-1577. 
O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM 
(2010) Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J 
Neurosci 30:14411-14419. 
Okamoto K, Nagai T, Miyawaki A, Hayashi Y (2004) Rapid and persistent modulation of actin 
dynamics regulates postsynaptic reorganization underlying bidirectional plasticity. Nat 
Neurosci 7:1104-1112. 
Oldham MC, Konopka G, Iwamoto K, Langfelder P, Kato T, Horvath S, Geschwind DH (2008) 
Functional organization of the transcriptome in human brain. Nat Neurosci 11:1271-
1282. 
Oliveira JM, Henriques AG, Martins F, Rebelo S, da Cruz ESOA (2015) Amyloid-beta 
Modulates Both AbetaPP and Tau Phosphorylation. J Alzheimers Dis. 
Ono K, Condron MM, Teplow DB (2009) Structure-neurotoxicity relationships of amyloid beta-
protein oligomers. Proc Natl Acad Sci U S A 106:14745-14750. 
Palmer CL, Lim W, Hastie PG, Toward M, Korolchuk VI, Burbidge SA, Banting G, 
Collingridge GL, Isaac JT, Henley JM (2005) Hippocalcin functions as a calcium sensor 
in hippocampal LTD. Neuron 47:487-494. 
  153 
Paterlini M, Revilla V, Grant AL, Wisden W (2000) Expression of the neuronal calcium sensor 
protein family in the rat brain. Neuroscience 99:205-216. 
Pauwels K, Williams TL, Morris KL, Jonckheere W, Vandersteen A, Kelly G, Schymkowitz J, 
Rousseau F, Pastore A, Serpell LC, Broersen K (2012) Structural basis for increased 
toxicity of pathological abeta42:abeta40 ratios in Alzheimer disease. J Biol Chem 
287:5650-5660. 
Paxinos G FK (2004) The Mouse Brain in Stereotaxic Coordinates: Compact Second Edition. 
Compact Second Edition:1-120. 
Phillips M, Boman E, Osterman H, Willhite D, Laska M (2011) Olfactory and visuospatial 
learning and memory performance in two strains of Alzheimer's disease model mice--a 
longitudinal study. PLoS One 6:e19567. 
Rabinovici GD, Miller BL (2010) Frontotemporal lobar degeneration: epidemiology, 
pathophysiology, diagnosis and management. CNS Drugs 24:375-398. 
Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to beta -
amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99:6364-6369. 
Regeur L, Jensen GB, Pakkenberg H, Evans SM, Pakkenberg B (1994) No global neocortical 
nerve cell loss in brains from patients with senile dementia of Alzheimer's type. 
Neurobiol Aging 15:347-352. 
Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, 
Ferrucci L, Kraut MA, Wong DF (2010) Longitudinal cognitive decline is associated 
with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74:807-815. 
Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke 
L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an 
Alzheimer's disease mouse model. Science 316:750-754. 
Ropacki SA, Jeste DV (2005) Epidemiology of and risk factors for psychosis of Alzheimer's 
disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 162:2022-
2030. 
Rossler M, Zarski R, Bohl J, Ohm TG (2002) Stage-dependent and sector-specific neuronal loss 
in hippocampus during Alzheimer's disease. Acta Neuropathol 103:363-369. 
Saab BJ, Georgiou J, Nath A, Lee FJ, Wang M, Michalon A, Liu F, Mansuy IM, Roder JC 
(2009) NCS-1 in the dentate gyrus promotes exploration, synaptic plasticity, and rapid 
acquisition of spatial memory. Neuron 63:643-656. 
Sanchez L, Madurga S, Pukala T, Vilaseca M, Lopez-Iglesias C, Robinson CV, Giralt E, Carulla 
N (2011) Abeta40 and Abeta42 amyloid fibrils exhibit distinct molecular recycling 
properties. J Am Chem Soc 133:6505-6508. 
  154 
Scheff SW, Price DA (1993) Synapse loss in the temporal lobe in Alzheimer's disease. Ann 
Neurol 33:190-199. 
Scheff SW, Price DA (2003) Synaptic pathology in Alzheimer's disease: a review of 
ultrastructural studies. Neurobiol Aging 24:1029-1046. 
Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 
in mild Alzheimer disease and mild cognitive impairment. Neurology 68:1501-1508. 
Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W (1995) Histopathologic 
correlates of white matter changes on MRI in Alzheimer's disease and normal aging. 
Neurology 45:883-888. 
Schnurra I, Bernstein HG, Riederer P, Braunewell KH (2001) The neuronal calcium sensor 
protein VILIP-1 is associated with amyloid plaques and extracellular tangles in 
Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link 
between calcium sensors and Alzheimer's disease? Neurobiol Dis 8:900-909. 
Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791. 
Selkoe DJ (2004) Alzheimer disease: mechanistic understanding predicts novel therapies. Ann 
Intern Med 140:627-638. 
Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and 
behavior. Behav Brain Res 192:106-113. 
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in 
Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189. 
Shabalin AA (2012) Matrix eQTL: ultra fast eQTL analysis via large matrix operations. 
Bioinformatics 28:1353-1358. 
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural 
oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by 
modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 
27:2866-2875. 
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, 
Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) 
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic 
plasticity and memory. Nat Med 14:837-842. 
Sharma AK, Rohrer B (2004) Calcium-induced calpain mediates apoptosis via caspase-3 in a 
mouse photoreceptor cell line. J Biol Chem 279:35564-35572. 
Shelton MA, Newman JT, Gu H, Sampson AR, Fish KN, MacDonald ML, Moyer CE, DiBitetto 
JV, Dorph-Petersen KA, Penzes P, Lewis DA, Sweet RA (2015) Loss of Microtubule-
  155 
Associated Protein 2 Immunoreactivity Linked to Dendritic Spine Loss in Schizophrenia. 
Biol Psychiatry. 
Sheng M, Hoogenraad CC (2007) The postsynaptic architecture of excitatory synapses: a more 
quantitative view. Annu Rev Biochem 76:823-847. 
Shimizu S, Abt A, Meucci O (2011) Bilaminar co-culture of primary rat cortical neurons and 
glia. J Vis Exp. 
Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, Dawson HN, Vitek MP, 
Wade-Martins R, Paulsen O, Vargas-Caballero M (2011) Tau protein is required for 
amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 
31:1688-1692. 
Simic G, Kostovic I, Winblad B, Bogdanovic N (1997) Volume and number of neurons of the 
human hippocampal formation in normal aging and Alzheimer's disease. J Comp Neurol 
379:482-494. 
Spilker C, Braunewell KH (2003) Calcium-myristoyl switch, subcellular localization, and 
calcium-dependent translocation of the neuronal calcium sensor protein VILIP-3, and 
comparison with VILIP-1 in hippocampal neurons. Mol Cell Neurosci 24:766-778. 
Spilker C, Dresbach T, Braunewell KH (2002) Reversible translocation and activity-dependent 
localization of the calcium-myristoyl switch protein VILIP-1 to different membrane 
compartments in living hippocampal neurons. J Neurosci 22:7331-7339. 
Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, 
Hyman BT (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic 
mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 
25:7278-7287. 
Stancu IC, Vasconcelos B, Terwel D, Dewachter I (2014) Models of beta-amyloid induced Tau-
pathology: the long and "folded" road to understand the mechanism. Mol Neurodegener 
9:51. 
Stejskal D, Sporova L, Svestak M, Karpisek M (2011) Determination of serum visinin like 
protein-1 and its potential for the diagnosis of brain injury due to the stroke: a pilot study. 
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155:263-268. 
Stutzmann GE, Caccamo A, LaFerla FM, Parker I (2004) Dysregulated IP3 signaling in cortical 
neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 
results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci 
24:508-513. 
Sugiyama Y, Kawabata I, Sobue K, Okabe S (2005) Determination of absolute protein numbers 
in single synapses by a GFP-based calibration technique. Nat Methods 2:677-684. 
  156 
Sweet RA, Fish KN, Lewis DA (2010) Mapping Synaptic Pathology within Cerebral Cortical 
Circuits in Subjects with Schizophrenia. Front Hum Neurosci 4:44. 
Sweet RA, Hamilton RL, Lopez OL, Klunk WE, Wisniewski SR, Kaufer DI, Healy MT, 
DeKosky ST (2000) Psychotic symptoms in Alzheimer's disease are not associated with 
more severe neuropathologic features. Int Psychogeriatr 12:547-558. 
Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann DM, Hyman 
BT, Iwatsubo T (2000) Age-related amyloid beta deposition in transgenic mice 
overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein 
Swedish mutant is not associated with global neuronal loss. Am J Pathol 157:331-339. 
Takuma H, Tomiyama T, Kuida K, Mori H (2004) Amyloid beta peptide-induced cerebral 
neuronal loss is mediated by caspase-3 in vivo. J Neuropathol Exp Neurol 63:255-261. 
Tantral L, Malathi K, Kohyama S, Silane M, Berenstein A, Jayaraman T (2004) Intracellular 
calcium release is required for caspase-3 and -9 activation. Cell Biochem Funct 22:35-40. 
Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun 
MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM (2011) Visinin-like protein-1: 
diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 70:274-285. 
Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM (2012) CSF VILIP-1 predicts 
rates of cognitive decline in early Alzheimer disease. Neurology 78:709-719. 
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R 
(1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the 
major correlate of cognitive impairment. Ann Neurol 30:572-580. 
Thal DR, Walter J, Saido TC, Fandrich M (2015) Neuropathology and biochemistry of Abeta 
and its aggregates in Alzheimer's disease. Acta Neuropathol 129:167-182. 
Tosun D, Joshi S, Weiner MW (2013) Neuroimaging predictors of brain amyloidosis in mild 
cognitive impairment. Ann Neurol 74:188-198. 
Tsai J, Grutzendler J, Duff K, Gan WB (2004) Fibrillar amyloid deposition leads to local 
synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 7:1181-1183. 
Urbanc B, Cruz L, Le R, Sanders J, Ashe KH, Duff K, Stanley HE, Irizarry MC, Hyman BT 
(2002) Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice 
and Alzheimer's disease. Proc Natl Acad Sci U S A 99:13990-13995. 
Valerio M, Porcelli F, Zbilut JP, Giuliani A, Manetti C, Conti F (2008) pH effects on the 
conformational preferences of amyloid beta-peptide (1-40) in HFIP aqueous solution by 
NMR spectroscopy. ChemMedChem 3:833-843. 
  157 
Valle-Delgado JJ, Alfonso-Prieto M, de Groot NS, Ventura S, Samitier J, Rovira C, Fernandez-
Busquets X (2010) Modulation of Abeta42 fibrillogenesis by glycosaminoglycan 
structure. FASEB J 24:4250-4261. 
Vatsavayi AV, Kofler J, Demichele-Sweet MA, Murray PS, Lopez OL, Sweet RA (2014) TAR 
DNA-binding protein 43 pathology in Alzheimer's disease with psychosis. Int 
Psychogeriatr 26:987-994. 
Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002) Amyloid-beta oligomers: their 
production, toxicity and therapeutic inhibition. Biochem Soc Trans 30:552-557. 
Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary 
JP, Ashe KH, Rowan MJ, Selkoe DJ (2005) The role of cell-derived oligomers of Abeta 
in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 
33:1087-1090. 
Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101:1172-
1184. 
Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine 
WB, Krafft GA, Trommer BL (2002) Soluble oligomers of beta amyloid (1-42) inhibit 
long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 
924:133-140. 
Watson RE, Jr., Wiegand SJ, Clough RW, Hoffman GE (1986) Use of cryoprotectant to maintain 
long-term peptide immunoreactivity and tissue morphology. Peptides 7:155-159. 
West MJ, Coleman PD, Flood DG, Troncoso JC (1994) Differences in the pattern of 
hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344:769-
772. 
West MJ, Kawas CH, Stewart WF, Rudow GL, Troncoso JC (2004) Hippocampal neurons in 
pre-clinical Alzheimer's disease. Neurobiol Aging 25:1205-1212. 
Wilmot B, McWeeney SK, Nixon RR, Montine TJ, Laut J, Harrington CA, Kaye JA, Kramer PL 
(2008) Translational gene mapping of cognitive decline. Neurobiol Aging 29:524-541. 
Wilson LM, Mok YF, Binger KJ, Griffin MD, Mertens HD, Lin F, Wade JD, Gooley PR, 
Howlett GJ (2007) A structural core within apolipoprotein C-II amyloid fibrils identified 
using hydrogen exchange and proteolysis. J Mol Biol 366:1639-1651. 
Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, Spires-Jones T, Xie H, 
Arbel-Ornath M, Grosskreutz CL, Bacskai BJ, Hyman BT (2010) Amyloid beta induces 
the morphological neurodegenerative triad of spine loss, dendritic simplification, and 
neuritic dystrophies through calcineurin activation. J Neurosci 30:2636-2649. 
Yang Y, Wang XB, Frerking M, Zhou Q (2008) Spine expansion and stabilization associated 
with long-term potentiation. J Neurosci 28:5740-5751. 
  158 
Zempel H, Thies E, Mandelkow E, Mandelkow EM (2010) Abeta oligomers cause localized 
Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and 
destruction of microtubules and spines. J Neurosci 30:11938-11950. 
Zhang Y, Rempel DL, Zhang J, Sharma AK, Mirica LM, Gross ML (2013) Pulsed hydrogen-
deuterium exchange mass spectrometry probes conformational changes in amyloid beta 
(Abeta) peptide aggregation. Proc Natl Acad Sci U S A 110:14604-14609. 
Zhao CJ, Noack C, Brackmann M, Gloveli T, Maelicke A, Heinemann U, Anand R, Braunewell 
KH (2009) Neuronal Ca2+ sensor VILIP-1 leads to the upregulation of functional 
alpha4beta2 nicotinic acetylcholine receptors in hippocampal neurons. Mol Cell Neurosci 
40:280-292. 
Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S (2002) Amyloid beta peptide induces tau 
phosphorylation and loss of cholinergic neurons in rat primary septal cultures. 
Neuroscience 115:201-211. 
Zhou Q, Homma KJ, Poo MM (2004) Shrinkage of dendritic spines associated with long-term 
depression of hippocampal synapses. Neuron 44:749-757. 
Zou F, Chai HS, Younkin CS, Allen M, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, 
Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, 
Bisceglio G, Georgescu C, Kouri N, Kolbert CP, Jen J, Haines JL, Mayeux R, Pericak-
Vance MA, Farrer LA, Schellenberg GD, Petersen RC, Graff-Radford NR, Dickson DW, 
Younkin SG, Ertekin-Taner N (2012) Brain expression genome-wide association study 
(eGWAS) identifies human disease-associated variants. PLoS Genet 8:e1002707. 
 
 
